
<html lang="en"     class="pb-page"  data-request-id="4b7c1ef5-7c40-4c6f-bdef-21e153d94ca5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm2008634;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2011.54.issue-23;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold" /></meta><meta name="dc.Creator" content="Tomoyasu  Ishikawa" /></meta><meta name="dc.Creator" content="Masaki  Seto" /></meta><meta name="dc.Creator" content="Hiroshi  Banno" /></meta><meta name="dc.Creator" content="Youichi  Kawakita" /></meta><meta name="dc.Creator" content="Mami  Oorui" /></meta><meta name="dc.Creator" content="Takahiko  Taniguchi" /></meta><meta name="dc.Creator" content="Yoshikazu  Ohta" /></meta><meta name="dc.Creator" content="Toshiya  Tamura" /></meta><meta name="dc.Creator" content="Akiko  Nakayama" /></meta><meta name="dc.Creator" content="Hiroshi  Miki" /></meta><meta name="dc.Creator" content="Hidenori  Kamiguchi" /></meta><meta name="dc.Creator" content="Toshimasa  Tanaka" /></meta><meta name="dc.Creator" content="Noriyuki  Habuka" /></meta><meta name="dc.Creator" content="Satoshi  Sogabe" /></meta><meta name="dc.Creator" content="Jason  Yano" /></meta><meta name="dc.Creator" content="Kathleen  Aertgeerts" /></meta><meta name="dc.Creator" content="Keiji  Kamiyama" /></meta><meta name="dc.Description" content="Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, la..." /></meta><meta name="Description" content="Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, la..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 4, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2008634" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2008634" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2008634" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2008634" /></link>
        
    
    

<title>Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2008634" /></meta><meta property="og:title" content="Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0015.jpeg" /></meta><meta property="og:description" content="Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors’ ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2008634"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2008634">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2008634&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2008634&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2008634&amp;href=/doi/10.1021/jm2008634" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 8030-8050</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm2008369" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm200868m" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold<a class="ref internalNav" href="#notes-1" aria-label=""></a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomoyasu++Ishikawa">Tomoyasu Ishikawa</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masaki++Seto">Masaki Seto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Banno">Hiroshi Banno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youichi++Kawakita">Youichi Kawakita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mami++Oorui">Mami Oorui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takahiko++Taniguchi">Takahiko Taniguchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshikazu++Ohta">Yoshikazu Ohta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshiya++Tamura">Toshiya Tamura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akiko++Nakayama">Akiko Nakayama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Miki">Hiroshi Miki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hidenori++Kamiguchi">Hidenori Kamiguchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshimasa++Tanaka">Toshimasa Tanaka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noriyuki++Habuka">Noriyuki Habuka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Sogabe">Satoshi Sogabe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Yano">Jason Yano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Aertgeerts">Kathleen Aertgeerts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keiji++Kamiyama">Keiji Kamiyama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-text">Structural Biology, Takeda San Diego, Inc., 10410 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info">Phone: +81-466-32-1155. Fax: +81-466-29-4449. E-Mail: <a href="/cdn-cgi/l/email-protection#bbf2c8d3d2d0daccdae4efd4d6d4c2dac8cefbcfdad0dedfda95d8d495d1cb"><span class="__cf_email__" data-cfemail="460f352e2f2d2731271912292b293f2735330632272d232227682529682c36">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2008634&amp;href=/doi/10.1021%2Fjm2008634" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 8030–8050</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 17, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 July 2011</li><li><span class="item_label"><b>Published</b> online</span>4 November 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 December 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2008634" title="DOI URL">https://doi.org/10.1021/jm2008634</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8030%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTomoyasu%2BIshikawa%252C%2BMasaki%2BSeto%252C%2BHiroshi%2BBanno%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D23%26contentID%3Djm2008634%26title%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528HER2%2529%252FEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BDual%2BInhibitors%2BBearing%2Ba%2BPyrrolo%255B3%252C2-d%255Dpyrimidine%2BScaffold%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8050%26publicationDate%3DDecember%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2008634"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5170</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">98</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2008634" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tomoyasu&quot;,&quot;last_name&quot;:&quot;Ishikawa&quot;},{&quot;first_name&quot;:&quot;Masaki&quot;,&quot;last_name&quot;:&quot;Seto&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Banno&quot;},{&quot;first_name&quot;:&quot;Youichi&quot;,&quot;last_name&quot;:&quot;Kawakita&quot;},{&quot;first_name&quot;:&quot;Mami&quot;,&quot;last_name&quot;:&quot;Oorui&quot;},{&quot;first_name&quot;:&quot;Takahiko&quot;,&quot;last_name&quot;:&quot;Taniguchi&quot;},{&quot;first_name&quot;:&quot;Yoshikazu&quot;,&quot;last_name&quot;:&quot;Ohta&quot;},{&quot;first_name&quot;:&quot;Toshiya&quot;,&quot;last_name&quot;:&quot;Tamura&quot;},{&quot;first_name&quot;:&quot;Akiko&quot;,&quot;last_name&quot;:&quot;Nakayama&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Miki&quot;},{&quot;first_name&quot;:&quot;Hidenori&quot;,&quot;last_name&quot;:&quot;Kamiguchi&quot;},{&quot;first_name&quot;:&quot;Toshimasa&quot;,&quot;last_name&quot;:&quot;Tanaka&quot;},{&quot;first_name&quot;:&quot;Noriyuki&quot;,&quot;last_name&quot;:&quot;Habuka&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Sogabe&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Yano&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Aertgeerts&quot;},{&quot;first_name&quot;:&quot;Keiji&quot;,&quot;last_name&quot;:&quot;Kamiyama&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;8030-8050&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2008634&quot;},&quot;abstract&quot;:&quot;Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors’ ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2008634&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2008634" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2008634&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2008634" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2008634&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2008634" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2008634&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2008634&amp;href=/doi/10.1021/jm2008634" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2008634" /></input><a href="/doi/pdf/10.1021/jm2008634" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26pmid%3D22003817%26genre%3Darticle%26aulast%3DIshikawa%26date%3D2011%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528HER2%2529%252FEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BDual%2BInhibitors%2BBearing%2Ba%2BPyrrolo%255B3%252C2-d%255Dpyrimidine%2BScaffold%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D23%26spage%3D8030%26epage%3D8050%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jmcmar.2011.54.issue-23/production/jmcmar.2011.54.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-<i>d</i>]pyrimidine derivatives capable of fitting into the receptors’ ATP binding site. Among the prepared compounds, <b>34e</b> showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of <b>34e</b> with both HER2 and EGFR demonstrated that <b>34e</b> interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, <b>34e</b> exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report <b>34e</b> (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span>†</span> Accession Codes</h4><p class="last">Protein Data Bank accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RCD">3RCD</a>.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinases play important roles in signal transduction pathways that regulate numerous cellular functions, including proliferation, differentiation, migration, apoptosis, and angiogenesis. Because signal transduction pathways are upregulated in many tumor cells, protein kinase inhibitors that target these upregulated pathways are attractive candidates for cancer therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The targeting of human epidermal growth factor receptor (HER) or epidermal growth factor receptor (EGFR) by tyrosine kinase inhibitors (TKIs) represents one such therapeutic approach. The HER kinase family contains 4 members (EGFR (HER1 or ErbB-1), HER2 (ErbB-2 or neu), HER3 (ErbB-3), and HER4 (ErbB-4)) that are multidomain proteins consisting of an extracellular ligand binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Several ligands that bind to the extracellular portion of EGFR, HER3, and HER4 have been identified. Upon ligand binding, these receptors form homo- or heterodimers to undergo autophosphorylation of each tyrosine residue within the intracellular kinase domain.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Although there is no known ligand for HER2, this receptor also undergoes spontaneous homo- or heterodimerization and activates downstream signaling.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">As for EGFR inhibitors, small molecules such as gefitinib<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and erlotinib<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), as well as anti-EGFR antibodies cetuximab<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and panitumumab,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> have been approved for the treatment of EGFR-overexpressing lung cancers and have been shown to be effective in a subset of patients. HER2 is overexpressed in a number of human cancers, including 20–40% of solid tumors, e.g., breast, ovarian, lung, gastric, and oral cancers, in which overexpression of this receptor correlates with poor prognosis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In addition, because HER2 is only expressed at low levels in normal human tissues, it is an attractive target for tumor-specific therapies. On the basis of this, two approaches have been developed for blocking the upregulated HER2 signal pathway. One approach utilizes the anti-HER2 monoclonal antibody, trastuzumab,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which blocks the extracellular ligand-binding region of the receptor, thereby interfering with its activation and modulating the resultant intracellular signal cascade. The other approach for blocking the upregulated HER2 signal pathway involves the use of orally active small molecule TKIs several of which have been developed. Many types of malignancies are characterized by overexpression of HER2 and EGFR. Lapatinib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> a dual TKI for HER2 and EGFR, was approved in 2007 in combination with capecitabine or letrozole in patients with metastatic breast cancer that overexpress the HER2 receptor. Irreversible inhibitors (Neratinib/HKI-272<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and Afatinib/BIBW-2992<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>) and reversible inhibitors (AEE-788<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and BMS-599626<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>) have also been tested in clinical trials. In addition to breast cancer, these HER2/EGFR dual kinase inhibitors are being investigated in a number of solid tumors including lung, gastric, and prostate cancers.<a onclick="showRef(event, 'ref9 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref12 ref13 ref14 ref15">(9, 11-15)</a> In addition, CP-724714<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> has been reported as a HER2-specific TKI. All of these small molecule inhibitors share a common structure characterized by a pyrimidine or pyrimidine analogue at its core.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0016.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of EGFR and/or HER2 small molecule inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the purpose of developing a novel HER2/EGFR TKI, we focused on the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold, which contains a pyrimidine core that interacts with Met801 and Thr862 in the ATP-binding site of the HER2 hinge region (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Nucleic acid research using pyrrolo[3,2-<i>d</i>]pyrimidine derivatives has been conducted in our laboratories,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a>but this pyrimidine core had not been previously utilized for drug development. Molecular modeling studies using HER2 homology models based on the EGFR cocrystal structure with erlotinib<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> suggested that the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold would fit into the ATP-binding site of the HER2/EGFR protein. In this model, introduction of a phenoxy anilino group at the <i>C</i>-4 position could occupy a lipophilic back pocket and enhance anti-HER2/EGFR kinase activity. In addition, because the linkages at the <i>N</i>-5 or <i>C</i>-6 positions are directed toward the solvent contact region, we envisioned that chemical modification of the R<sup>2</sup> or R<sup>3</sup> groups at these positions could be utilized to further improve the cellular activity and pharmacokinetic properties of this chemotype.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0017.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of pyrrolo[3,2-<i>d</i>]pyrimidine scaffold as HER2 kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper, we describe the structure–activity relationships (SAR) and in vivo efficacy of our pyrrolo[3,2-<i>d</i>]pyrimidine derivatives. Crystallographic studies of <b>34e</b> (TAK-285),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> our candidate for clinical development, with HER2 and EGFR revealed key molecular details related to compound binding and specificity.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">With the aim of examining substituent effects on the terminal phenoxy rings, 4-substituted anilino-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine derivatives (<b>6a</b>–<b>n</b>) were synthesized by the method shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Condensation of commercially available 2-chloro-1-fluoro-4-nitrobenzene (<b>1</b>) with phenols (<b>2a</b>–<b>n</b>) was carried out in the presence of potassium carbonate in dimethylformamide (DMF), followed by reduction of the nitro group with platinum on carbon under hydrogen atmosphere to afford substituted anilines (<b>4a</b>–<b>e</b>, <b>4i</b>–<b>n</b>) in good yields (61–99% in 2 steps). In the case of <b>4f</b>–<b>h</b> containing a cyano group, the nitro group was reduced using reduced-iron and calcium chloride in ethanol (EtOH) (56–71% in 2 steps). The obtained anilines <b>4a</b>–<b>n</b> were reacted with 4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>5</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> in 1-methyl-2-pyrrolidone (NMP) at 100 °C to afford <b>6a</b>–<b>n</b> in moderate yields (31–83%). In Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, the pyrrolo[3,2-<i>d</i>]pyrimidine derivatives <b>6o</b>–<b>q</b> were prepared from reported anilines <b>4o</b>–<b>q</b><a onclick="showRef(event, 'cit11c cit12a cit16c'); return false;" href="javascript:void(0);" class="ref cit11c cit12a cit16c">(11c, 12a, 16c)</a> in a similar manner to that shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0022.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives <b>6a</b>–<b>n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>2a</b>–<b>n</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 2 h; (b) H<sub>2</sub>, Pt–C, AcOEt, rt, 2 h, or Fe, CaCl<sub>2</sub>, EtOH, 100 °C, 15 h, 56–99% for 2 steps; (c) <b>5</b>, NMP, 100 °C, 3 h, 31–83%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives <b>6o</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>4o</b>–<b>4q</b>, NMP, 100 °C, 3 h, 66–80%.</p></p></figure><div class="NLM_p">Next, we selected 3 anilino groups (<b>e</b>: −Cl; <b>j</b>: −CF<sub>3</sub>; <b>l</b>: −OCF<sub>3</sub>) and examined the introduction of methyl (<b>8e</b>–<b>l</b>), 2-hydroxyethyl (<b>10e</b>–<b>l</b>), and 2-(2-hydroxyethoxy)ethyl (<b>12e</b>–<b>l</b>) moieties as representative alkyl substituents at the <i>N</i>-5 position. The synthesis is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The 4-chloro derivative <b>5</b> was reacted with iodomethane under basic conditions using potassium carbonate in DMF to afford 5-methyl intermediate <b>7</b> (93% yield). The methylated adduct <b>7</b> was converted into the desired products <b>8e</b>–<b>l</b> by coupling with aniline <b>4e</b> (92%), <b>4j</b> (75%), and <b>4l</b> (77%), respectively. Similarly, alkylation of compound <b>5</b> with 2-iodoethyl benzoate or 2-(2-iodoethoxy)ethyl benzoate in the presence of cesium carbonate in DMF gave the adducts <b>9</b> and <b>11</b> in 70% and 55% yield, respectively. After reaction of <b>9</b> or <b>11</b> with aniline (<b>4e</b>, <b>4j</b>, <b>4l</b>), the terminal benzoyl group was hydrolyzed by 1N aqueous sodium hydroxide (NaOH) to afford the desired target compounds (<b>10e</b>–<b>l</b>, <b>12e</b>–<b>l</b>) in 46–72% yields. A similar reaction was carried out for the synthesis of <b>12r</b>, which is a pyridine analogue of <b>12j</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>8</b>, <b>10</b>, and <b>12</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) iodomethane, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 3 h, 93%; (b) aniline <b>4e</b> or <b>4j</b> or <b>4l</b>, NMP, 140 °C, 4 h, 75–92%; (c) 2-iodoethyl benzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 70%; (d) (i) aniline <b>4e</b> or <b>4j</b> or <b>4</b>l NMP, 140 °C, 2.5 h, (ii) 1N NaOH, MeOH, rt, 46–72%; (e) 2-(2-iodoethoxy)ethyl benzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 55%; (f) (i) 2,3-dichloro-5-nitropyridine, NaH, THF, rt, 2.5 h, (ii) Fe, CaCl<sub>2</sub>, EtOH, 80 °C, 8 h, 39% from <b>2j</b>.</p></p></figure><div class="NLM_p">On the basis of this SAR study, we focused on the 2-(2-hydroxyethoxy)ethyl group of compound <b>12</b> at the <i>N</i>-5 position. We selected a trifluoromethyl group <b>j</b> as an anilino substituent on the terminal phenoxy ring, and carried out further optimization of the 2-(2-hydroxyethoxy)ethyl group at the <i>N</i>-5 position.</div><div class="NLM_p">The synthesis of the <i>N</i>-5-hydroxypentyl derivative <b>15</b>, where the ether linkage in <b>12j</b> was replaced with a methylene bridge, is shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Alkylation of compound <b>5</b> with 5-chloropentyl acetate in the presence of cesium carbonate in DMF gave 5-(4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)pentyl acetate (<b>13</b>) in 69% yield. The obtained compound <b>13</b> was reacted with aniline <b>4j</b> in 2-propanol followed by hydrolysis of the acetate group with 1N aqueous NaOH to afford the desired compound <b>15</b> in 79% yield in two steps.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-5 Hydroxypentyl Pyrrolo[3,2-<i>d</i>]pyrimidine derivative <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 5-chloropentyl acetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 69%; (b) <b>4j</b>, 2-PrOH, 80 °C, 14 h; (c) 1N NaOH, rt, 1 h, MeOH, 79% for 2 steps.</p></p></figure><div class="NLM_p">The pyrrolo[3,2-<i>d</i>]pyrimidine derivative <b>20</b> with substitution of the nitrogen atom for <i>N</i>-5 ether oxygen in <b>12j</b> was synthesized as shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Reaction of compound <b>5</b> with 2-bromo-1,1-diethoxyethane gave alkylated product <b>16</b> in 72% yield. The obtained compound <b>16</b> was heated with phenol in the presence of potassium carbonate in NMP to afford phenoxy diethylacetal derivative (<b>17</b>) in excellent yield. After deprotecting the diethylacetal moiety with trifluoroacetic acid, reductive amination of the obtained ethanediol derivative (<b>18</b>) with 2-hydroxyethylamine provided 2-{[2-(4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]amino}ethanol (<b>19</b>) in good yield. Finally, compound <b>19</b> was coupled with aniline <b>4j</b> using pyridinium chloride as an acidic promoter in phenol to afford the desired product <b>20</b> in 19% yield. The low yield was due to formation of tricyclic compound <b>21</b>, resulting from intramolecular cyclization of molecule <b>19</b>, as the major product.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of a <i>N</i>-5 Hydroxyethylaminoethyl Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-bromo-1,1-diethoxyethane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4.5 h, 72%; (b) PhOH, K<sub>2</sub>CO<sub>3</sub>, NMP, 140 °C, 6 h, 95%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 91%; (d) 2-aminoethanol, NaB(OAc)<sub>3</sub>H, AcOH, DMF, rt, 16 h, 52%; (e) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 16 h, 19%.</p></p></figure><div class="NLM_p">The pyrrolo[3,2-<i>d</i>]pyrimidine derivatives <b>28</b>–<b>30</b>, possessing a sulfur atom-containing side chain, were synthesized as shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. The alkylbromide (<b>25</b>) was prepared from 2-iodoethyl benzoate derivative (<b>22</b>) and 2-mercaptoethanol derivative (<b>23</b>), which were coupled in the presence of ethyldiisopropylamine to give the thioether derivative (<b>24</b>) in 77% yield. Bromination of compound <b>24</b> with carbon tetrabromide and triphenylphosphine provided the desired alkylbromide (<b>25</b>) in 76% yield. The obtained alkylbromide derivative (<b>25</b>) was introduced into the <i>N</i>-5 position of compound <b>5</b> in the usual manner to afford adduct <b>26</b> in 80% yield. Compound <b>26</b> was reacted with aniline derivative <b>4j</b> in 2-propanol followed by hydrolysis of the benzoyl ester with 1N aqueous NaOH to afford the thioether derivative <b>28</b> in 59% yield in 2 steps. The sulfoxide (<b>29</b>) was obtained by oxidization of compound <b>28</b> with 3-chloroperbenzoic acid (<i>m</i>CPBA) in 85% yield. Further oxidization of sulfoxide (<b>29</b>) with 70% aqueous <i>tert</i>-butyl hydroperoxide in the presence of titanium tetraisopropoxide provided its sulfone derivative (<b>30</b>) in 74% yield.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of a <i>N</i>-5 Sulfur-Containing Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>28</b>, <b>29</b>, and <b>30</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>iso</i>-Pr<sub>2</sub>EtN, 40 °C, 3 days, 77%; (b) PPh<sub>3</sub>, CBr<sub>4</sub>, rt, 3 days, 76%; (c) <b>5</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 80%; (d) <b>4j</b>, 2-PrOH, 80 °C, 15 h; (e) 1N NaOH, MeOH, rt, 1 h, 59% for 2 steps; (f) <i>m</i>CPBA, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 1 h, 85%; (g) <i>tert</i>-BuO<sub>2</sub>H, Ti(O<sup><i>iso</i></sup>Pr)<sub>4</sub>, MeOH, H<sub>2</sub>O, rt, 2 days, 74%.</p></p></figure><div class="NLM_p">Preparation of the <i>N</i>-5 carboxamide derivatives <b>34a</b>–<b>e</b> has been summarized in Schemes <a class="ref internalNav" href="#sch7" aria-label="7">7</a> and <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. Alkylation of compound <b>5</b> with <i>tert</i>-butyl (2-bromoethyl)carbamate in the usual manner gave intermediate (<b>31a</b>) in 71% yield. Condensation of compound <b>31a</b> with aniline <b>4j</b> was carried out in 2-propanol, followed by deprotecting the terminal Boc group of the obtained molecule <b>32a</b> with 2N aqueous hydrochloric acid (HCl) to afford key intermediate (<b>33a</b>) in 85% yield in 2 steps. Amidation of the key intermediate <b>33a</b> with a variety of carboxylic acids in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (water-soluble carbodiimide, WSC) and 1-hydroxybenzotriazole monohydrate (HOBt) provided the corresponding desired carboxamides (<b>34a</b>, <b>34c</b>, and <b>34e</b>, Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>). Carboxamide <b>34d</b> was isolated a methanesulfonic acid salt. The synthesis of carboxamide <b>34b</b> was achieved using 2-[(<i>tert</i>-butoxycarbonyl)(methyl)amino]ethyl methanesulfonate as an <i>N</i>-5 alkylating agent in a similar manner, shown in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of a <i>N</i>-5 Carboxamido Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>34a</b> and <b>34c</b>–<b>34e</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>tert</i>-butyl (2-bromoethyl)carbamate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 71%; (b) <b>4j</b>, 2-PrOH, 80 °C, 12 h, 85%; (c) 2N HCl, THF, 60 °C, 20 h, quant; (d) WSC, HOBt, Et<sub>3</sub>N, carboxylic acid, DMF, 3 days, 74–86%; (e) MsOH, AcOEt, rt, 2 h, 25% from <b>33a</b>.</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0007.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of a <i>N</i>-5 Carboxamido Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>34b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-[(<i>tert</i>-butoxycarbonyl)(methyl)amino]ethyl methanesulfonate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 33%; (b) <b>4j</b>, 2-PrOH, 80 °C, 12 h, 76%; (c) 2N HCl, THF, 60 °C, 20 h, 91%; (d) WSC, HOBt, Et<sub>3</sub>N, hydroxyacetic acid, DMF, 3 days, 62%.</p></p></figure><div class="NLM_p">Next, we examined the introduction of representative alkyl groups at the <i>C</i>-6 position in <b>12j</b>. The synthesis of the <i>C</i>-6 methyl derivative <b>40</b> is shown in Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>. The Sonogashira cross-coupling reaction of 4-iodo-6-phenoxypyrimidine-5-amine (<b>35</b>) with trimethyl(prop-1-yn-1-yl)silane gave acetylene derivative <b>36</b> in 73% yield. Intramolecular cyclization of compound <b>36</b> with sodium <i>tert</i>-butoxide afforded 6-methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>37</b>) in 67% yield. The obtained molecule (<b>37</b>) was reacted with 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate in the usual manner to afford adduct <b>38</b> in 93% yield. Reaction of compound <b>38</b> with aniline <b>4j</b> followed by hydrolysis of the benzoyl ester with 1N aqueous NaOH afforded the desired product <b>40</b> in good yield.</div><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0008.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of a <i>C</i>-6 Methyl Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) trimethyl(prop-1-yn-1-yl)silane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, KF, DMF, Et<sub>3</sub>N, 60 °C, 16 h, 73%; (b) <i>tert</i>-BuOK, THF, 0 °C, 40 min, 67%; (c) 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 21 h, 93%; (d) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 17 h, 58%; (e) 1N NaOH, MeOH, rt, 2 h, 90%.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a> shows the preparation of the 6-cyano derivative <b>49</b>. The Sonogashira reaction of compound <b>35</b> with 3,3-diethoxyprop-1-yne, followed by intramolecular cyclization using sodium <i>tert</i>-butoxide, provided intermediate <b>42</b>. After deprotecting the diethylacetal group in compound <b>42</b> with 1N aqueous HCl, the aldehyde group of the resulting product <b>43</b> was oxidized with sodium chlorite to provide carboxylic acid (<b>44</b>) in good yield. Conversion of compound <b>44</b> into the acid chloride using thionyl chloride was followed by reaction with ammonia to afford carboxamide (<b>45</b>) in 92% yield. Treatment of compound <b>45</b> with phosphorus oxychloride gave carbonitrile (<b>46</b>) in 61% yield. The obtained product <b>46</b> led to the desired 6-cyano pyrrolo[3,2-<i>d</i>]pyrimidine derivative (<b>49</b>) in a manner similar to that shown in Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>.</div><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0009.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of a <i>C</i>-6 Cyano Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 3,3-diethoxyprop-1-yne, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, MeCN, Et<sub>3</sub>N, rt, 16.5 h, 89%; (b) <i>tert</i>-BuOK, THF, rt, 1.5 h, 51%; (c) 1N HCl, THF, rt, 2 h, 90%; (d) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, DMSO, H<sub>2</sub>O, rt, 2 h, quant; (e) (i) SOCl<sub>2</sub>, 75 °C, 2 h, (ii) NH<sub>3</sub>, THF, 0 °C, 92%; (f) POCl<sub>3</sub>, 70 °C, 1.5 h, 61%; (g) 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 7 h, 61%; (h) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 17 h, 74%; (i) 1N NaOH, MeOH, rt, 1 h, 61%.</p></p></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Biological Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To examine the potential of a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold for use as a HER2/EGFR kinase inhibitor, a variety of substituted 4-anilino derivatives (<b>6a</b>–<b>q</b>) were evaluated. Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>shows their HER2/EGFR kinase and tumor cell growth (BT-474, HER2-overexpressing human breast cancer cell line) inhibitory activities as well as their in vitro human metabolic stability. Almost all of the derivatives showed good HER2/EGFR inhibitory activities with IC<sub>50</sub> values less than 1 μM, especially against HER2. In addition, the reported anilino derivatives <b>6o</b> and <b>6p</b> showed HER2/EGFR dual inhibitory activity, and derivative <b>6q</b> showed HER2-selective activity similar to those of quinazoline analogues.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These results suggested that the <i>N</i>-1/<i>N</i>-3 nitrogen atoms of the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold can interact with the Met801 and Thr862 residues in the hinge region of the HER2 ATP-binding pocket and that the 4-anilino group fits into the lipophilic back pocket as expected by our designs. All anilino substituents at the <i>C</i>-2 or <i>C</i>-3 positions of the phenoxy ring gave rise to better than 130 nM HER2 inhibitory activity, although the cyano group at the <i>C</i>-4 position in <b>6h</b> resulted in reduced HER2/EGFR inhibitory activity. Reflecting their potent inhibitory activities, especially against HER2, a variety of compounds (<b>6b</b>, <b>6e</b>, <b>6f</b>, <b>6g</b>, <b>6j</b>, <b>6l</b>, and <b>6m</b>) showed good growth inhibitory (GI) activity against BT-474 cells with GI<sub>50</sub> values of 480–1100 nM, comparable to those of the reported anilino derivatives <b>6o</b>–<b>q</b>. Among them, we selected the 3-chloro (<b>6e</b>), 3-trifluoromethyl (<b>6j</b>), and 3-trifluoromethoxy (<b>6l</b>) anilino derivatives because these compounds showed good in vitro oxidative metabolic stability against human hepatic microsomes.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Data for <i>C</i>-4-Anilino Substituted Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">enzyme<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">cell growth <a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">metabolic stability <a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" align="center">GI<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" align="center" char=".">μL/min/mg</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">HER2</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center">BT-474</th><th class="colsep0 rowsep0" align="center" char=".">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">16 (13–19)</td><td class="colsep0 rowsep0" align="left">110 (93–130)</td><td class="colsep0 rowsep0" align="left">869 (730–1034)</td><td class="colsep0 rowsep0" align="char" char=".">122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">9.3 (7.3–12)</td><td class="colsep0 rowsep0" align="left">61 (41–90)</td><td class="colsep0 rowsep0" align="left">737 (601–903)</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">20 (15–26)</td><td class="colsep0 rowsep0" align="left">150 (94–250)</td><td class="colsep0 rowsep0" align="left">1267 (1070–1501)</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">11 (7.2–17)</td><td class="colsep0 rowsep0" align="left">27 (18–42)</td><td class="colsep0 rowsep0" align="left">1413 (1181–1692)</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">8.3 (6.4–11)</td><td class="colsep0 rowsep0" align="left">35 (23–51)</td><td class="colsep0 rowsep0" align="left">459 (385–544)</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="left">2-CN</td><td class="colsep0 rowsep0" align="left">8.0 (5.9–11)</td><td class="colsep0 rowsep0" align="left">51 (43–60)</td><td class="colsep0 rowsep0" align="left">956 (835–1094)</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="left">3-CN</td><td class="colsep0 rowsep0" align="left">8.2 (6.1–11)</td><td class="colsep0 rowsep0" align="left">150 (84–280)</td><td class="colsep0 rowsep0" align="left">787 (548–1131)</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">720 (590–880)</td><td class="colsep0 rowsep0" align="left">590 (460–740)</td><td class="colsep0 rowsep0" align="left">4473 (3795–5279)</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6i</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">120 (110–130)</td><td class="colsep0 rowsep0" align="left">150 (110–220)</td><td class="colsep0 rowsep0" align="left">2328 (1918–2828)</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">30 (23–39)</td><td class="colsep0 rowsep0" align="left">67 (40–110)</td><td class="colsep0 rowsep0" align="left">875 (750–1020)</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6k</b></td><td class="colsep0 rowsep0" align="left">2-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">55 (40–76)</td><td class="colsep0 rowsep0" align="left">210 (110–390)</td><td class="colsep0 rowsep0" align="left">2543 (2198–2944)</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6l</b></td><td class="colsep0 rowsep0" align="left">3-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">41(31–56)</td><td class="colsep0 rowsep0" align="left">220 (130–370)</td><td class="colsep0 rowsep0" align="left">1063 (905–1250)</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6m</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4.6 (4–5.3)</td><td class="colsep0 rowsep0" align="left">20 (13–31)</td><td class="colsep0 rowsep0" align="left">762 (605–959)</td><td class="colsep0 rowsep0" align="char" char=".">187</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6n</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">26 (19–36)</td><td class="colsep0 rowsep0" align="left">290 (220–400)</td><td class="colsep0 rowsep0" align="left">1216 (1067–1386)</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6o</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">13 (9.8–17)</td><td class="colsep0 rowsep0" align="left">7.7 (5–12)</td><td class="colsep0 rowsep0" align="left">650 (426–994)</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6p</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">22 (16–30)</td><td class="colsep0 rowsep0" align="left">18 (12–27)</td><td class="colsep0 rowsep0" align="left">1160 (890–1510)</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6q</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">60 (49–73)</td><td class="colsep0 rowsep0" align="left">1900 (1300–2800)</td><td class="colsep0 rowsep0" align="left">2049 (1806–2324)</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">These measurements were showed in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values and 95% confidence intervals (CI) were calculated by nonlinear regression analysis of the percentage inhibitions (<i>n</i> = 2).</p></div></div></div><div class="NLM_p">Next, with the aim of further enhancing their cellular activity, we examined the introduction of <i>N</i>-5 substituents into the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold. As representative <i>N</i>-5 alkyl substituents, methyl (<b>8</b>), 2-hydroxyethyl (<b>10</b>), and 2-(2-hydroxyethoxy)ethyl (<b>12</b>) moieties were selected and their corresponding derivatives with a 3-chloro (<b>e</b>), 3-trifluoromethyl (<b>j</b>), or 3-trifluoromethoxy (<b>l</b>) anilino group were evaluated. These results are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Introduction of these substituents at the <i>N</i>-5 position maintained the potent HER2/EGFR inhibitory activities. This result was consistent with our design that <i>N</i>-5 chemical modifications would be directed toward the solvent contact region of the HER2/EGFR kinases. On the other hand, their cellular activity had a tendency to be higher when the molecule had a longer side chain. Among the prepared compounds, the 2-(2-hydroxyethoxy)ethyl derivatives <b>12e</b>–<b>l</b> showed significantly more potent cell growth inhibitory activity than those of the corresponding derivatives <b>8</b> and <b>10</b>. In addition, compounds <b>12e</b>–<b>l</b> showed acceptable metabolic stability and PK profiles in mice. On the basis of its potent GI activity and PK profile in mice, we selected the 3-trifluoromethyl derivative <b>12j</b> as lead compound for further optimization. Compared with <b>12j</b>, the pyridine analogue <b>12r</b> reduced EGFR inhibitory activity together with cellular GI activity. As cocrystal structure<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> of <b>12r</b> with HER2 was successfully obtained, we focused on structural discussions of EGFR.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Data for <i>N</i>5- and <i>C</i>4-Substituted Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">enzyme <a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#tbl2-fn1" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">cell growth<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">metabolic stability<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" align="center">GI<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">μL/min/mg</th><th class="rowsep1 colsep0" align="center" char=".">AUC<sub>0–8 h</sub><a class="ref internalNav" href="#t2fn2" aria-label="c">c</a>μg·h/mL</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">HER2</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center">BT-474</th><th class="colsep0 rowsep0" align="center" char=".">mice</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">mice</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.3 (2.6–4.3)</td><td class="colsep0 rowsep0" align="left">9.2 (5.9–14)</td><td class="colsep0 rowsep0" align="left">184 (142–232)</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8j</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11 (8.9–14)</td><td class="colsep0 rowsep0" align="left">27 (20–37)</td><td class="colsep0 rowsep0" align="left">692 (565–846)</td><td class="colsep0 rowsep0" align="char" char=".">–13</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">4.545</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8l</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">17 (12–25)</td><td class="colsep0 rowsep0" align="left">50 (36–69)</td><td class="colsep0 rowsep0" align="left">1884 (1750–2028)</td><td class="colsep0 rowsep0" align="char" char=".">–9</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2- hydroxy ethyl</td><td class="colsep0 rowsep0" align="left">4.1 (3.5–4.7)</td><td class="colsep0 rowsep0" align="left">9.5 (5.9–15)</td><td class="colsep0 rowsep0" align="left">97 (81–115)</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">1.882</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10j</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12 (11–14)</td><td class="colsep0 rowsep0" align="left">34 (26–44)</td><td class="colsep0 rowsep0" align="left">212 (179–249)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">6.381</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10l</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">29 (23–38)</td><td class="colsep0 rowsep0" align="left">110 (68–180)</td><td class="colsep0 rowsep0" align="left">582 (481–704)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">11.546</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">2-(2- hydroxy ethoxy) ethyl</td><td class="colsep0 rowsep0" align="left">2.1 (1.8–2.5)</td><td class="colsep0 rowsep0" align="left">5.7 (4.1–8)</td><td class="colsep0 rowsep0" align="left">54 (46–63)</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">2.633</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5.1 (4.1–6.3)</td><td class="colsep0 rowsep0" align="left">15 (11–21)</td><td class="colsep0 rowsep0" align="left">27 (21–33)</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">3.324</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.4 (5.8–12)</td><td class="colsep0 rowsep0" align="left">49 (31–78)</td><td class="colsep0 rowsep0" align="left">116 (100–132)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">3.342</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12r</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11 (7.8–15)</td><td class="colsep0 rowsep0" align="left">420 (170–1000)</td><td class="colsep0 rowsep0" align="left">2170 (1978–2382)</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">3.996</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">These measurements were showed in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="tbl2-fn1"><sup>b</sup><p class="last">IC<sub>50</sub> values and 95% confidence intervals (CI) were calculated by nonlinear regression analysis of the percentage inhibitions (<i>n</i> = 2).</p></div><div class="footnote" id="t2fn2"><sup>c</sup><p class="last">The animals used in the study were female BALB/cAJcl mice (7-weeks old; CLEA Japan, Inc.). A mixture of 5 test compounds was suspended in 0.5% (w/v) methylcellulose solution for oral administration at a dose of 10 mg each/10 mL/kg. The concentrations of compounds in the plasma were determined by LC/MS/MS.</p></div></div></div><div class="NLM_p">Considering the in vivo oxidative metabolism in the ether linkage of <i>N</i>-5 2-(2-hydroxyethoxy)ethyl moiety in <b>12j</b>, we focused on replacement of its ether oxygen with a carbon, nitrogen, and sulfur atom. Furthermore, to investigate substituent effects at the <i>C</i>-6 position of the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold, we introduced representative methyl (<b>40</b>) and cyano groups (<b>49</b>) to <b>12j</b>. These results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Similar to the 2-(2-hydroxyethoxy)ethyl moiety in <b>12j</b>, replacement of its ether oxygen with carbon (<b>15</b>), nitrogen (<b>20</b>), and sulfur (<b>28</b>–<b>30</b>) maintained good HER2/EGFR kinase inhibitory activities. On the other hand, these derivatives showed reduced GI activity compared with <b>12j</b>, although polar linkages such as sulfoxide (<b>29</b>) and sulfone (<b>30</b>) moieties improved the human metabolic stability. We believed that log <i>D</i> at pH 7.4 would be an important factor for enhancing their GI activity. In addition, introduction of the methyl (<b>40</b>) and cyano (<b>49</b>) group at the <i>C</i>-6 position led to a decrease of the cellular GI activities.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Data for <i>C</i>6-, <i>N</i>5-, and <i>C</i>4-Substituted Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">enzyme<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#tbl3-fn1" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">cell growth<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">metabolic stability<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">PK</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" align="center">GI<sub>50</sub> (nM) (95% CI)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">μL/min/mg</th><th class="rowsep1 colsep0" align="center" char=".">AUC<sub>0–8h</sub><a class="ref internalNav" href="#tbl3-fn2" aria-label="c">c</a>μg·h/mL</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">HER2</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center">BT-474</th><th class="colsep0 rowsep0" align="center" char=".">mice</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">mice</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i> pH 7.4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5.1 (4.1–6.3)</td><td class="colsep0 rowsep0" align="left">15 (11–21)</td><td class="colsep0 rowsep0" align="left">27 (21–33)</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">3.324</td><td class="colsep0 rowsep0" align="char" char=".">3.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">15 (12–19)</td><td class="colsep0 rowsep0" align="left">33 (25–45)</td><td class="colsep0 rowsep0" align="left">406 (337–487)</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">0.856</td><td class="colsep0 rowsep0" align="char" char=".">4.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">7.7 (5.3–11)</td><td class="colsep0 rowsep0" align="left">22 (15–32)</td><td class="colsep0 rowsep0" align="left">601 (561–643)</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">2.476</td><td class="colsep0 rowsep0" align="char" char=".">3.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">9.4 (7.4–12)</td><td class="colsep0 rowsep0" align="left">44 (26–73)</td><td class="colsep0 rowsep0" align="left">699 (604–807)</td><td class="colsep0 rowsep0" align="char" char=".">163</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">0.284</td><td class="colsep0 rowsep0" align="char" char=".">4.77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">SO</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">12 (11–15)</td><td class="colsep0 rowsep0" align="left">31 (25–40)</td><td class="colsep0 rowsep0" align="left">1378 (1284–1479)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">2.272</td><td class="colsep0 rowsep0" align="char" char=".">2.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">12 (10–14)</td><td class="colsep0 rowsep0" align="left">40 (32–49)</td><td class="colsep0 rowsep0" align="left">1076 (991–1168)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">2.080</td><td class="colsep0 rowsep0" align="char" char=".">3.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">12 (10–15)</td><td class="colsep0 rowsep0" align="left">38 (26–56)</td><td class="colsep0 rowsep0" align="left">69 (37–105)</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">1.607</td><td class="colsep0 rowsep0" align="char" char=".">4.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">19 (12–29)</td><td class="colsep0 rowsep0" align="left">230 (75–690)</td><td class="colsep0 rowsep0" align="left">1143 (1025–1274)</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">4.425</td><td class="colsep0 rowsep0" align="char" char=".">3.62</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">These measurements were showed in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="tbl3-fn1"><sup>b</sup><p class="last">IC<sub>50</sub> values and 95% confidence intervals (CI) were calculated by nonlinear regression analysis of the percentage inhibitions (<i>n</i> = 2).</p></div><div class="footnote" id="tbl3-fn2"><sup>c</sup><p class="last">The animals used in the study were female BALB/cAJcl mice (7-weeks old; CLEA Japan, Inc.). A mixture of 5 test compounds was suspended in 0.5% (w/v) methylcellulose solution for oral administration at a dose of 10 mg each/10 mL/kg. The concentrations of compounds in the plasma were determined by LC/MS/MS.</p></div></div></div><div class="NLM_p">With the aim of pursuing compatibility between cellular activity and metabolic stability, we envisioned that replacement of the ether with a carboxamide linkage could provide a good profile with favorable polarity for our purpose (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). These prepared derivatives (<b>34a</b>–<b>e</b>) were found to show potent HER2/EGFR inhibitory activities. Although the 2-hydroxyacetamide derivatives <b>34a</b>,<b>b</b> (log <i>D</i> at pH 7.4: 3.45–3.51) showed slightly reduced cellular activity, higher lipophilicity, comparable to that of <b>12j</b>, could be achieved by the addition of a methyl or methylene group to the side chain to recover cellular GI activity (<b>34c</b>–<b>e</b>, log <i>D</i> at pH 7.4: 3.54–4.18).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Data for <i>N</i>5- and <i>C</i>4-Substituted Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0024.gif" alt="" id="GRAPHIC-d771e2969-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>Table a</sup><p class="last">These measurements were showed in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="tbl4-fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> values and 95% confidence intervals (CI) were calculated by nonlinear regression analysis of the percentage inhibitions (<i>n</i> = 2).</p></div><div class="footnote" id="tbl4-fn3"><sup>Table c</sup><p class="last">The animals used in the study were female BALB/cAJcl mice (7-weeks old; CLEA Japan, Inc.). A mixture of 5 test compounds was suspended in 0.5% (w/v) methylcellulose solution for oral administration at a dose of 10 mg each/10 mL/kg. The concentrations of compounds in the plasma were determined by LC/MS/MS.</p></div><div class="footnote" id="tbl4-fn4"><sup>Table d</sup><p class="last">Compounds suspended in a 0.5% (w/v) methylcellulose solution was administered orally twice daily (100 mg/kg) to the BT-474 xenograft mice for 14 days.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>34c</b>–<b>e</b>, together with <b>12j</b>, were selected for in vivo efficacy studies in a HER2-overexpressing BT-474 tumor xenograft mouse model (100 mg/kg, twice daily, orally for 14 days). Among these compounds, <b>34e</b> and <b>12j</b> exhibited significant in vivo efficacy (tumor/control ratio [T/C]): 29% and 48%, respectively,) without body weight loss (data not shown). On the basis of its potent in vivo efficacy and good in vitro profiles, <b>34e</b> was selected as a candidate for further investigation.</div><div class="NLM_p">As shown in Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, <b>34e</b> was evaluated using 4–1ST (HER2-overexpressing human gastric cancer tumor) xenograft models in mice and rats. Similar to the BT-474 model, <b>34e</b> exhibited dose-dependent tumor growth inhibition (T/C: 44% and 11% at 50 and 100 mg/kg, twice daily, respectively) without significant body weight loss in mice (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Furthermore, <b>34e</b> showed potent in vivo efficacy in rats in a dose-dependent manner and inhibited the growth of 4–1ST tumors with T/C of 38% and 14% at doses of 6.25 and 12.5 mg/kg and, particularly noteworthy, tumor regression with T/C of −12% and −16% at doses of 25 and 50 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). During the study, <b>34e</b> caused no significant body weight loss in rats (data not shown).</div><figure id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0018.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor efficacy of <b>34e</b> in 4–1ST xenograft models in mice. Dose levels 50 and 100 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0019.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor efficacy of <b>34e</b> in 4–1ST xenograft models in rats. (A) Dose levels 6.25 mg/kg and 12.5 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test). (B) Dose levels 25 and 50 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To clarify the potent efficacy of <b>34e</b>, we investigated the pharmacokinetic profile of <b>34e</b> in mice and rats, which is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. The oral bioavailability of <b>34e</b> was 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. In addition, we found that the concentration of <b>34e</b> in the tumor was much higher than that in the plasma of rats (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Consequently, we concluded that the potent efficacy of <b>34e</b> was achieved by a combination of good PK profiles and high concentration levels of <b>34e</b> in the tumor. These results suggested that <b>34e</b> is a promising candidate for further evaluation.</div><figure id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0020.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Concentration of <b>34e</b> in tumor (μg/g) and plasma (μg/mL) in rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of <b>34e</b> in Rats and Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IV (5 mg/kg)</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">PO (50 mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>5 min</sub> (μg/mL)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–24h</sub>(μg·h/mL)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MRT (h)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/mL)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–24 h</sub>(μg·h/mL)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">BA (%)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">2.277</td><td class="colsep0 rowsep0" align="char" char=".">5.63</td><td class="colsep0 rowsep0" align="char" char=".">3.39</td><td class="colsep0 rowsep0" align="char" char=".">4.157</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">55.03</td><td class="colsep0 rowsep0" align="char" char=".">97.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">4.060</td><td class="colsep0 rowsep0" align="char" char=".">2.72</td><td class="colsep0 rowsep0" align="char" char=".">0.96</td><td class="colsep0 rowsep0" align="char" char=".">4.364</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">19.64</td><td class="colsep0 rowsep0" align="char" char=".">72.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Plasma concentration at 5 min after dosing.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Area under the plasma concentration–time curve for 0–24 h after dosing.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Mean residual time of <b>34e</b> in the plasma.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Maximum plasma concentration after oral dosing.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Time to reach <i>C</i><sub>max</sub>.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">Bioavailability.</p></div></div></div><div class="NLM_p">The inhibitory activity of <b>34e</b> against various kinases is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Besides HER2 and EGFR, <b>34e</b> exhibited HER4 inhibitory activity with an IC<sub>50</sub> value of 260 nM. With these results, we confirmed that <b>34e</b> is a selective HER family inhibitor.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Selectivity of <b>34e</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR (HER1)</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="char" char=".">2400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">CSK</td><td class="colsep0 rowsep0" align="char" char=".">4700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4</td><td class="colsep0 rowsep0" align="char" char=".">260</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="left">Lyn A</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEK5</td><td class="colsep0 rowsep0" align="char" char=".">5700</td><td class="colsep0 rowsep0" align="left">Lyn B</td><td class="colsep0 rowsep0" align="char" char=".">5200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="char" char=".">4200</td><td class="colsep0 rowsep0" align="left">ASK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="char" char=".">1700</td><td class="colsep0 rowsep0" align="left">TAK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">MEKK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR 2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">IKK bata</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">JNK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR 3</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">ERK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR α</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">P38 alpha</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR β</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRK</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">PKC thete</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TIE2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">GSK3 beta</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-kit</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">B-raf</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF-1R</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">TTK</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="left">PLK 1</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr></tbody></table></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Structural Analysis and Discussion for Compound <b>34e</b> and <b>12r</b></h3><div class="NLM_p">The crystal structures of a pyridine analogue <b>12r</b> in complex with HER2 and <b>34e</b> in complex with EGFR were described previously by Aertgeerts et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although the resolution is still low (3.21 Å), we also determined the cocrystal structure of <b>34e</b> with HER2<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and a cartoon presentation is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A. This is the first time that crystal structures have been reported for both HER2 and EGFR in complex with the same inhibitor. From the two cocrystal structures of <b>34e</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A,B), we confirmed that the <i>N</i>-1 nitrogen of the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold was hydrogen-bonded to the main chain NH of the hinge region (Met801 in HER2 or Met793 in EGFR), whereas the <i>N</i>-3 nitrogen formed a water-mediated hydrogen bond network only with the side chain of Thr854 in EGFR. In the case of <b>34e</b> with HER2, this hydrogen bond network by the <i>N</i>-3 nitrogen was not observed, probably because of a moderate resolution level. The bulky 3-trifluoromethyl phenyl group of <b>34e</b> was not accommodated in the active form of both kinases and likely displaced the C-helix away from its position in the active conformation. Compared with the crystal structure of the pyridine analogue <b>12r</b> with HER2 (2.25 Å, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C), <b>34e</b> showed similar interactions to that of <b>12r</b>, which formed a water-mediated hydrogen bond network with the side chain of Thr862. In addition, the 4-anilino groups of <b>34e</b> and <b>12r</b> occupied the same hydrophobic pocket formed by the side chain of amino acids near the DFG motif, and a remarkable difference was observed at the conformation of 3-trifluoromethyl phenyl group. The 3-trifluoromethyl group in <b>12r</b> was flipped by approximately 150° relative to its orientation in both the HER2/<b>34e</b> and EGFR/<b>34e</b> structures. In the costructure of <b>12r</b> with HER2, the nitrogen in the pyridine ring interacted with the main chain of Asp863 in the DFG motif. Furthermore, hydroxy group of R<sup>2</sup> side chain of <b>12r</b> was also hydrogen bonded with the side chain of Asp863. As a result, the conformation of the DFG motif in the HER2/<b>12r</b> was slightly different from those of the HER2/<b>34e</b> and EGFR/<b>34e</b> structures, which was considered to lead to the flip of 3-trifluoromethyl group. This difference may contribute to the difference between HER2 and EGFR inhibitory activity in <b>12r</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). It was noted that HER2/<b>34e</b> and EGFR/<b>34e</b> structures were inactive conformations with a DFG-in and C-helix-out conformation similar to that of the EGFR/Lapatinib structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>).</div><figure id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0021.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray cocrystal structures of compound <b>34e</b> (TAK-285) with HER2 (A) and EGFR (B), together with that of compound <b>12r</b> with HER2 (C).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The <i>N</i>-5-substituents containing a carboxamide moiety of <b>34e</b> is suitably positioned at the solvent interface for both HER2 and EGFR with small conformational differences. Thus, a dramatic difference between the HER2 and EGFR cocrystal structures of <b>34e</b> was not observed. From the structural similarities found for the binding mode of <b>34e</b> to the HER2 and EGFR kinases, we confirmed that <b>34e</b> is an ATP-competitive HER2/EGFR dual inhibitor.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We designed pyrrolo[3,2-<i>d</i>]pyrimidine derivatives and modified them chemically to develop novel HER2/EGFR TKIs. As expected, the prepared derivatives showed good HER2 and EGFR inhibitory activities. On the basis of results from <i>N</i>-5 side chain optimization studies, we selected <b>34e</b> for further evaluation. From the X-ray cocrystal structures of <b>34e</b> with both HER2 and EGFR, we confirmed that the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold fits into the ATP pocket and that the <i>N</i>-1 nitrogen interact with Met801 of HER2 or Met793 of EGFR. In a further investigation, <b>34e</b> exhibited potent and selective kinase inhibitory profiles against the HER family as well as good cellular GI activity. Reflecting its desirable cellular activity, metabolic stability, and good PK profiles, <b>34e</b> showed potent in vivo antitumor efficacy in mice and rats. These data combined with our preliminary studies revealing that the HER2 inhibitory activity of <b>34e</b> compares favorably to that of lapatinib<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and is superior to that of erlotinib<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> support the position that compound <b>34e</b> is a promising candidate for clinical development as a dual HER2/EGFR inhibitor. Compound <b>34e</b> (TAK-285) is currently in phase 1 clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Melting points were determined on a Yanagimoto micro melting point apparatus or SRS OptiMelt melting point apparatus and are uncorrected. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Varian Gemini-200 (200 MHz) spectrometer or Varian Mercury-300 (300 MHz) spectrometer. Chemical shifts are given in parts per million (ppm) with tetramethylsilane as an internal standard, and coupling constants (<i>J</i> values) are given in hertz (Hz). Splitting patterns and apparent multiplicities are designated as s (singlet), d (doublet), dd (double doublet), t (triplet), dt (double triplet), q (quartet), m (multiplet), br s (broad singlet). Elemental analyses were carried out by Takeda Analytical Research Laboratories, Ltd., and the results obtained were within ±0.4% of the theoretical values. MS spectra were collected with a Waters LC-MS system (ZMD-1) and were used to confirm ≥95% purity of each compound. The column used was an L-column 2 ODS (3.0 mm × 50 mm I.D., CERI, Japan) with a temperature of 40 °C and a flow rate of 1.2 mL/min. Mobile phase A was 0.05% TFA in ultrapure water. Mobile phase B was 0.05% TFA in acetonitrile, which was increased linearly from 5% to 90% over 2 min, 90% over the next 1.5 min, after which the column was equilibrated to 5% for 0.5 min.</div><div class="NLM_p">Column chromatography was carried out on a silica gel column (Kieselgel 60, 63–200 mesh, Merck or Chromatorex NH-DM1020, 100–200 mesh, Fuji Silysia Chemical, Ltd., Japan). Yields were not optimized.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3-Chloro-4-phenoxyaniline (<b>4a</b>)</h3><div class="NLM_p">To a mixture of 2-chloro-1-fluoro-4-nitrobenzene (<b>1</b>, 1.75 g, 10.0 mmol) and potassium carbonate (2.07 g, 10.0 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) (20 mL) was added phenol (<b>2a</b>, 941 mg, 10.0 mmol). After being stirred at 80 °C for 2 h, water (40 mL) was added to the mixture and the mixture was extracted with ethyl acetate (EtOAc). The organic layer was washed with saturated brine (30 mL), dried over anhydrous magnesium sulfate (MgSO<sub>4</sub>), and concentrated in vacuo to give <b>3a</b> (2.32 g) as brown oil. To a solution of <b>3a</b> (2.32 g, 9.31 mmol) in EtOAc (50 mL) was added 5% platinum–carbon (Pt–C) (200 mg), and the mixture was stirred under hydrogen atmosphere at room temperature for 2 h. After 5% Pt–C was filtered off, the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:9 to 5:5) to give 1.96 g (89%) of <b>4a</b> as brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.65 (br s, 2H), 6.56 (dd, 1H, <i>J</i> = 8.6, 2.7 Hz), 6.79 (d, 1H, <i>J</i> = 2.7 Hz), 6.84–6.95 (m, 3H), 6.98–7.06 (m, 1H), 7.19–7.35 (m, 2H).</div><div class="NLM_p last">The following compounds (<b>4b</b>–<b>4e</b>, <b>4i</b>–<b>4n</b>) were prepared from <b>1</b> and the corresponding phenols (<b>2b</b>–<b>2e</b>, <b>2i</b>–<b>2n</b>) by a method similar to that described for <b>4a</b>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-Chloro-4-(2-fluorophenoxy)aniline (<b>4b</b>)</h3><div class="NLM_p last">Yield 89%, brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.65 (br s, 2H), 6.55 (dd, 1H, <i>J</i> = 8.6, 2.7 Hz), 6.70–6.82 (m, 2H), 6.86 (d, 1H, <i>J</i> = 8.6 Hz), 6.96–7.04 (m, 2H), 7.10–7.21 (m, 1H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-Chloro-4-(3-fluorophenoxy)aniline (<b>4c</b>)</h3><div class="NLM_p last">Yield 76%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.69 (br s, 2H), 6.50–6.81 (m, 5H), 6.92 (d, 1H, <i>J</i> = 8.7 Hz), 7.14–7.28 (m, 1H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3-Chloro-4-(2-chlorophenoxy)aniline (<b>4d</b>)</h3><div class="NLM_p last">Yield 97%, brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.69 (br s, 2H), 6.56 (dd, 1H, <i>J</i> = 8.7, 2.8 Hz), 6.68 (dd, 1H, <i>J</i> = 8.0, 1.5 Hz), 6.79 (d, 1H, <i>J</i> = 2.8 Hz), 6.86 (d, 1H, <i>J</i> = 8.7 Hz), 6.94–7.04 (m, 1H), 7.07–7.17 (m, 1H), 7.42 (dd, 1H, <i>J</i> = 8.0, 1.5 Hz).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-Chloro-4-(3-chlorophenoxy)aniline (<b>4e</b>)</h3><div class="NLM_p last">Yield 65%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (br s, 2H), 6.58 (dd, 1H, <i>J</i> = 8.6, 2.7 Hz), 6.73–7.04 (m, 5H), 7.19 (t, 1H, <i>J</i> = 8.6 Hz).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-Chloro-4-[2-(trifluoromethyl)phenoxy]aniline (<b>4i</b>)</h3><div class="NLM_p last">Yield 84%, yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (br s, 2H), 6.53–6.69 (m, 2H), 6.79 (d, 1H, <i>J</i> = 2.6 Hz), 6.92 (d, 1H, <i>J</i> = 8.7 Hz), 7.07 (t, 1H, <i>J</i> = 7.6 Hz), 7.34–7.42 (m, 1H), 7.64 (dd, 1H, <i>J</i> = 7.6, 0.9 Hz).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-Chloro-4-[3-(trifluoromethyl)phenoxy]aniline (<b>4j</b>)</h3><div class="NLM_p last">Yield 72%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.71 (br s, 2H), 6.59 (dd, 1H, <i>J</i> = 8.6, 2.7 Hz), 6.80 (d, 1H, <i>J</i> = 2.7 Hz), 6.92 (d, 1H, <i>J</i> = 8.6 Hz), 7.03 (dd, 1H, <i>J</i> = 8.0, 2.1 Hz), 7.10 (s, 1H), 7.23–7.32 (m, 1H), 7.38 (t, 1H, <i>J</i> = 8.0 Hz).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-Chloro-4-[2-(trifluoromethoxy)phenoxy]aniline (<b>4k</b>)</h3><div class="NLM_p last">Yield 96%, brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.68 (br s, 2H), 6.57 (dd, 1H, <i>J</i> = 8.7, 2.6 Hz), 6.69 (dd, 1H, <i>J</i> = 8.2, 1.6 Hz), 6.79 (d, 1H, <i>J</i> = 2.6 Hz), 6.87 (d, 1H, <i>J</i> = 8.7 Hz), 6.97–7.08 (m, 1H), 7.11–7.20 (m, 1H), 7.28–7.35 (m, 1H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-Chloro-4-[3-(trifluoromethoxy)phenoxy]aniline (<b>4l</b>)</h3><div class="NLM_p last">Yield 61%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.70 (br s, 2H), 6.59 (dd, 1H, <i>J</i> = 8.7, 2.8 Hz), 6.73 (s, 1H), 6.76–6.96 (m, 4H), 7.23–7.33 (m, 1H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-Chloro-4-(3-methylphenoxy)aniline (<b>4m</b>)</h3><div class="NLM_p last">Yield 92%, white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.31 (s, 3H), 3.65 (br s, 2H), 6.56 (dd, 1H, <i>J</i> = 8.7, 2.6 Hz), 6.63–6.93 (m, 5H), 7.16 (t, 1H, <i>J</i> = 7.8 Hz).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-Chloro-4-(3-methoxyphenoxy)aniline (<b>4n</b>)</h3><div class="NLM_p last">Yield 99%, brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.66 (br s, 2H), 3.77 (s, 3H), 6.42–6.50 (m, 2H), 6.53–6.61 (m, 2H), 6.78 (d, 1H, <i>J</i> = 2.6 Hz), 6.91 (d, 1H, <i>J</i> = 8.7 Hz), 7.17 (t, 1H, <i>J</i> = 8.1 Hz).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-(4-Amino-2-chlorophenoxy)benzonitrile (<b>4f</b>)</h3><div class="NLM_p">To a mixture of <b>1</b> (4.40 g, 184 mmol) and potassium carbonate (5.20 g, 221 mmol) in DMF (60 mL) was added 2-hydroxybenzonitrile (<b>2f</b>, 3.00 g, 257 mmol). After being stirred at 100 °C for 2 h, water (300 mL) was added to the mixture under ice-cooling and the mixture was stirred at room temperature for 10 min. The resulting precipitate was collected by filtration. The precipitate was washed with <i>n</i>-hexane and dried under vacuum to give a yellow cake. To a suspension of the cake and reduced iron (8.80 g) in EtOH (90 mL) was added a solution of calcium chloride (1.50 g, 257 mmol) in water (10 mL), and the reaction mixture was stirred at 100 °C for 15 h. The solid was removed by filtration, and the resulting filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 2:8 to 10:0) to give 3.50 g (65%) of <b>4f</b> as brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.78 (br s, 2H), 6.58–6.65 (m, 2H), 6.76 (d, 1H, <i>J</i> = 2.7 Hz), 6.97 (d, 1H, <i>J</i> = 8.4 Hz), 7.04–7.10 (m, 1H), 7.39–7.45 (m, 1H), 7.62–7.65 (m, 1H).</div><div class="NLM_p last">The following compounds (<b>4g</b>,<b>4h</b>) were prepared from <b>1</b> and the corresponding phenols (<b>4g</b>,<b>4h</b>) by a method similar to that described for <b>4f</b>.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-(4-Amino-2-chlorophenoxy)benzonitrile (<b>4g</b>)</h3><div class="NLM_p last">Yield 71%, yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.75 (br s, 2H), 6.58–6.62 (m, 1H), 6.79 (d, 1H, <i>J</i> = 2.7 Hz), 6.92 (d, 1H, <i>J</i> = 8.4 Hz), 7.05–7.16 (m, 2H), 7.26–7.41 (m, 2H).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-(4-Amino-2-chlorophenoxy)benzonitrile (<b>4h</b>)</h3><div class="NLM_p last">Yield 56%, beige solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.76 (br s, 2H), 6.60 (dd, 1H, <i>J</i> = 8.6, 2.7 Hz), 6.79 (d, 1H, <i>J</i> = 2.7 Hz), 6.84–7.00 (m, 3H), 7.51–7.62 (m, 2H).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 5-Chloro-6-[3-(trifluoromethyl)phenoxy]pyridin-3-amine (<b>4r</b>)</h3><div class="NLM_p last">To a solution of <b>2j</b> (0.42 g, 2.59 mmol) in THF (8.0 mL) was added NaH (60% dispersion in mineral oil, 0.11 g, 2.75 mmol) under ice-cooling. After being stirred for 1 h, to the reaction mixture was added 2,3-dichloro-5-nitropyridine (0.50 g, 2.61 mmol). The reaction mixture was stirred at room temperature for 2.5 h. Water (100 mL) was added to the reaction mixture, and then the mixture was extracted with EtOAc (200 mL). The organic layer was washed with saturated brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:9 to 3:1) to give colorless oil. To a suspension of the oil and reduced iron (0.65 g, 11.6 mmol) in a mixture of EtOH (19.5 mL) and water (3.5 mL) was added calcium chloride (0.13 g, 1.17 mmol), and the mixture was stirred at 80 °C for 8 h. The solid was removed by filtration, and filtrate was poured into water (100 mL). The organic layer was washed with saturated brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:4 to 1:1) to give 0.29 g (39%) of <b>4r</b> as brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.65 (br s, 2H), 7.20 (d, 1H, <i>J</i> = 2.9 Hz), 7.22–7.26 (m, 1H), 7.27–7.32 (m, 1H), 7.37–7.40 (m, 1H), 7.44–7.50 (m, 1H), 7.59 (d, 1H, <i>J</i> = 2.9 Hz).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(3-Chloro-4-phenoxyphenyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6a</b>)</h3><div class="NLM_p">A solution of <b>4a</b> (264 mg, 1.20 mmol) and 4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<b>5</b>, 154 mg, 1.00 mmol) in 1-methyl-2-pyrrolidone (3.0 mL) was stirred with heating at 100 °C for 3 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (80 mL) and partitioned with saturated sodium hydrogen carbonate (30 mL). The organic layer was washed with brine (30 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 5:95) to give 105 mg (31%) of <b>6a</b> as colorless crystals, mp 247–250 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.51 (br s, 1H), 6.94 (d, 2H, <i>J</i> = 7.9 Hz), 7.10 (t, 1H, <i>J</i> = 7.3 Hz), 7.20 (d, 1H, <i>J</i> = 8.9 Hz), 7.31–7.45 (m, 2H), 7.63–7.73 (m, 2H), 8.32–8.43 (m, 2H), 9.47 (br s, 1H), 11.17 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O: C, 64.19; H, 3.89; N, 16.64. Found: C, 63.81; H, 3.91; N, 16.66.</div><div class="NLM_p last">The following compounds (<b>6b</b>–<b>6q</b>) were prepared from corresponding <b>4b</b>–<b>4q</b> and <b>5</b> by a method similar to that described for <b>6a</b>.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-[3-Chloro-4-(2-fluorophenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6b</b>)</h3><div class="NLM_p last">Yield 51%, colorless crystals, mp 282–285 °C.<sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.50 (dd, 1H, <i>J</i> = 2.9, 2.0 Hz), 6.90–7.03 (m, 1H), 7.09–7.25 (m, 3H), 7.33–7.49 (m, 1H), 7.55–7.73 (m, 2H), 8.39 (s, 2H), 9.41 (br s, 1H), 11.08 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>ClFN<sub>4</sub>O: C, 60.94; H, 3.41; N, 15.79. Found: C, 61.03; H, 3.43; N, 15.65.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-[3-Chloro-4-(3-fluorophenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6c</b>)</h3><div class="NLM_p last">Yield 74%, colorless crystals, mp 239–241 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.46–6.54 (m, 1H), 6.70–6.85 (m, 2H), 6.89–7.02 (m, 1H), 7.29 (d, 1H, <i>J</i> = 8.9 Hz), 7.34–7.45 (m, 1H), 7.62–7.76 (m, 2H), 8.36–8.43 (m, 2H), 9.47 (s, 1H), 11.11 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>ClFN<sub>4</sub>O: C, 60.94; H, 3.41; N, 15.79. Found: C, 61.00; H, 3.41; N, 15.81.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-[3-Chloro-4-(2-chlorophenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6d</b>)</h3><div class="NLM_p last">Yield 33%, colorless crystals, mp 251–254 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.51 (dd, 1H, <i>J</i> = 2.8, 2.1 Hz), 6.88 (dd, 1H, <i>J</i> = 8.2, 1.4 Hz), 7.09–7.21 (m, 2H), 7.28–7.37 (m, 1H), 7.56–7.74 (m, 3H), 8.40 (s, 2H), 9.44 (br s, 1H), 11.09 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O: C, 58.24; H, 3.26; N, 15.09. Found: C, 58.31; H, 3.32; N, 14.98.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-[3-Chloro-4-(3-chlorophenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6e</b>)</h3><div class="NLM_p last">Yield 71%, colorless crystals, mp 229–231 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.51 (dd, 1H, <i>J</i> = 2.8, 2.2 Hz), 6.84–6.95 (m, 1H), 6.99 (t, 1H, <i>J</i> = 2.2 Hz), 7.17 (dd, 1H, <i>J</i> = 8.0, 1.1 Hz), 7.30 (d, 1H, <i>J</i> = 8.9 Hz), 7.40 (t, 1H, <i>J</i> = 8.0 Hz), 7.65–7.75 (m, 2H), 8.32–8.42 (m, 2H), 9.47 (br s, 1H), 11.11 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O: C, 58.24; H, 3.26; N, 15.09. Found: C, 58.25; H, 3.22; N, 15.17.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-[2-Chloro-4-(5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-ylamino)phenoxy]benzonitrile (<b>6f</b>)</h3><div class="NLM_p last">Yield 61%, yellow crystals, mp 264–266 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.50 (s, 1H, s), 6.85 (d, 1H, <i>J</i> = 8.4 Hz), 7.22–7.60 (m, 2H), 7.65–7.74 (m, 3H), 7.88 (d, 1H, <i>J</i> = 7.8 Hz), 8.40 (s, 2H), 9.50 (br s, 1H), 11.09 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClN<sub>5</sub>O: C, 63.08; H, 3.34; N, 19.36. Found: C, 63.10; H, 3.25; N, 19.15.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-[2-Chloro-4-(5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-ylamino)phenoxy]benzonitrile (<b>6g</b>)</h3><div class="NLM_p last">Yield 71%, yellow crystals, mp 273–275 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.53 (s, 1H), 7.26 (m, 1H), 7.32 (d, 1H, <i>J</i> = 8.7 Hz), 7.45 (s, 1H), 7.58 (d, 2H, <i>J</i> = 5.7 Hz), 7.70–7.73 (m, 2H), 8.41 (s, 2H), 9.50 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClN<sub>5</sub>O: C, 63.08; H, 3.34; N, 19.36. Found: C, 62.97; H, 3.30; N, 19.48.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-[2-Chloro-4-(5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-ylamino)phenoxy]benzonitrile (<b>6h</b>)</h3><div class="NLM_p last">Yield 48%, yellow crystals, mp 318 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.52 (dd, 1H, <i>J</i> = 3.0, 1.9 Hz), 6.99–7.18 (m, 2H), 7.37 (d, 1H, <i>J</i> = 8.9 Hz), 7.68–7.79 (m, 2H), 7.79–7.90 (m, 2H), 8.41 (s, 2H), 9.55 (br s, 1H), 11.15 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClN<sub>5</sub>O·0.3H<sub>2</sub>O: C, 62.15; H, 3.46; N, 19.07. Found: C, 62.25; H, 3.49; N, 18.84.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-{3-Chloro-4-[2-(trifluoromethyl)phenoxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6i</b>)</h3><div class="NLM_p last">Yield 69%, colorless crystals, mp 273–276 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) 6.52 (dd, 1H, <i>J</i> = 3.0, 1.9 Hz), 6.83 (d, 1H, <i>J</i> = 8.5 Hz), 7.19–7.33 (m, 2H), 7.56–7.83 (m, 4H), 8.41 (s, 2H), 9.48 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O: C, 56.38; H, 2.99; N, 13.84. Found: C, 56.58; H, 2.97; N, 13.98.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6j</b>)</h3><div class="NLM_p last">Yield 62%, colorless crystals, mp 258–260 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.42–6.56 (m, 1H), 7.15–7.27 (m, 2H), 7.33 (d, 1H, <i>J</i> = 8.9 Hz), 7.47 (d, 1H, <i>J</i> = 8.0 Hz), 7.61 (t, 1H, <i>J</i> = 8.0 Hz), 7.66–7.78 (m, 2H), 8.41 (s, 2H), 9.48 (br s, 1H), 11.11 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O: C, 56.38; H, 2.99; N, 13.84. Found: C, 56.34; H, 2.95; N, 13.91.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-{3-Chloro-4-[2-(trifluoromethoxy)phenoxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6k</b>)</h3><div class="NLM_p last">Yield 63%, colorless crystals, mp 228–230 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) 6.51 (dd, 1H, <i>J</i> = 2.9, 2.0 Hz), 6.90 (dd, 1H, <i>J</i> = 8.3, 1.5 Hz), 7.15–7.26 (m, 2H), 7.32–7.43 (m, 1H), 7.49–7.57 (m, 1H), 7.63–7.77 (m, 2H), 8.35–8.48 (m, 2H), 9.46 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.23; H, 2.87; N, 13.32. Found: C, 54.43; H, 3.01; N, 13.13.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-{3-Chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6l</b>)</h3><div class="NLM_p last">Yield 63%, colorless crystals, mp 234–236 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.52 (dd, 1H, <i>J</i> = 3.0, 1.9 Hz), 6.90–6.97 (m, 2H), 7.07–7.15 (m, 1H), 7.32 (d, 1H, <i>J</i> = 8.9 Hz), 7.49 (t, 1H, <i>J</i> = 8.9 Hz), 7.67–7.75 (m, 2H), 8.37–8.43 (m, 2H), 9.47 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.23; H, 2.87; N, 13.32. Found: C, 54.23; H, 2.83; N, 13.33.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-[3-Chloro-4-(3-methylphenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6m</b>)</h3><div class="NLM_p last">Yield 70%, colorless crystals, mp 232–234 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.29 (s, 3H), 6.51 (dd, 1H, <i>J</i> = 2.9, 2.0 Hz), 6.67–6.81 (m, 2H), 6.92 (d, 1H, <i>J</i> = 7.5 Hz), 7.12–7.31 (m, 2H), 7.56–7.74 (m, 2H), 8.28–8.44 (m, 2H), 9.42 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>ClN<sub>4</sub>O: C, 65.05; H, 4.31; N, 15.97. Found: C, 64.88; H, 4.36; N, 15.84.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-[3-Chloro-4-(3-methoxyphenoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6n</b>)</h3><div class="NLM_p last">Yield 83%, colorless crystals, mp 204–207 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.74 (s, 3H), 6.38–6.56 (m, 3H), 6.69 (dd, 1H, <i>J</i> = 8.2, 2.0 Hz), 7.13–7.34 (m, 2H), 7.58–7.74 (m, 2H), 8.32–8.43 (m, 2H), 9.42 (br s, 1H), 11.10 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 62.21; H, 4.12; N, 15.27. Found: C, 62.11; H, 4.07; N, 15.33.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6o</b>)</h3><div class="NLM_p last">Yield 80%, colorless crystals, mp 269–270 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 5.15 (s, 2H), 6.52 (d, 1H, <i>J</i> = 3.0 Hz), 6.90–7.70 (m, 7H), 7.97 (d, 1H, <i>J</i> = 3.0 Hz), 8.44 (s, 1H), 8.84 (br s, 1H), 10.74 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>14</sub>ClFN<sub>4</sub>O: C, 61.88; H, 3.83; N, 15.19. Found: C, 61.83; H, 3.89; N, 15.08.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6p</b>)</h3><div class="NLM_p last">Yield 78%, yellow crystals, mp 236–238 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 5.27 (s, 2H), 6.48 (d, 1H, <i>J</i> = 2.4 Hz), 7.25 (d, 1H, <i>J</i> = 8.7 Hz), 7.37 (dd, 1H, <i>J</i> = 7.5, 5.1 Hz), 7.55–7.60 (m, 2H), 7.66 (s, 1H), 7.89 (t, 1H, <i>J</i> = 7.5 Hz), 8.20 (dd, 1H, <i>J</i> = 2.4, 1.5 Hz), 8.35 (d, 1H, <i>J</i> = 1.5 Hz), 8.60 (dd, 1H, <i>J</i> = 4.8, 0.6 Hz), 9.25 (br s, 1H), 12.78 (br s, 1H). Anal. Calcd for C<sub>18</sub>H<sub>14</sub>ClN<sub>5</sub>O: C, 61.46; H, 4.01; N, 19.91. Found: C, 61.20; H, 4.04; N, 19.66.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-{3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine (<b>6q</b>)</h3><div class="NLM_p last">Yield 66%, yellow crystals, mp 111–113 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.16 (s, 3H), 2.51 (s, 3H), 6.56 (d, 1H, <i>J</i> = 3.0 Hz), 6.80 (d, 1H, <i>J</i> = 9.0 Hz), 7.0–7.6 (m, 5H), 8 17 (m, 1H), 8.59 (s, 1H), 8.76 (br s, 1H), 11.08 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O·0.2H<sub>2</sub>O: C, 68.13; H, 5.24; N, 20.91. Found: C, 68.18; H, 5.22; N, 20.82.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-Chloro-5-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>7</b>)</h3><div class="NLM_p last">To a suspension of <b>5</b> (0.32 g, 2.09 mmol) and potassium carbonate (0.45 g, 3.27 mmol) in DMF (2.0 mL) was added iodomethane (0.44 g, 3.13 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was poured into water (25 mL), and extracted with EtOAc (90 mL). The organic layer was washed with brine (60 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:4 to 9:1) to give 0.33 g (93%) of <b>7</b> as yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.16 (s, 3H), 6.70 (d, 1H, <i>J</i> = 3.9 Hz), 7.42 (d, 1H, <i>J</i> = 3.9 Hz), 8.69 (s, 1H).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-[3-Chloro-4-(3-chlorophenoxy)phenyl]-5-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine Hydrochloride (<b>8e</b>)</h3><div class="NLM_p">A solution of <b>4e</b> (100 mg, 0.597 mmol) and <b>7</b> (227 mg, 0.893 mmol) in 1-methyl-2-pyrrolidone (1.19 mL) was stirred at 140 °C for 4 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (30 mL). The resulting crystals were collected by filtration, washed with EtOAc (10 mL), and dried under vacuum to give 231 mg (92%) of <b>8e</b> as colorless hydrochloride salt crystals, mp 168–170 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 4.31 (d, 3H, <i>J</i> = 4.0 Hz), 6.65 (dd, 1H, <i>J</i> = 3.0, 1.0 Hz), 6.95 (dd, 1H, <i>J</i> = 9.0, 2.0 Hz), 7.03 (m, 1H), 7.22 (m, 1H), 7.34 (d, 1H, <i>J</i> = 9.0 Hz), 7.44 (t, 1H, <i>J</i> = 9.0 Hz), 7.69 (m, 1H), 7.97 (m, 2H), 8.72 (s, 1H), 9.94 (br s, 1H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>Cl<sub>3</sub>N<sub>4</sub>O·0.5H<sub>2</sub>O: C, 52.98; H, 3.74; N, 13.01. Found: C, 53.00; H, 3.76; N, 13.26.</div><div class="NLM_p last">The following compounds (<b>8j</b>,<b>8l</b>) were prepared from corresponding <b>4j</b>,<b>4l</b> with <b>7</b> by a method similar to that described for <b>8e</b>.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N</i>-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-5-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine hydrochloride (<b>8j</b>)</h3><div class="NLM_p last">Yield 75%, colorless crystals, mp 175–177 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 4.31 (s, 3H), 6.64 (dd, 1H, <i>J</i> = 3.0, 1.0 Hz), 7.26 (m, 2H), 7.37 (d, 1H, <i>J</i> = 9.0 Hz), 7.51 (d, 1H, <i>J</i> = 8.0 Hz), 7.67 (m, 2H), 7.96 (m, 2H), 8.71 (s, 1H), 9.89 (br s, 1H). Anal. Calcd for C<sub>20</sub>H<sub>15</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O·0.5H<sub>2</sub>O: C, 51.74; H, 3.47; N, 12.07. Found: C, 52.20; H, 3.37; N, 12.25.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-{3-Chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}-5-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine Hydrochloride (<b>8l</b>)</h3><div class="NLM_p last">Yield 77%, colorless crystals, mp 169–171 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 4.30 (s, 3H), 6.63 (dd, 1H, <i>J</i> = 3.0, 2.0 Hz), 6.97 (m, 2H), 7.15 (d, 1H, <i>J</i> = 9.0 Hz), 7.35 (d, 1H, <i>J</i> = 9.0 Hz), 7.53 (t, 1H, <i>J</i> = 9.0 Hz), 7.68 (m, 1H), 7.96 (m, 2H), 8.70 (s, 1H), 9.87 (br s, 1H). Anal. Calcd for C<sub>20</sub>H<sub>15</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 50.97; H, 3.21; N, 11.89. Found: C, 50.99; H, 3.13; N, 11.84.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 2-(4-Chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl Benzoate (<b>9</b>)</h3><div class="NLM_p last">To a suspension of <b>5</b> (0.31 g, 2.01 mmol) and cesium carbonate (0.98 g, 5.08 mmol) in DMF (2.0 mL) was added 2-iodoethyl benzoate (1.45 g, 5.25 mmol), and the reaction mixture was stirred at room temperature for 15 h. The reaction mixture was poured into saturated sodium hydrogen carbonate (100 mL) and extracted with EtOAc (150 mL × 3). The organic layer was washed with brine (100 mL) and dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 6:4 to 95:5) to give 0.42 g (70%) of <b>9</b> as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ4.71 (t, 2H, <i>J</i> = 5.3 Hz), 4.91 (t, 2H, <i>J</i> = 5.3 Hz), 6.76 (d, 1H, <i>J</i> = 3.2 Hz), 7.35–7.67 (m, 4H), 7.84–7.97 (m, 2H), 8.73 (s, 1H).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethanol (<b>10e</b>)</h3><div class="NLM_p">A solution of <b>9</b> (100 mg, 0.331 mmol) and <b>4e</b> (126 mg, 0.496 mmol) in 1-methyl-2-pyrrolidone (0.66 mL) was stirred at 140 °C for 2.5 h. After cooling to room temperature, to the reaction mixture was added saturated sodium hydrogen carbonate (80 mL), and the mixture was extracted with EtOAc (80 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:9 to 1:0) to give white solid. To a solution of the solid in a mixture of MeOH (1.18 mL) and THF (1.18 mL) was added 1 N NaOH (0.27 mL), and the mixture was stirred at room temperature for 1.5 h. To the reaction mixture was added 1 N HCl (0.27 mL), and the mixture was extracted with a mixture of EtOAc (2.0 mL) and THF (1.8 mL). The organic layer was washed with brine (30 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crystallized residue was recrystallized from EtOAc/diisopropyl ether (2:1) to give 81 mg (72%) of <b>10e</b> as colorless crystals, mp 208–209 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.87 (m, 2H), 4.53 (t, 2H, <i>J</i> = 4.5 Hz), 6.31 (br s, 1H,), 6.51 (d, 1H, <i>J</i> = 3.0 Hz), 6.88 (d, 1H, <i>J</i> = 9.0 Hz), 6.95 (s, 1H), 7.15 (d, 1H, <i>J</i> = 9.0 Hz), 7.28 (d, 1H, <i>J</i> = 9.0 Hz), 7.38 (t, 1H, <i>J</i> = 9.0 Hz), 7.60 (dd, 1H, <i>J</i> = 9.0, 2.0 Hz), 7.66 (d, 1H, <i>J</i> = 3.0 Hz), 7.97 (d, 1H, <i>J</i> = 2.0 Hz), 8.34 (s, 1H), 9.89 (br s, 1H). Anal. Calcd for C<sub>20</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 57.84; H, 3.88; N, 13.49. Found: C, 57.75; H, 3.66; N, 13.48.</div><div class="NLM_p last">The following compounds (<b>10j</b>,<b>10l</b>) were prepared from <b>9</b>,<b>11</b> with corresponding anilines (<b>4e</b>,<b>4j</b>,<b>4l</b>) by a method similar to that described for <b>10e</b>.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethanol (<b>10j</b>)</h3><div class="NLM_p last">Yield 46%, colorless crystals, mp 193–194 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.16 (t, 2H, <i>J</i> = 4.4 Hz), 4.38 (t, 2H, <i>J</i> = 4.4 Hz), 6.12 (d, 1H, <i>J</i> = 3.2 Hz), 6.97 (d, 1H, <i>J</i> = 3.2 Hz), 7.09 (d, 1H, <i>J</i> = 8.8 Hz), 7.10–7.17 (m, 1H), 7.21 (s, 1H), 7.32 (d, 1H, <i>J</i> = 7.7 Hz), 7.43 (t, 1H, <i>J</i> = 8.0 Hz), 7.52 (dd, 1H, <i>J</i> = 8.8, 2.6 Hz), 7.84 (d, 1H, <i>J</i> = 2.6 Hz), 8.24 (s, 1H), 9.59 (br s, 1H). Anal. Calcd for C<sub>21</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 56.20; H, 3.59; N, 12.48. Found: C, 56.20; H, 3.54; N, 12.49.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-[4-({3-Chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethanol (<b>10l</b>)</h3><div class="NLM_p last">Yield 71%, colorless crystals, mp 168–170 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.09–4.19 (m, 2H), 4.30–4.38 (m, 2H), 6.05 (d, 1H, <i>J</i> = 3.2 Hz), 6.79–6.97 (m, 5H), 7.10 (d, 1H, <i>J</i> = 8.9 Hz), 7.32 (t, 1H, <i>J</i> = 8.3 Hz), 7.51 (dd, 1H, <i>J</i> = 8.8, 2.5 Hz), 7.83 (d, 1H, <i>J</i> = 2.6 Hz), 8.18 (s, 1H), 9.67 (br s, 1H). Anal. Calcd for C<sub>21</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>: C, 54.26; H, 3.47; N, 12.05. Found: C, 54.56; H, 3.55; N, 12.06.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 2-[2-(4-Chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethoxy]ethyl Benzoate (<b>11</b>)</h3><div class="NLM_p">To a suspension of <b>5</b> (0.66 g, 4.31 mmol) and cesium carbonate (3.13 g, 9.61 mmol) in DMF (5.0 mL) was added 2-(2-iodoethoxy)ethyl benzoate (1.45 g, 4.53 mmol), and the reaction mixture was stirred at room temperature for 15 h. The reaction mixture was poured into saturated sodium hydrogen carbonate (100 mL) and extracted with EtOAc (450 mL). The organic layer was washed with brine (100 mL) and dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:19 to 2:3) to give 0.82 g (55%) of <b>11</b> as colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ3.71 (dt, 2H, <i>J</i> = 6.6, 3.0 Hz), 3.89 (t, 2H, <i>J</i> = 5.1 Hz), 4.41 (dt, 2H, <i>J</i> = 6.6, 3.0 Hz), 4.68 (t, 2H, <i>J</i> = 5.1 Hz), 6.56 (d, 1H, <i>J</i> = 3.3 Hz), 7.40–7.46 (m, 2H), 7.54–7.60 (m, 2H), 7.94–7.98 (m, 2H), 8.66 (s, 1H).</div><div class="NLM_p last">The following compounds (<b>12e</b>–<b>12l</b>) were prepared from <b>11</b> with corresponding anilines (<b>4e</b>,<b>4j</b>,<b>4l</b>) by a method similar to that described for <b>10e</b>.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2-[2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethoxy]ethanol (<b>12e</b>)</h3><div class="NLM_p last">Yield 68%, colorless crystals, mp 135–137 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.05 (br s, 1H), 3.71–3.84 (m, 4H), 4.03 (t, 2H, <i>J</i> = 4.5 Hz), 4.57 (t, 2H, <i>J</i> = 4.5 Hz), 6.61 (d, 1H, <i>J</i> = 3.0 Hz), 6.83–6.88 (m, 1H), 6.92 (t, 1H, <i>J</i> = 2.2 Hz), 7.01–7.06 (m, 1H), 7.06 (d, 1H, <i>J</i> = 8.9 Hz), 7.19–7.27 (m, 2H), 7.61 (dd, 1H, <i>J</i> = 8.9, 2.6 Hz), 7.89 (d, 1H, <i>J</i> = 2.6 Hz), 8.52 (s, 1H), 8.82 (br s, 1H). Anal. Calcd for C<sub>22</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub>: C, 57.53; H, 4.39; N, 12.20. Found: C, 57.28; H, 4.37; N, 12.16.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 2-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethanol (<b>12j</b>)</h3><div class="NLM_p last">Yield 57%, colorless crystals, mp 130–132 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.94 (br s, 1H), 3.71–3.85 (m, 4H), 4.03 (t, 2H, <i>J</i> = 4.4 Hz), 4.57 (t, 2H, <i>J</i> = 4.4 Hz), 6.63 (d, 1H, <i>J</i> = 3.2 Hz), 7.07 (d, 1H, <i>J</i> = 8.9 Hz), 7.08–7.14 (m, 1H), 7.19 (s, 1H), 7.22 (d, 1H, <i>J</i> = 3.2 Hz), 7.31 (d, 1H, <i>J</i> = 7.7 Hz), 7.42 (t, 1H, <i>J</i> = 8.0 Hz), 7.63 (dd, 1H, <i>J</i> = 8.9, 2.6 Hz), 7.91 (d, 1H, <i>J</i> = 3.0 Hz), 8.52 (s, 1H), 8.83 (br s, 1H). Anal. Calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>: C, 56.05; H, 4.09; N, 11.37. Found: C, 56.05; H, 4.09; N, 11.28.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-{2-[4-({3-Chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethanol (<b>12l</b>)</h3><div class="NLM_p last">Yield 58%, colorless crystals, mp 148–150 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.95 (br s, 1H), 3.71–3.84 (m, 4H), 4.03 (t, 2H, <i>J</i> = 4.5 Hz), 4.57 (t, 2H, <i>J</i> = 4.5 Hz), 6.62 (d, 1H, <i>J</i> = 3.2 Hz), 6.80–6.95 (m, 3H), 7.08 (d, 1H, <i>J</i> = 8.8 Hz), 7.21 (d, 1H, <i>J</i> = 3.2 Hz), 7.30 (t, 1H, <i>J</i> = 8.2 Hz), 7.62 (dd, 1H, <i>J</i> = 8.8, 2.6 Hz), 7.90 (d, 1H, <i>J</i> = 2.6 Hz), 8.52 (s, 1H), 8.82 (br s, 1H). Anal. Calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>: C, 54.29; H, 3.96; N, 11.01. Found: C, 54.49; H, 3.93; N, 10.96.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 2-{2-[4-({5-Chloro-6-[3-(trifluoromethyl)phenoxy]pyridin-3-yl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethanol (<b>12r</b>)</h3><div class="NLM_p last">Yield 58%, yellow crystals, mp 171–172 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.69–3.80 (m, 4H), 4.00–4.04 (m, 2H), 4.54–4.59 (m, 2H), 6.65 (d, 1H, <i>J</i> = 3.3 Hz), 7.23 (d, 1H, <i>J</i> = 3.3 Hz), 7.31–7.36 (m, 1H), 7.40–7.55 (m, 3H), 8.24 (d, 1H, <i>J</i> = 2.7 Hz), 8.47 (d, 1H, <i>J</i> = 2.7 Hz), 8.51 (s, 1H), 8.83 (s, 1H). Anal. Calcd for C<sub>22</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 53.50; H, 3.88; N, 14.18. Found: C, 53.47; H, 3.80; N, 14.08.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 5-(4-Chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)pentyl Acetate (<b>13</b>)</h3><div class="NLM_p last">To a suspension of <b>5</b> (0.50 g, 3.26 mmol) and cesium carbonate (1.59 g, 4.88 mmol) in DMF (5.0 mL) was added 5-chloropentyl acetate (0.71 mL, 3.26 mmol) at 40 °C, and the reaction mixture was stirred at 40 °C for 4 days. Water (150 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:3 to 3:2) to give 0.64 g (69%) of <b>13</b> as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.33–1.46 (m, 2H), 1.61–1.72 (m, 2H), 1.84–1.97 (m, 2H), 2.04 (s, 3H), 4.05 (t, 2H, <i>J</i> = 6.6 Hz), 4.48 (t, 2H, <i>J</i> = 7.5 Hz), 6.71 (d, 1H, <i>J</i> = 3.3 Hz), 7.46 (d, 1H, <i>J</i> = 3.3 Hz), 8.69 (s, 1H).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 5-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]pentan-1-ol (<b>15</b>)</h3><div class="NLM_p last">A mixture of <b>13</b> (0.20 g, 0.71 mmol) and <b>4j</b> (0.27 g, 0.94 mmol) in 2-propanol (3.5 mL) was stirred at 80 °C for 14 h. After cooling to 0 °C, to the reaction mixture was added 1 N NaOH (2.1 mL), and the mixture was stirred at room temperature for 1 h. To the reaction mixture was added 1 N HCl (2.1 mL) under ice-cooling, and the mixture was extracted with EtOAc (150 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:19) to give 0.28 g (79%) of <b>15</b> as colorless crystals, mp 146–148 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.35 (t, 1H, <i>J</i> = 4.7 Hz), 1.50–1.69 (m, 4H), 1.92–2.05 (m, 2H), 3.63–3.71 (m, 2H), 4.32 (t, 2H, <i>J</i> = 7.4 Hz), 6.59 (d, 1H, <i>J</i> = 3.3 Hz), 6.70 (s, 1H), 7.08 (d, 1H, <i>J</i> = 8.7 Hz), 7.09–7.12 (m, 1H), 7.15–7.27 (m, 2H), 7.30–7.35 (m, 1H), 7.40–7.43 (m, 1H), 7.47 (dd, 1H, <i>J</i> = 8.7, 2.7 Hz), 7.82 (d, 1H, <i>J</i> = 2.7 Hz), 8.53 (s, 1H). Anal. Calcd for C<sub>24</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 58.72; H, 4.52; N, 11.41. Found: C, 58.73; H, 4.53; N, 11.40.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 4-Chloro-5-(2,2-diethoxyethyl)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>16</b>)</h3><div class="NLM_p last">To a suspension of <b>5</b> (1.00 g, 6.51 mmol) and cesium carbonate (6.37 g, 19.5 mmol) in DMF (13 mL) was added 2-bromo-1,1-diethoxyethane (2.9 mL, 19.5 mmol) at room temperature, and the reaction mixture was stirred at 80 °C for 4.5 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (80 mL). The organic layer was separated, dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:1 to 1:0) to give 1.26 g (72%) of <b>16</b> as pale-yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.14 (t, 6H, <i>J</i> = 6.0 Hz), 3.40 (m, 2H), 3.72 (m, 2H), 4.08 (m, 1H), 4.56 (d, 2H, <i>J</i> = 5.0 Hz), 6.71 (d, 1H, <i>J</i> = 3.0 Hz), 7.55 (d, 1H, <i>J</i> = 3.0 Hz), 8.69 (s, 1H).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 5-(2,2-Diethoxyethyl)-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>17</b>)</h3><div class="NLM_p last">A mixture of <b>16</b> (1.00 g, 3.71 mmol), phenol (0.42 g, 4.46 mmol), potassium carbonate (0.62 g, 4.46 mmol) in 1-methyl-2-pyrrolidone (6.7 mL) was stirred at 140 °C for 6 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (100 mL) and washed with water (80 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:9 to 6:4) to give 1.15 g (95%) of <b>17</b> as yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.13 (t, 6H, <i>J</i> = 7.0 Hz), 3.40 (m, 2H), 3.69 (m, 2H), 4.51 (d, 2H, <i>J</i> = 6.0 Hz), 4.76 (t, 1H, <i>J</i> = 6.0 Hz), 6.65 (d, 1H, <i>J</i> = 3.0 Hz), 7.20–7.50 (m, 6H), 8.45 (s, 1H).</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 2-(4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethane-1,1-diol (<b>18</b>)</h3><div class="NLM_p last">A solution of <b>17</b> (1.10 g, 3.36 mmol) in a mixture of dichloromethane (4.5 mL) and trifluoroacetic acid (4.5 mL) was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (100 mL). The solution was washed with saturated sodium hydrogen carbonate (80 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo to give 0.83 g (91%) of <b>18</b> as white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 4.35 (d, 2H, <i>J</i> = 6.0 Hz), 5.17 (t, 1H, <i>J</i> = 6.0 Hz), 6.14 (d, 2H, <i>J</i> = 6.0 Hz), 6.59 (d, 1H, <i>J</i> = 3.0 Hz), 7.20–7.60 (m, 5H), 7.75 (d, 1H, <i>J</i> = 3.0 Hz), 8.28 (s, 1H).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 2-{[2-(4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]amino}ethanol (<b>19</b>)</h3><div class="NLM_p last">A solution of <b>18</b> (0.50 g, 1.84 mmol) and 2-hydroxyethylamine (167 mg, 2.73 mmol) in a mixture of DMF (29 mL) and acetic acid (2.9 mL) was stirred at room temperature for 1.5 h. To the reaction mixture was added sodium triacetoxyborohydride (579 mg, 2.73 mmol), and the mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 3:7) to give 286 mg (52%) of <b>19</b> as gel. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.80 (t, 2H, <i>J</i> = 5.0 Hz), 3.19 (t, 2H, <i>J</i> = 6.0 Hz), 3.63 (t, 2H, <i>J</i> = 5.0 Hz), 4.59 (t, 2H, <i>J</i> = 6.0 Hz), 6.68 (d, 1H, <i>J</i> = 3.0 Hz), 7.20–7.35 (m, 3H), 7.40–7.51 (m, 3H), 8.46 (s, 1H).</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 2-({2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}amino)ethanol (<b>20</b>)</h3><div class="NLM_p last">A mixture of <b>19</b> (154 mg, 0.516 mmol), <b>4j</b> (223 mg, 0.775 mmol), pyridinium chloride (179 mg, 1.55 mmol), and phenol (396 mg, 4.21 mmol) was heated at 140 °C for 16 h. After cooling to room temperature, the reaction mixture was diluted with dichloromethane (40 mL), and washed with saturated sodium hydrogen carbonate (30 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:methanol = 1:0 to 7:3) to give 48 mg (19%) of <b>20</b> as colorless crystals, mp 188–189 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.48 (m, 2H), 3.05 (m, 2H), 3.34 (m, 2H), 4.45 (m, 2H), 4.56 (t, 1H, <i>J</i> = 5.0 Hz), 6.49 (d, 1H, <i>J</i> = 3.0 Hz), 7.20 (m, 2H), 7.29 (d, 1H, <i>J</i> = 9.0 Hz), 7.45 (d, 1H, <i>J</i> = 8.0 Hz), 7.66 (m, 3H, m), 8.05 (d, 1H, <i>J</i> = 3.0 Hz), 8.32 (s, 1H). Anal. Calcd for C<sub>23</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>2</sub>: C, 56.16; H, 4.30; N, 14.24. Found: C, 56.35; H, 4.30; N, 14.03.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 2-(5,6-Dihydro-4<i>H</i>-pyrrolo[3,2,1-de]pteridin-4-yl)ethanol (<b>21</b>)</h3><div class="NLM_p last"><b>21</b> was obtained as a main product (29 mg, 28%) in this reaction. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.78 (t, 2H, <i>J</i> = 4.0 Hz), 3.84 (t, 2H, <i>J</i> = 5.0 Hz), 3.94 (t, 2H, <i>J</i> = 4.0 Hz), 4.26 (t, 2H, <i>J</i> = 5.0 Hz), 6.49 (d, 1H, <i>J</i> = 3.0 Hz), 7.14 (d, 1H, <i>J</i> = 3.0 Hz), 8.35 (s, 1H). LC-MS 205.09 (MH).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 2-[(2-Hydroxyethyl)thio]ethyl benzoate (<b>24</b>)</h3><div class="NLM_p last">A solution of 2-iodoethyl benzoate (<b>22</b>, 6.00 g, 21.7 mmol), 2-sulfanylethanol (<b>23</b>, 1.5 mL, 22.0 mmol), and ethyldiisopropylamine (4.5 mL) in DMF (60 mL) was stirred at 40 °C for 3 days. Water (300 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (300 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:4 to 7:3) to give 3.77 g (77%) of <b>24</b> as orange oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.15 (t, 1H, <i>J</i> = 6.0 Hz), 2.83 (t, 2H, <i>J</i> = 5.9 Hz), 2.92 (t, 2H, <i>J</i> = 6.8 Hz), 3.79 (dt, 2H, <i>J</i> = 6.0, 6.0 Hz), 4.50 (t, 2H, <i>J</i> = 6.8 Hz), 7.43–7.48 (m, 2H), 7.55–7.61 (m, 1H), 8.03–8.08 (m, 2H).</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 2-[(2-Bromoethyl)thio]ethyl Benzoate (<b>25</b>)</h3><div class="NLM_p last">To a solution of <b>24</b> (1.00 g, 4.42 mmol) and carbon tetrabromide (2.78 g, 8.38 mmol) in THF (30 mL) was added dropwise a solution of triphenylphosphine (2.20 g, 8.38 mmol) in THF (10 mL) under ice-cooling. After stirring at room temperature for 3 days, water (200 mL) was added, and then the mixture was extracted with EtOAc (300 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:9 to 4:6) to give 0.98 g (76%) of <b>25</b> as colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.95 (t, 2H, <i>J</i> = 6.8 Hz), 3.02–3.08 (m, 2H), 3.50–3.56 (m, 2H), 4.49 (t, 2H, <i>J</i> = 6.8 Hz), 7.43–7.48 (m, 2H), 7.55–7.61 (m, 1H), 8.03–8.06 (m, 2H).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 2-{[2-(4-Chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]thio}ethyl benzoate (<b>26</b>)</h3><div class="NLM_p last">Compound <b>26</b> was obtained as colorless oil from <b>25</b> by a method similar to that described for <b>11</b>. Yield 80%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 2.81 (t, 2H, <i>J</i> = 6.8 Hz), 3.08 (t, 2H, <i>J</i> = 6.9 Hz), 4.45 (t, 2H, <i>J</i> = 6.8 Hz), 4.69 (t, 2H, <i>J</i> = 6.9 Hz), 6.73 (d, 1H, <i>J</i> = 3.3 Hz), 7.39–7.46 (m, 2H), 7.53–7.62 (m, 2H), 7.96–8.06 (m, 2H), 8.71 (s, 1H).</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 2-{[2-(4-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]benzyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]thio}ethanol (<b>28</b>)</h3><div class="NLM_p last">Compound <b>28</b> was obtained as colorless crystals in 59% yield from <b>26</b> by a method similar to that described for <b>15</b>; mp 108–109 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.92–2.00 (m, 1H), 2.52 (t, 2H, <i>J</i> = 5.6 Hz), 3.13 (t, 2H, <i>J</i> = 6.5 Hz), 3.65–3.75 (m, 2H), 4.61 (t, 2H, <i>J</i> = 6.5 Hz), 6.67 (d, 1H, <i>J</i> = 3.3 Hz), 7.08 (d, 1H, <i>J</i> = 8.7 Hz), 7.09–7.13 (m, 1H), 7.18–7.23 (m, 1H), 7.29 (d, 1H, <i>J</i> = 3.3 Hz), 7.32–7.35 (m, 1H), 7.41–7.46 (m, 1H), 7.51 (dd, 1H, <i>J</i> = 8.7, 2.7 Hz), 7.77 (d, 1H, <i>J</i> = 2.7 Hz), 7.80 (s, 1H), 8.55 (s, 1H). Anal. Calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S: C, 54.28; H, 3.96; N, 11.01. Found: C, 54.35; H, 3.94; N, 11.02.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 2-{[2-(4-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]benzyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]sulfinyl}ethanol (<b>29</b>)</h3><div class="NLM_p last">To a solution of <b>28</b> (0.10 g, 0.20 mmol) in dichloromethane (10 mL) was added dropwise a 70% solution of 3-chloroperbenzoic acid (0.058 g, 0.34 mmol) in dichloromethane (5.0 mL) at −78 °C. The mixture was stirred at −78 °C for 1 h, and aqueous sodium thiosulfate (100 mL) was added. After stirring at room temperature for 30 min, the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (50 mL) and dried over MgSO<sub>4</sub>. After concentration in vacuo, the residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:4) to give 87 mg (85%) of <b>29</b> as colorless crystals, mp 158–159 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.78–3.01 (m, 2H), 3.27–3.40 (m, 1H), 3.42–3.58 (m, 1H), 3.71–3.79 (m, 2H), 4.80–4.90 (m, 2H), 5.02–5.09 (m, 1H), 6.58–6.63 (m, 1H), 7.16–7.25 (m, 2H), 7.27–7.31 (m, 1H), 7.44–7.50 (m, 1H), 7.59–7.64 (m, 1H), 7.66–7.72 (m, 1H), 7.74–7.82 (m, 1H), 7.96–8.03 (m, 1H), 8.37 (s, 1H), 9.38 (s, 1H). Anal. Calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S: C, 52.62; H, 3.84; N, 10.67. Found: C, 52.62; H, 3.82; N, 10.67.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 2-{[2-(4-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]benzyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]sulfonyl}ethanol (<b>30</b>)</h3><div class="NLM_p last">A mixture of <b>29</b> (0.15 g, 0.29 mmol), titanium tetraisopropoxide (0.043 mL), methanol (0.024 mL), and water (0.010 mL) in dichloromethane (10 mL) was stirred at room temperature for 30 min. 70% aqueous <i>tert</i>-butyl hydroperoxide (0.12 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 2 days. Aqueous sodium thiosulfate (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:4) to give 0.12 g (74%) of <b>30</b> as colorless crystals, mp 196–197 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.09–3.15 (m, 2H), 3.62–3.75 (m, 4H), 4.92–5.02 (m, 2H), 5.09–5.15 (m, 1H), 6.50–6.57 (m, 1H), 7.16–7.32 (m, 3H), 7.45–7.48 (m, 1H), 7.58–7.74 (m, 3H), 7.91–7.97 (m, 1H), 8.37 (br s, 1H), 8.69–8.79 (m, 1H). Anal. Calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S: C, 51.07; H, 3.73; N, 10.36. Found: C, 51.10; H, 3.63; N, 10.34.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>tert</i>-Butyl [2-(4-Chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]carbamate (<b>31a</b>)</h3><div class="NLM_p last">To a suspension of <b>5</b> (0.50 g, 3.26 mmol) and cesium carbonate (1.59 g, 8.24 mmol) in DMF (10 mL) was added <i>tert</i>-butyl (2-bromoethyl)carbamate (1.09 g, 4.89 mmol) at 40 °C, and the mixture was stirred at 40 °C for 4 days. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:3 to 3:2) to give 0.69 g (71%) of <b>31a</b> as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.31–1.46 (m, 9H), 3.55 (dt, 2H, <i>J</i> = 6.0 Hz), 4.51–4.68 (m, 3H), 6.74 (d, 1H, <i>J</i> = 3.2 Hz), 7.47 (d, 1H, <i>J</i> = 3.2 Hz), 8.71 (s, 1H).</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>tert</i>-Butyl{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}carbamate (<b>32a</b>)</h3><div class="NLM_p last">A mixture of <b>31a</b> (0.71 g, 2.39 mmol) and <b>4j</b>(0.83 g, 2.79 mmol) in 2-propanol (7.1 mL) was stirred at 80 °C for 12 h. To the reaction mixture was added saturated sodium hydrogen carbonate (50 mL) under ice-cooling, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine and dried over MgSO<sub>4</sub>. The solvent was concentrated in vacuo, and the residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:1 to 1:0) to give 1.12 g (85%) of <b>32a</b> as white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.49 (s, 9H), 3.43–3.54 (m, 2H), 4.43–4.51 (m, 2H), 5.10 (t, 1H, <i>J</i> = 5.6 Hz), 6.60 (d, 1H, <i>J</i> = 3.3 Hz), 7.07 (m, 1H), 7.09–7.14 (m, 1H), 7.16–7.22 (m, 2H), 7.25–7.30 (m, 1H), 7.37–7.45 (m, 1H), 7.89 (dd, 1H, <i>J</i> = 8.7, 2.4 Hz), 8.02 (d, 1H, <i>J</i> = 2.4 Hz), 8.50 (s, 1H), 8.64 (br s, 1H).</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 5-(2-Aminoethyl)-<i>N</i>-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine dihydrochloride (<b>33a</b>)</h3><div class="NLM_p last">A mixture of <b>32a</b> (1.12 g, 2.04 mmol), 2 N HCl (15 mL), and THF (30 mL) was stirred at 60 °C for 20 h. After the mixture was concentrated under reduced pressure, ethanol (50 mL) was added to the concentrate, and then the mixture was further concentrated in vacuo. The residual crystals were collected by filtration and washed with ethyl acetate to give 1.07 g (quant) of <b>33a</b> as pale-yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.21–3.35 (m, 2H), 4.92–5.02 (m, 2H), 6.71–6.76 (m, 1H), 7.24–7.32 (m, 2H), 7.37 (d, 1H, <i>J</i> = 9.0 Hz), 7.50–7.56 (m, 1H), 7.64–7.71 (m, 2H), 7.91–7.97 (m, 1H), 7.98–8.06 (m, 1H), 8.13–8.26 (m, 3H), 8.71 (br s, 1H), 9.90 (br s, 1H).</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>N</i>-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}-2-hydroxyacetamide (<b>34a</b>)</h3><div class="NLM_p">A mixture of <b>33a</b> (0.11 g, 0.21 mmol), glycolic acid (0.044 g, 0.58 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC) (0.17 g, 0.89 mmol), 1-hydroxybenzotriazole monohydrate (HOBt) (0.13 g 0.96 mmol), and triethylamine (0.40 mL) in DMF (5.0 mL) was stirred at room temperature for 3 days. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:9) to give 0.11 g (74%) of <b>34a</b> as colorless crystals, mp 145–147 °C. 1H-NMR (CDCl<sub>3</sub>) δ: 2.93–3.09 (m, 1H), 3.59–3.73 (m, 2H), 4.24 (s, 2H), 4.43–4.53 (m, 2H), 6.59 (d, 1H, <i>J</i> = 3.3 Hz), 7.07 (d, 1H, <i>J</i> = 8.7 Hz), 7.09–7.46 (m, 6H), 7.72 (dd, 1H, <i>J</i> = 8.7, 2.4 Hz), 8.06 (d, 1H, <i>J</i> = 2.4 Hz), 8.49 (s, 1H), 8.57 (1H, s). Anal. Calcd for C<sub>23</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 54.61; H, 3.79; N, 13.84. Found: C, 54.77; H, 3.82; N, 13.89.</div><div class="NLM_p last">The following compounds (<b>34c</b>,<b>34e</b>) were prepared from <b>33a</b> with the corresponding carboxylic acid by a method similar to that described for <b>34a</b>.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N</i>-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}-2-hydroxy-2-methylpropanamide (<b>34c</b>)</h3><div class="NLM_p last">Yield 86%, colorless crystals, mp 183–185 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.49 (s, 6H), 2.12–2.27 (m, 1H), 3.56–3.67 (m, 2H), 4.42–4.52 (m, 2H), 6.61 (d, 1H, <i>J</i> = 3.3 Hz), 7.06 (d, 1H, <i>J</i> = 9.0 Hz), 7.08–7.14 (m, 1H), 7.15–7.43 (m, 5H), 7.86 (dd, 1H, <i>J</i> = 9.0, 2.7 Hz), 8.10 (d, 1H, <i>J</i> = 2.7 Hz), 8.51 (s, 1H), 8.72 (s, 1H). Anal. Calcd for C<sub>25</sub>H<sub>23</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 56.24; H, 4.34; N, 13.12. Found: C, 56.33; H, 4.38; N, 13.10.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide (<b>34e</b>)</h3><div class="NLM_p last">Yield 77%, colorless crystals, mp 167–169 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.33 (s, 6H), 2.49 (s, 2H), 2.65–2.77 (m, 1H), 3.57–3.68 (m, 2H), 4.44–4.53 (m, 2H), 6.61 (d, 1H, <i>J</i> = 3.0 Hz), 6.93–7.01 (m, 1H), 7.07 (d, 1H, <i>J</i> = 9.0 Hz), 7.09–7.15 (m, 1H), 7.19 (d, 1H, <i>J</i> = 3.0 Hz), 7.23–7.35 (m, 2H), 7.40–7.45 (m, 1H), 7.77 (dd, 1H, <i>J</i> = 9.0, 2.7 Hz), 8.08 (d, 1H, <i>J</i> = 2.7 Hz), 8.52 (s, 1H), 8.66 (s, 1H). Anal. Calcd for C<sub>26</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 56.99; H, 4.60; N, 12.78. Found: C, 57.22; H, 4.61; N, 12.80.</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>N</i>-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}-3-hydroxypropanamide methanesulfonate (<b>34d</b>)</h3><div class="NLM_p last">A solution of <b>33a</b> (3.50 g, 6.72 mmol), 3.6 M aqueous 3-hydroxypropanoic acid (5.6 mL, 20.1 mmol), WSC (10.1 g, 52.7 mmol), HOBt (4.56 g 33.7 mmol), and triethylamine (0.80 mL) in THF (17 mL) and DMF (17 mL) was stirred at room temperature for 3 days. Water (300 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (400 mL). The organic layer was washed with water (100 mL) and brine (100 mL) successively, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:9) to give white solid. To a solution of the white solid in EtOAc (50 mL) was added methanesulfonic acid (0.16 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure, and the residue was recrystallized from EtOAc to give 1.04 g (25%) of <b>34d</b> as colorless crystals, mp 154–155 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.22 (t, 2H, <i>J</i> = 6.3 Hz), 2.31 (s, 3H), 3.41–3.51 (m, 4H), 3.56 (t, 2H, <i>J</i> = 6.5 Hz), 6.67 (d, 1H, <i>J</i> = 3.0 Hz), 7.25–7.32 (m, 2H), 7.37 (d, 1H, <i>J</i> = 8.8 Hz), 7.50–7.56 (m, 1H), 7.62–7.74 (m, 2H), 7.98 (d, 1H, <i>J</i> = 2.8 Hz), 8.33 (t, 1H, <i>J</i> = 5.5 Hz), 8.75 (s, 1H), 10.11 (br s, 1H). Anal. Calcd for C<sub>25</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S: C, 48.74; H, 4.09; N, 11.37. Found: C, 48.60; H, 4.08; N, 11.24.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>tert</i>-Butyl [2-(4-chloro-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl]methylcarbamate (<b>31b</b>)</h3><div class="NLM_p last">To a solution of 2-(methylamino)ethanol (1.00 g, 13.3 mmol) in THF (10 mL) was added di-<i>tert</i>-butyl dicarbonate (3.6 mL) at room temperature. After stirring at room temperature for 2 h, the mixture was concentrated under reduced pressure. The residue was dissolved in THF (50 mL), and to the solution was added dropwise triethylamine (3.7 mL) and methanesulfonyl chloride (1.6 mL) at 0 °C successively, and the reaction mixture was stirred at 0 °C for 1 h. Then, saturated sodium hydrogen carbonate (10 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo to give colorless oil. To a suspension of <b>5</b> (1.34 g, 8.76 mmol) and cesium carbonate (5.69 g, 29.5 mmol) in DMF (20 mL) was added the obtained colorless oil, and the reaction mixture was stirred at 40 °C for 4 days. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (300 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent, EtOAc:hexane = 1:3 to 3:2) to give 0.90 g (33%) of <b>31b</b> as pale-yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.12 (s, 4.5H), 1.43 (m, 4.5H), 2.55 (s, 1.5H), 2.81 (s, 1.5H), 3.58–3.60 (m, 2H), 4.54–4.69 (m, 2H), 6.73 (d, 1H, <i>J</i> = 3.0 Hz), 7.29–7.35 (m, 0.5H), 7.38–7.46 (m, 0.5H), 8.71 (s, 1H).</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>tert</i>-Butyl{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}methylcarbamate (<b>32b</b>)</h3><div class="NLM_p last">Compound <b>32b</b> was obtained as white solid in 76% yield from <b>31b</b> by a method similar to that described for <b>32a</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 1.51 (s, 9H), 3.01 (s, 3H), 3.51–3.59 (m, 2H), 4.41–4.51 (m, 2H), 6.60 (d, 1H, <i>J</i> = 3.0 Hz), 7.06 (d, 1H, <i>J</i> = 8.7 Hz), 7.08–7.13 (m, 1H), 7.15–7.24 (m, 2H), 7.30 (d, 1H, <i>J</i> = 8.4 Hz), 7.38–7.44 (m, 1H), 7.85–7.93 (m, 1H), 7.99–8.04 (m, 1H), 8.50 (s, 1H), 8.82 (s, 1H).</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> <i>N</i>-{3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-5-[2-(methylamino)ethyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amine Dihydrochloride (<b>33b</b>)</h3><div class="NLM_p last">Compound <b>33b</b> was obtained as white solid in 91% yield from <b>32b</b> by a method similar to that described for <b>33a</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.54 (t, 3H, <i>J</i> = 5.3 Hz), 3.32–3.44 (m, 2H), 5.01–5.15 (m, 2H), 6.74 (d, 1H, <i>J</i> = 3.3 Hz), 7.22–7.27 (m, 2H), 7.36 (d, 1H, <i>J</i> = 8.7 Hz), 7.51 (d, 1H, <i>J</i> = 8.4 Hz), 7.60–7.69 (m, 2H), 7.91–7.96 (m, 1H), 8.01–8.07 (m, 1H), 8.72 (s, 1H), 9.00–9.18 (m, 2H), 10.06 (br s, 1H).</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> <i>N</i>-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethyl}-2-hydroxy-<i>N</i>-methylacetamide (<b>34b</b>)</h3><div class="NLM_p last">Compound <b>34b</b> was obtained as colorless crystals in 62% yield from <b>33b</b> by a method similar to that described for <b>34a</b>; mp 176–178 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.02 (s, 3H), 3.29 (t, 1H, <i>J</i> = 4.5 Hz), 3.72–3.81 (m, 2H), 4.26 (d, 2H, <i>J</i> = 4.5 Hz), 4.45–4.53 (m, 2H), 6.64 (d, 1H, <i>J</i> = 3.3 Hz), 7.08 (d, 1H, <i>J</i> = 8.7 Hz), 7.09–7.15 (m, 1H), 7.23–7.28 (m, 1H), 7.32–7.37 (m, 1H), 7.30–7.35 (m, 1H), 7.39–7.46 (m, 1H), 7.74 (dd, 1H, <i>J</i> = 8.7, 2.7 Hz), 8.05 (d, 1H, <i>J</i> = 2.7 Hz), 8.39 (s, 1H), 8.53 (s, 1H). Anal. Calcd for C<sub>24</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 55.44; H, 4.07; N, 13.47. Found: C, 55.54; H, 4.09; N, 13.36.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 4-Iodo-6-phenoxypyrimidine-5-amine (<b>35</b>)</h3><div class="NLM_p last">To a solution of 4,6-diiodo-pyrimidine-5-amine (40.0 g, 115 mmol) in 1-methyl-2-pyrrolidone (200 mL) were added phenol (11.9 g, 127 mmol) and potassium carbonate (17.5 g, 127 mmol), and the reaction mixture was stirred at 100 °C for 12 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc (600 mL), and washed with water (700 mL) and brine (500 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent, EtOAc:hexane = 1:4 to 1:1) to give 33.0 g (91%) of <b>35</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.34 (br s, 2H), 7.14–7.46 (m, 5H), 7.87 (s, 1H).</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 4-Phenoxy-6-prop-1-yn-1-ylpyrimidin-5-amine (<b>36</b>)</h3><div class="NLM_p last">A mixture of 4-iodo-6-phenoxypyrimidine-5-amine (<b>35</b>, 5.00 g, 16.0 mmol), 1-(trimethylsilyl)-1-propyne (3.3 mL, 22.3 mmol), dichlorobis(triphenylphosphine)palladium(II) (558 mg, 0.795 mmol), triphenylphosphine (421 mg, 0.161 mmol), copper iodide (303 mg, 0.159 mmol), potassium fluoride (1.29 g, 22.2 mmol), and triethylamine (50 mL) in DMF (100 mL) was stirred at 60 °C for 16 h. The reaction mixture was diluted with diethyl ether (50 mL) and quenched with saturated sodium hydrogen carbonate (100 mL). The mixture was extracted with diethyl ether (100 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:4 to 1:1) to give 2.64 g (73%) of <b>36</b> as orange solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.20 (s, 3H), 4.37 (br s, 2H), 7.15–7.19 (m, 2H), 7.24–7.29 (m, 1H), 7.40–7.46 (m, 2H), 8.08 (s, 1H).</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 6-Methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>37</b>)</h3><div class="NLM_p last">To a solution of <b>36</b> (2.56 g, 11.4 mmol) in THF (100 mL) was added dropwise 1 N potassium <i>tert</i>-butoxide in THF solution (12 mL, 12.0 mmol) at 0 °C, and the reaction mixture was stirred at 0 °C for 40 min. The reaction mixture was diluted with EtOAc (100 mL) and quenched with water (100 mL) at 0 °C. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 4:1 to 1:1) to give 1.71 g (67%) of <b>37</b> as pale-orange solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.54 (d, 3H, <i>J</i> = 0.9 Hz), 6.44 (q, 1H, <i>J</i> = 0.9 Hz), 7.21–7.30 (m, 3H), 7.42–7.47 (m, 2H), 8.46 (m, 2H).</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 2-[2-(6-Methyl-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethoxy]ethyl benzoate (<b>38</b>)</h3><div class="NLM_p last">A mixture of <b>37</b> (300 mg, 1.33 mmol), 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate (464 mg, 1.61 mmol), and potassium carbonate (431 mg, 3.19 mmol) in DMF (7 mL) was stirred at 60 °C for 21 h. The reaction mixture was diluted with EtOAc (10 mL), quenched with water (10 mL), and extracted with EtOAc (10 mL). The organic layer was washed with brine (10 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:hexane = 1:4 to 4:1) to give 518 mg (93%) of <b>38</b> as yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.50 (s, 3H), 3.62–3.74 (m, 2H), 3.92 (t, 2H, <i>J</i> = 5.3 Hz), 4.33–4.44 (m, 2H), 4.57 (t, 2H, <i>J</i> = 5.1 Hz), 6.36 (s, 1H), 7.15–7.34 (m, 3H), 7.34–7.51 (m, 4H), 7.51–7.65 (m, 1H), 7.87–8.00 (m, 2H), 8.40 (s, 1H).</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 2-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-6-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethyl benzoate (<b>39</b>)</h3><div class="NLM_p last">A mixture of <b>38</b> (270 mg, 0.65 mmol), <b>4j</b> (279 mg, 0.97 mmol), pyridinium chloride (235 mg, 2.03 mmol), and phenol (496 mg) was stirred at 140 °C for 17 h. After cooling to room temperature, the mixture was diluted with dichloromethane (50 mL), and the organic layer was washed with saturated sodium hydrogen carbonate (30 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:4 to 1:0) to give 228 mg (58%) of <b>39</b> as yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.44 (s, 3H), 3.93–4.12 (m, 4H), 4.47–4.51 (m, 4H), 6.40 (s, 1H), 6.77 (d, 1H, <i>J</i> = 9.0 Hz), 7.01–7.03 (m, 1H), 7.15 (s, 1H), 7.20–7.50 (m, 5H), 7.75–7.86 (m, 3H), 8.44 (s, 1H), 8.72 (br s, 1H).</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 2-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-6-methyl-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethanol (<b>40</b>)</h3><div class="NLM_p last">To a suspension of <b>39</b> (220 mg, 0.36 mmol) in MeOH (1.6 mL) was added 1 N NaOH (0.5 mL), and the reaction mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 N HCl (0.5 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine (30 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, MeOH:EtOAc = 0:1 to 1:4) and crystallized from diisopropylether to give 164 mg (90%) of <b>40</b> as colorless crystals, mp 168–169 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.46 (s, 3H), 3.49–3.51 (m, 4H), 3.84 (t, 2H, <i>J</i> = 4.0 Hz), 4.55 (br s, 2H), 4.76 (t, 2H, <i>J</i> = 4.0 Hz), 7.17–7.21 (m, 2H), 7.27 (d, 1H, <i>J</i> = 9.0 Hz), 7.44 (d, 1H, <i>J</i> = 8.0 Hz), 7.50–7.70 (m, 2H), 8.01 (d, 1H, <i>J</i> = 2.0 Hz), 8.29 (s, 1H), 8.98 (br s, 1H). Anal. Calcd for C<sub>24</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>: C, 56.87; H, 4.37; N, 11.05. Found: C, 56.89; H, 4.34; N, 11.05.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 4-(3,3-Diethoxyprop-1-yn-1-yl)-6-phenoxypyrimidin-5-amine (<b>41</b>)</h3><div class="NLM_p last">A mixture of <b>35</b> (7.00 g, 22.4 mmol), 3,3-diethoxyprop-1-yne (3.8 mL, 26.5 mmol), dichlorobis(triphenylphosphine)palladium(II) (783 mg, 1.12 mmol), copper iodide (255 mg, 1.34 mmol), and triethylamine (120 mL) in acetonitrile (160 mL) was stirred at room temperature for 16.5 h. The mixture was concentrated in vacuo, and the residue was purified by column chromatography (eluent, EtOAc:hexane = 1:9 to 1:1) to give 6.20 g (89%) of <b>41</b> as brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.29 (t, 6H, <i>J</i> = 7.2 Hz), 3.62–3.77 (m, 2H), 3.77–3.91 (m, 2H), 4.48 (br s, 2H), 5.56 (s, 1H), 7.14–7.21 (m, 2H), 7.27–7.33 (m, 1H), 7.39–7.50 (m, 2H), 8.11 (s, 1H).</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 6-(Diethoxymethyl)-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine (<b>42</b>)</h3><div class="NLM_p last">To a solution of <b>41</b> (6.20 g, 19.8 mmol) in THF (100 mL) was added 1 N potassium <i>tert</i>-butoxide in THF (25 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 1.5 h. The mixture was diluted with EtOAc (100 mL), quenched with saturated aqueous ammonium chloride (100 mL), and extracted with EtOAc (100 mL). The organic layer was washed with brine (50 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:9 to 1:1) to give 3.15 g (51%) of <b>42</b> as orange solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.20–1.37 (m, 6H), 3.55–3.79 (m, 4H), 5.81 (d, 1H, <i>J</i> = 0.6 Hz), 6.69 (dd, 1H, <i>J</i> = 2.2, 0.6 Hz), 7.18–7.36 (m, 3H), 7.39–7.52 (m, 2H), 8.50 (s, 1H), 8.92 (br s, 1H).</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine-6-carbaldehyde (<b>43</b>)</h3><div class="NLM_p last">To a solution of <b>42</b> (3.15 g, 10.1 mmol) in THF (40 mL) was added 1 N HCl (40 mL), and the reaction mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 N NaOH (40 mL) and extracted with a mixture of EtOAc (30 mL)/THF (30 mL). The organic layer was washed with brine (20 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residual solid was collected by filtration and washed with diisopropylether to give 2.17 g (90%) of <b>43</b> as khaki powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.25–7.40 (m, 3H), 7.43–7.58 (m, 3H), 8.44 (s, 1H), 10.06 (s, 1H), 13.26 (br s, 1H).</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> 4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine-6-carboxylic Acid (<b>44</b>)</h3><div class="NLM_p last">To a mixture of <b>43</b> (2.17 g, 9.07 mmol) in DMSO (21 mL) and sodium dihydrogen phosphate (5.45 g, 45.4 mmol) in water (14 mL) was added dropwise a solution of sodium chlorite (2.06 g, 22.8 mmol) in water (14 mL), and the reaction mixture was stirred at room temperature for 2 h. The mixture was quenched with saturated sodium hydrogen carbonate (10 mL) gradually, and the pH was adjusted to pH 2 by addition of 1 N HCl. The resulting precipitate was collected by filtration and washed with diisopropylether to give 2.40 g (quant) of <b>44</b> as white powder. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.09 (s, 1H), 7.23–7.36 (m, 3H), 7.41–7.54 (m, 2H), 8.36 (s, 1H), 12.82 (br s, 1H).</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine-6-carboxamide (<b>45</b>)</h3><div class="NLM_p last">A mixture of <b>44</b> (465 mg, 1.82 mmol) and thionyl chloride (7 mL) was stirred at 75 °C for 2 h. After cooling to room temperature, the mixture was concentrated in vacuo and the residue was suspended in THF (10 mL). The suspension was poured into 28% ammonia (20 mL) at 0 °C, and the resulting precipitate was collected by filtration. The filtrate was extracted with a mixture of EtOAc (10 mL)/THF (10 mL). The organic layer was washed with brine (5 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residual solid was collected by filtration, and combined with the above precipitate to give 427 mg (92%) of <b>45</b> as pale-yellow powder. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.25 (s, 1H), 7.27–7.35 (m, 3H), 7.39–7.57 (m, 2H), 7.75 (s, 1H), 8.17 (s, 1H), 8.36 (s, 1H), 12.58 (br s, 1H).</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 4-Phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine-6-carbonitrile (<b>46</b>)</h3><div class="NLM_p last">A mixture of <b>45</b> (427 mg, 1.68 mmol) in phosphoryl chloride (5 mL) was stirred at 70 °C for 1.5 h. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was dissolved in THF (10 mL), and to the solution were added water (5 mL) and 28% ammonia (10 mL) at 0 °C. The mixture was extracted with a mixture of EtOAc (10 mL)/THF (10 mL). The organic layer was washed with brine (5 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:9 to 1:1) to give 240 mg (61%) of <b>46</b> as pale-yellow powder. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.29–7.37 (m, 3H), 7.45–7.54 (m, 2H), 7.58 (s, 1H), 8.46 (s, 1H), 13.77 (br s, 1H).</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 2-[2-(6-Cyano-4-phenoxy-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethoxy]ethyl benzoate (<b>47</b>)</h3><div class="NLM_p last">A mixture of <b>46</b> (240 mg, 1.02 mmol), 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate (354 mg, 1.23 mmol), and potassium carbonate (355 mg, 2.57 mmol) in DMF (5 mL) was stirred at 60 °C for 7 h. To the mixture was added additional 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate (133 mg, 0.462 mmol), and the reaction mixture was stirred at 60 °C for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc (10 mL), quenched with aqueous ammonium chloride (20 mL), and extracted with EtOAc (20 mL). The organic layer was washed with brine (5 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:4 to 4:1) to give 267 mg (61%) of <b>47</b> as colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.73–3.79 (m, 2H), 3.96 (t, 2H, <i>J</i> = 4.9 Hz), 4.37–4.43 (m, 2H), 4.83 (t, 2H, <i>J</i> = 4.9 Hz), 7.17 (s, 1H), 7.18–7.23 (m, 2H), 7.27–7.35 (m, 1H), 7.36–7.49 (m, 4H), 7.51–7.58 (m, 1H), 7.85–7.92 (m, 2H), 8.49 (s, 1H).</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 2-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-6-cyano-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl]ethoxy}ethyl Benzoate (<b>48</b>)</h3><div class="NLM_p last">A mixture of <b>47</b> (262 mg, 0.610 mmol), <b>4j</b> (264 mg, 0.919 mmol), pyridinium chloride (222 mg, 1.92 mmol), and phenol (462 mg) was stirred at 140 °C for 17 h. After cooling to room temperature, the mixture was diluted with dichloromethane (10 mL), washed with brine (5 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:4 to 1:1) to give 283 mg (74%) of <b>48</b> as yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.96–4.06 (m, 2H), 4.16–4.22 (m, 2H), 4.45–4.54 (m, 2H), 4.68–4.79 (m, 2H), 6.80 (d, 1H, <i>J</i> = 8.8 Hz), 7.01–7.09 (m, 1H), 7.14–7.20 (m, 1H), 7.24 (s, 1H), 7,27–7.53 (m, 6H), 7.68–7.76 (m, 2H), 7.92 (d, 1H, <i>J</i> = 2.5 Hz), 8.53 (s, 1H), 8.95 (s, 1H).</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5-[2-(2-hydroxyethoxy)ethyl]-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine-6-carbonitrile (<b>49</b>)</h3><div class="NLM_p last">To a solution of <b>48</b> (283 mg, 0.454 mmol) in MeOH (3 mL) was added 1 N NaOH (0.6 mL), and the reaction mixture was stirred at room temperature for 1 h. The mixture was neutralized with 1 N HCl (0.6 mL) and extracted with EtOAc (5 mL). The organic layer was washed with brine (20 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc:hexane = 1:2 to 4:1) and crystallized from diisopropylether to give 143 mg (61%) of <b>49</b> as colorless crystals, mp 143–144 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.74–3.88 (m, 4H), 4.08–4.16 (m, 2H), 4.70–4.80 (m, 2H), 7.05–7.15 (m, 2H), 7.16–7.21 (m, 1H), 7.25 (s, 1H), 7.30–7.36 (m, 1H), 7.43 (t, 1H, <i>J</i> = 7.8 Hz), 7.67 (dd, 1H, <i>J</i> = 8.8, 2.8 Hz), 7.96 (d, 1H, <i>J</i> = 2.8 Hz), 8.58 (s, 1H), 9.03 (br s, 1H). Anal. Calcd for C<sub>24</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 55.66; H, 3.70; N, 13.52. Found: C, 55.70; H, 3.54; N, 13.33.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109"><a href="/doi/suppl/10.1021/jm2008634">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Methods used in molecular modeling, enzyme assays, cell line, and animal models, pharmacokinetics, metabolic stability, and structural analyses.  This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2008634/suppl_file/jm2008634_si_001.pdf">jm2008634_si_001.pdf (114.44 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm2008634" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoyasu Ishikawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#59102a313032382e38060d36343620382a2c192d38323c3d38773a36773329"><span class="__cf_email__" data-cfemail="70390318191b1107112f241f1d1f091103053004111b1514115e131f5e1a00">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masaki Seto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Banno</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youichi Kawakita</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mami Oorui</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiko Taniguchi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshikazu Ohta</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshiya Tamura</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akiko Nakayama</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Miki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hidenori Kamiguchi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshimasa Tanaka</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noriyuki Habuka</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Sogabe</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Yano</span> - <span class="hlFld-Affiliation affiliation">Structural Biology, Takeda San Diego,
Inc., 10410 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Aertgeerts</span> - <span class="hlFld-Affiliation affiliation">Structural Biology, Takeda San Diego,
Inc., 10410 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keiji Kamiyama</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi
2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack" id="ACK-d771e7445-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i111">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to structural biology group members (Bi Ching Sang, Hua Zou, Darbi Witmer, Gyorgy Snell, Ryan Bertsch, and Jason Yano) and management at Takeda San Diego for determining the first X-ray cocrystal structure of <b>34e</b> with HER2. We also acknowledge the editing assistance of Stephen Mosley of KnowledgePoint360 Group Ltd. in the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This paper was published ASAP on November 4, 2011 with an incorrect image for Scheme 6. The corrected version was published on November 10, 2011.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i112" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i112"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i113" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i113"> Abbreviations Used</h2><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">growth inhibitory</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole monohydrate</p></td></tr><tr><td class="NLM_term">mCPBA</td><td class="NLM_def"><p class="first last">3-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">MgSO<sub>4</sub></td><td class="NLM_def"><p class="first last">magnesium sulfate</p></td></tr><tr><td class="NLM_term">NaOH</td><td class="NLM_def"><p class="first last">sodium hydroxide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last">1-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">Pt–C</td><td class="NLM_def"><p class="first last">platinum–carbon</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">WSC</td><td class="NLM_def"><p class="first last">water-soluble carbodiimide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 21 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ooi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, K.</span><span> </span><span class="NLM_article-title">The erbB gene of avian erythroblastosis virus is a member of the <i>src</i> gene family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1983&pages=71-78&author=T.+Yamamotoauthor=T.+Nishidaauthor=N.+Miyajimaauthor=S.+Kawaiauthor=T.+Ooiauthor=K.+Toyoshima&title=The+erbB+gene+of+avian+erythroblastosis+virus+is+a+member+of+the+src+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DT.%26aulast%3DToyoshima%26aufirst%3DK.%26atitle%3DThe%2520erbB%2520gene%2520of%2520avian%2520erythroblastosis%2520virus%2520is%2520a%2520member%2520of%2520the%2520src%2520gene%2520family%26jtitle%3DCell%26date%3D1983%26volume%3D35%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets in cancer therapy—successes and failures</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1517%2F14728222.7.2.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12667099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=215-234&author=P.+Traxler&title=Tyrosine+kinases+as+targets+in+cancer+therapy%E2%80%94successes+and+failures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets in cancer therapy - successes and failures</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-234</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction and also in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth-related kinases, esp. Tyr kinases, might therefore provide new therapies for diseases such as cancer.  Due to the enormous progress that was made in the past few years in the identification of the human genome, in mol. and cell biol. technologies, in structural biol. and in bioinformatics, the no. of receptor and non-receptor Tyr kinases that were identified as valuable mol. targets has greatly increased.  Currently, > 20 different Tyr kinase targets are under evaluation in drug discovery projects in oncol.  The progress made in the crystn. of protein kinases, in most cases complexed with ATP-site-directed inhibitors, has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for rational drug design; > 20 ATP-competitive, low mol. wt. inhibitors are in various phases of clin. evaluation.  Meanwhile, clin. proof-of-concept (POC) was achieved with several antibodies and small mols. targeted against Tyr kinases.  With Herceptin, Glivec, and Iressa (registered in Japan), the 1st kinase drugs have entered the market.  This review describes the preclin. and clin. status of low mol. wt. drugs targeted against different Tyr kinases (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Kit, Fms-like Tyr kinase [Flt]-3), briefly describes new targets, and provides a crit. anal. of the current situation in the area of Tyr kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyxUqnX26eLVg90H21EOLACvtfcHk0liJflXaevxLSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D&md5=aac69b84205b6525b0acb4ab2a43f219</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1517%2F14728222.7.2.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.7.2.215%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520in%2520cancer%2520therapy%25E2%2580%2594successes%2520and%2520failures%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2003%26volume%3D7%26spage%3D215%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0liJflXaevxLSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Burgess, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">An Open-and-Shut Case? Recent Insights into the Activation of EGF/erbB2 Receptors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=541-552&author=A.+W.+Burgessauthor=H.+S.+Choauthor=C.+Eigenbrotauthor=K.+M.+Fergusonauthor=T.+P.+Garrettauthor=D.+J.+Leahyauthor=M.+A.+Lemmonauthor=M.+X.+Sliwkowskiauthor=C.+W.+Wardauthor=S.+Yokoyama&title=An+Open-and-Shut+Case%3F+Recent+Insights+into+the+Activation+of+EGF%2FerbB2+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DK.%2BM.%26aulast%3DGarrett%26aufirst%3DT.%2BP.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DWard%26aufirst%3DC.%2BW.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DAn%2520Open-and-Shut%2520Case%253F%2520Recent%2520Insights%2520into%2520the%2520Activation%2520of%2520EGF%252FerbB2%2520Receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D12%26spage%3D541%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0lhljJRs6Foo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, D. F.</span><span> </span><span class="NLM_article-title">The biology of erbB-2/neu/HER-2 and its role in cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">1198</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1198&publication_year=1994&pages=165-184&author=N.+E.+Hynesauthor=D.+F.+Stern&title=The+biology+of+erbB-2%2Fneu%2FHER-2+and+its+role+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DStern%26aufirst%3DD.%2BF.%26atitle%3DThe%2520biology%2520of%2520erbB-2%252Fneu%252FHER-2%2520and%2520its%2520role%2520in%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1994%26volume%3D1198%26spage%3D165%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthom, L. R.</span><span> </span><span class="NLM_article-title">#4251 ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=633&author=J.+R.+Woodburnauthor=A.+J.+Barkerauthor=K.+H.+Gilsonauthor=S.+E.+Ashtonauthor=A.+E.+Wakelingauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+R.+Henthom&title=%234251+ZD+1839%2C+an+epidermal+growth+factor+tyrosine+kinase+inhibitor+selected+for+clinical+trial+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGilson%26aufirst%3DK.%2BH.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthom%26aufirst%3DL.%2BR.%26atitle%3D%25234251%2520ZD%25201839%252C%2520an%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitor%2520selected%2520for%2520clinical%2520trial%2520development%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D1997%26volume%3D38%26spage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+Leading+to+the+Identification+of+ZD1839+%28Iressa%29%3A+An+Orally+Active%2C+Selective+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Targeted+to+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lhljJRs6Foo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520Leading%2520to%2520the%2520Identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520An%2520Orally%2520Active%252C%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Targeted%2520to%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, K. H.</span><span> </span><span class="NLM_article-title">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12384534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gilson&title=ZD1839+%28Iressa%29%3A+An+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span></div><div class="casAuthors">Wakeling, Alan E.; Guy, Simon P.; Woodburn, Jim R.; Ashton, Susan E.; Curry, Brenda J.; Barker, Andrew J.; Gibson, Keith H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5749-5754</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy.  We have developed a low-mol.-wt. EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa).  ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC50 = 0.033 μM) that selectively inhibits EGF-stimulated tumor cell growth (IC50 = 0.054 μM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells.  In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner.  The level of expression of EGFR did not det. xenograft tumor sensitivity to ZD1839.  Long-term ZD1839 (>3 mo) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors.  No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal.  These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkoHZ9zL06abVg90H21EOLACvtfcHk0lh-I3BqJZsO4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D&md5=f5f86c652786db476a2d23b5bbd1a9e9</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGilson%26aufirst%3DK.%2BH.%26atitle%3DZD1839%2520%2528Iressa%2529%253A%2520An%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_contrib-group">Matar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Bueno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosimo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">6487</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15475436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1OitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=6487-6501&author=P.+Matarauthor=F.+Rojoauthor=R.+Cassiaauthor=G.+Moreno-Buenoauthor=S.+D.+Cosimoauthor=J.+Taberneroauthor=M.+Guzmanauthor=S.+Rodriguezauthor=J.+Arribasauthor=J.+Palaciosauthor=J.+Baselga&title=Combined+epidermal+growth+factor+receptor+targeting+with+the+tyrosine+kinase+inhibitor+gefitinib+%28ZD1839%29+and+the+monoclonal+antibody+cetuximab+%28IMC-C225%29%3A+superiority+over+single-agent+receptor+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting</span></div><div class="casAuthors">Matar, Pablo; Rojo, Federico; Cassia, Raul; Moreno-Bueno, Gema; Di Cosimo, Serena; Tabernero, Jose; Guzman, Marta; Rodriguez, Sonia; Arribas, Joaquin; Palacios, Jose; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6487-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and low-mol.-wt. tyrosine kinase inhibitors, have shown antitumor activity in patients.  Because these two classes of antireceptor agents target the EGFR at different sites, we decided to explore whether the combined administration of gefitinib, a tyrosine kinase inhibitor, and cetuximab, a monoclonal antibody, had superior antitumor activity than either agent given alone.  We studied the effects of the combination of gefitinib and cetuximab in a panel of human cancer cell lines and in an EGFR-dependent human tumor xenograft model (A431).  The effects of these two agents on EGFR signaling, proliferation, apoptosis, and vascularization were evaluated.  In addn., we analyzed, with cDNA arrays, changes in gene expression profiles induced by both agents.  The combined treatment with gefitinib and cetuximab resulted in a synergistic effect on cell proliferation and in superior inhibition of EGFR-dependent signaling and induction of apoptosis.  In a series of in vivo expts., single-agent gefitinib or cetuximab resulted in transient complete tumor remission only at the highest doses.  In contrast, suboptimal doses of gefitinib and cetuximab given together resulted in a complete and permanent regression of large tumors.  In the combination-treated tumors, there was a superior inhibition of EGFR, mitogen-activated protein kinase, and Akt phosphorylation, as well as greater inhibition of cell proliferation and vascularization and enhanced apoptosis.  Using cDNA arrays, we found 59 genes that were coregulated and 45 genes differentially regulated, including genes related to cell proliferation and differentiation, transcription, DNA synthesis and repair, angiogenesis, signaling mols., cytoskeleton organization, and tumor invasion and metastasis.  Our findings suggest both shared and complementary mechanisms of action with gefitinib and cetuximab and support combined EGFR targeting as a clin. exploitable strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXVcoupyARorVg90H21EOLACvtfcHk0lh-I3BqJZsO4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1OitbY%253D&md5=b62bd5319dfbf9a453324158c1ae6122</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0870%26sid%3Dliteratum%253Aachs%26aulast%3DMatar%26aufirst%3DP.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DCassia%26aufirst%3DR.%26aulast%3DMoreno-Bueno%26aufirst%3DG.%26aulast%3DCosimo%26aufirst%3DS.%2BD.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DCombined%2520epidermal%2520growth%2520factor%2520receptor%2520targeting%2520with%2520the%2520tyrosine%2520kinase%2520inhibitor%2520gefitinib%2520%2528ZD1839%2529%2520and%2520the%2520monoclonal%2520antibody%2520cetuximab%2520%2528IMC-C225%2529%253A%2520superiority%2520over%2520single-agent%2520receptor%2520targeting%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D6487%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramukai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, M.</span><span> </span><span class="NLM_article-title">Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer—a retrospective analysis: JMTO LC03–02</span> <span class="citation_source-journal">BMC Res. Notes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1186%2F1756-0500-2-157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=19656374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A280%3ADC%252BD1MrpsF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=157&author=M.+Nakagawaauthor=T.+Nishimuraauthor=S.+Teramukaiauthor=H.+Tadaauthor=F.+Tanakaauthor=K.+Yanagiharaauthor=K.+Furuseauthor=H.+Wadaauthor=M.+Fukushima&title=Interstitial+lung+disease+in+gefitinib-treated+Japanese+patients+with+non-small+cell+lung+cancer%E2%80%94a+retrospective+analysis%3A+JMTO+LC03%E2%80%9302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02</span></div><div class="casAuthors">Nakagawa Masatsugu; Nishimura Tsutomu; Teramukai Satoshi; Tada Harue; Tanaka Fumihiro; Yanagihara Kazuhiro; Furuse Kiyoyuki; Wada Hiromi; Fukushima Masanori</div><div class="citationInfo"><span class="NLM_cas:title">BMC research notes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC).  We investigated the efficacy of gefitinib, the incidence of ILD and risk factors for ILD in these patients.  FINDINGS:  We obtained patient data retrospectively using questionnaires sent to 22 institutions.  We asked for demographic and clinical data on NSCLC patients for whom gefitinib treatment had begun between July 2002 and February 2003.  Data from a total of 526 patients were analyzed.  The patient characteristics were as follows: 64% male, 69% with adenocarcinoma, 61% with a performance score of 0-1, and 5% with concurrent interstitial pneumonitis.  The objective response proportion was 80/439 (18.2%; 95% CI: 14.7-22.0).  ILD developed in 17 patients (3.2%; 95% CI 1.9-5.1%), of whom 7 died.  According to multivariate analysis, female sex, history of prior chemotherapy, low absolute neutrophil count before gefitinib treatment, and adenocarcinoma histology were associated with response to gefitinib treatment.  None of the factors we evaluated were associated with the development of ILD.  CONCLUSION:  The results of this study are consistent with previously published values for treatment response proportions and incidence of ILD during gefitinib treatment in Japanese patients.  Future studies should be aimed at identifying factors indicating that a patient has a high probability of receiving benefit from gefitinib and a low risk of developing ILD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjgPlh7Q_C477NkxioyDXTfW6udTcc2eYjs40qQzeTIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrpsF2hsQ%253D%253D&md5=44854536d62576b45cd5b34fa87cddfc</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1186%2F1756-0500-2-157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-0500-2-157%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DTeramukai%26aufirst%3DS.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DF.%26aulast%3DYanagihara%26aufirst%3DK.%26aulast%3DFuruse%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DM.%26atitle%3DInterstitial%2520lung%2520disease%2520in%2520gefitinib-treated%2520Japanese%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%25E2%2580%2594a%2520retrospective%2520analysis%253A%2520JMTO%2520LC03%25E2%2580%259302%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2009%26volume%3D2%26spage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+EGF+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520EGF%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_contrib-group">Sorbera, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestre, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayes, M.</span><span> </span><span class="NLM_article-title">Erlotinib Hydrochloride</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1358%2Fdof.2002.027.10.697002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=923&author=L.+A.+Sorberaauthor=J.+Casta%C3%B1erauthor=J.+S.+Silvestreauthor=M.+Bayes&title=Erlotinib+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib hydrochloride: oncolytic EGF receptor inhibitor</span></div><div class="casAuthors">Sorbera, L. A.; Castaner, J.; Silvestre, J. S.; Bayes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">923-934</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a type 1 receptor tyrosine kinase that is involved in the modulation of cellular differentiation and is overexpressed in many types of human cancers such as lung, pancreatic, ovarian, renal cell, gastric, hepatocellular and breast.  Overexpression of EGFR is frequently correlated with increased tumor grade, increased metastatic potential and poor prognosis.  Thus, inhibition of EGFR signaling is an attractive therapeutic option for the treatment of cancer.  One method that can interfere with EGFR is the direct inhibition of EGFR tyrosine kinase activity.  Several tyrosine kinase inhibitors have been developed and evaluated over the past 10 yr of which the majority are reversible competitors with ATP for binding to the intracellular catalytic domain of the tyrosine kinase.  One such EGFR tyrosine kinase inhibitor that has shown excellent antitumor activity is erlotinib hydrochloride, an oral quinazoline deriv. that reversibly and selectively inhibits tyrosine kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHlS4LhWq4u7Vg90H21EOLACvtfcHk0lipAj5aJbi7rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFelsg%253D%253D&md5=e2fe2bf52a2521acebd6ea695aadfa0c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.10.697002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.10.697002%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DJ.%26aulast%3DSilvestre%26aufirst%3DJ.%2BS.%26aulast%3DBayes%26aufirst%3DM.%26atitle%3DErlotinib%2520Hydrochloride%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroog, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Soler, R.</span><span> </span><span class="NLM_article-title">Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1572</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15746062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1572-1578&author=Q.+Daiauthor=Y.-H.+Lingauthor=M.+Lieauthor=Y.-Y.+Zouauthor=G.+Kroogauthor=K.+K.+Iwataauthor=R.+Perez-Soler&title=Enhanced+Sensitivity+to+the+HER1%2FEpidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Erlotinib+Hydrochloride+in+Chemotherapy-Resistant+Tumor+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines</span></div><div class="casAuthors">Dai, Qun; Ling, Yi-He; Lia, Marie; Zou, Yi-Yu; Kroog, Glenn; Iwata, Kenneth K.; Perez-Soler, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1572-1578</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the HER1/epidermal growth factor receptor (EGFR) tyrosine kinase.  In phase II clin. studies, oral erlotinib monotherapy has shown antitumor activity in patients with advanced non-small cell lung cancer, head and neck cancer, and ovarian cancer after the failure of std. chemotherapy.  We hypothesized that some tumors treated with multiple cytotoxic therapies may become more dependent on the HER1/EGFR signaling pathways for survival.  The growth-inhibitory effect of erlotinib was tested on 10 pairs of chemosensitive, parental, and chemoresistant tumor cell lines.  Enhanced sensitivity to erlotinib was obsd. in the doxorubicin-resistant human breast cancer cell line MCF-7, paclitaxel-resistant human ovarian carcinoma cell line A2780, and cisplatin-resistant human cervical carcinoma cell line ME180.  The IC50 values of erlotinib in the resistant cell lines were 2- to 20-fold lower than those in the corresponding parental cell lines.  This enhanced sensitivity to erlotinib correlated with higher HER1/EGFR and phospho-HER1/EGFR expression when compared with the corresponding parental cell lines.  Acquired resistance to cytotoxic agents was not assocd. with cross-resistance to erlotinib.  AE-ME180/CDDP-resistant xenografts showed greater sensitivity to erlotinib than parental ME180 xenografts did.  Our findings suggest that acquired resistance to cytotoxic therapy in some tumors is assocd. with enhanced sensitivity to HER1/EGFR inhibitors, which correlates with increased HER1/EGFR expression.  These data may explain some of the obsd. clin. activity of HER1/EGFR inhibitors in patients previously treated with multiple therapies.  HER1/EGFR tyrosine kinase inhibitors may be more effective as second- or third-line treatment for certain patients with tumors that were previously treated with multiple chemotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeXCdcqp21VrVg90H21EOLACvtfcHk0lipAj5aJbi7rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVSrtrs%253D&md5=eb368294959fdf32f666cf5bdf8b4c5a</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0993%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DLing%26aufirst%3DY.-H.%26aulast%3DLie%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DY.-Y.%26aulast%3DKroog%26aufirst%3DG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DEnhanced%2520Sensitivity%2520to%2520the%2520HER1%252FEpidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Erlotinib%2520Hydrochloride%2520in%2520Chemotherapy-Resistant%2520Tumor%2520Cell%2520Lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D1572%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_contrib-group">Melosky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agulnik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assi, H.</span><span> </span><span class="NLM_article-title">Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=279-285&author=B.+Meloskyauthor=J.+Agulnikauthor=H.+Assi&title=Retrospective+practice+review+of+treatment+of+metastatic+non-small-cell+lung+cancer+with+second-line+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelosky%26aufirst%3DB.%26aulast%3DAgulnik%26aufirst%3DJ.%26aulast%3DAssi%26aufirst%3DH.%26atitle%3DRetrospective%2520practice%2520review%2520of%2520treatment%2520of%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520with%2520second-line%2520erlotinib%26jtitle%3DCurr.%2520Oncol.%26date%3D2008%26volume%3D6%26spage%3D279%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasser, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekele, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, N. J.</span><span> </span><span class="NLM_article-title">Cetuximab and Irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-05-1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=16428506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=600-607&author=S.+Kimauthor=N.+C.+Prichardauthor=N.+M.+Younesauthor=D.+Y.+Yaziciauthor=A.+S.+Jasserauthor=N.+B.+Bekeleauthor=N.+J.+Myers&title=Cetuximab+and+Irinotecan+interact+synergistically+to+inhibit+the+growth+of+orthotopic+anaplastic+thyroid+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice</span></div><div class="casAuthors">Kim, Seungwon; Prichard, Christopher N.; Younes, Maher N.; Yazici, Yasemin D.; Jasser, Samar A.; Bekele, B. Nebiyou; Myers, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">600-607</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers.  Targeted mol. therapy with cetuximab, a monoclonal antibody against epidermal growth factor receptor, offers new treatment potentials for patient with ATC.  Cetuximab has also been reported to have synergistic effects when combined with irinotecan, a topoisomerase inhibitor.  Therefore, we hypothesized that cetuximab and irinotecan would be effective in inhibiting the growth and progression of ATC in a murine orthotopic model.  Exptl. Design: The in vitro antiproliferative effects of cetuximab and irinotecan on ATC cell line ARO were examd.  We also studied the in vivo effects of cetuximab and irinotecan on the growth, invasion, and metastasis of orthotopic ATC tumors in nude mice.  The in vivo antitumor efficacy of cetuximab/irinotecan combination was also compared with that of doxorubicin.  Results: Cetuximab alone did not show any antiproliferative or proapoptotic effect on this cell line.  However, when combined with irinotecan, cetuximab potentiated the in vitro antiproliferative and proapoptotic effect of irinotecan.  Cetuximab, irinotecan, and cetuximab/irinotecan combination resulted in 77%, 79%, and 93% in vivo inhibition of tumor growth, resp.  Incidences of lymph node metastasis, laryngeal invasion, and tumor microvessel d. were also significantly decreased in these treatment groups.  Furthermore, the cetuximab/irinotecan combination was significantly more effective than doxorubicin in inhibiting the growth of orthotopic ATC xenografts.  Conclusions: Combination therapy with cetuximab/irinotecan inhibits the growth and progression of orthotopic ATC xenografts in nude mice.  Given the lack of curative options for patients with ATC, combination therapy with cetuximab and irinotecan treatment warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsHzVhsFHwebVg90H21EOLACvtfcHk0lio_IDW2ypYKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D&md5=90f0a52d3c65268632c168a4cb4b633c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1325%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPrichard%26aufirst%3DN.%2BC.%26aulast%3DYounes%26aufirst%3DN.%2BM.%26aulast%3DYazici%26aufirst%3DD.%2BY.%26aulast%3DJasser%26aufirst%3DA.%2BS.%26aulast%3DBekele%26aufirst%3DN.%2BB.%26aulast%3DMyers%26aufirst%3DN.%2BJ.%26atitle%3DCetuximab%2520and%2520Irinotecan%2520interact%2520synergistically%2520to%2520inhibit%2520the%2520growth%2520of%2520orthotopic%2520anaplastic%2520thyroid%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group">Balin-Gauthier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delord, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillaire, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochaix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugat, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allal, B. C.</span><span> </span><span class="NLM_article-title">Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18182978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=120-128&author=D.+Balin-Gauthierauthor=J.-P.+Delordauthor=M.-J.+Pillaireauthor=P.+Rochaixauthor=J.-S.+Hoffmanauthor=R.+Bugatauthor=C.+Cazauxauthor=P.+Canalauthor=B.+C.+Allal&title=Cetuximab+potentiates+oxaliplatin+cytotoxic+effect+through+a+defect+in+NER+and+DNA+replication+initiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation</span></div><div class="casAuthors">Balin-Gauthier, D.; Delord, J.-P.; Pillaire, M.-J.; Rochaix, P.; Hoffman, J.-S.; Bugat, R.; Cazaux, C.; Canal, P.; Allal, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-128</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Preclin. studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum deriv., is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors.  To explore the mechanism of this synergistic benefit, we used HCT-8 and HCT-116, two human colon cancer cell lines, resp., responsive and non-responsive to the oxaliplatin/cetuximab combination.  We examd. the effect of drug exposure on glutathione-S-transferase-mediated oxaliplatin detoxification, DNA-platinum adducts formation, cell cycle distribution, apoptosis, and the expression of multiple targets involved in DNA replication, recombination, and repair.  The major changes we found in HCT-8 were a stimulation of oxaliplatin-DNA adduct formation assocd. with reduced expression of the key enzyme (excision repair cross complementation group 1: ERCC1) in the key repair process of oxaliplatin-DNA platinum adduct, the nucleotide excision repair (NER), both at the mRNA and protein levels.  We also obsd. a reduced expression of factors involved in DNA replication initiation, which correlates with an enrichment of cells in the G1 phase of the cell cycle as well as an acceleration of apoptosis.  None of these changes occurred in the non-responsive HCT-116 cell that we used as a neg. control.  These findings support the fact that cetuximab potentiates the oxaliplatin-mediated cytotoxic effect as the result of inhibition of NER and also DNA replication initiation.  British Journal of Cancer (2008) 98, 120-128. doi:10.1038/sj.bjc.6604134 www.bjcancer.com Published online 8 Jan. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbmecY6u2Qz7Vg90H21EOLACvtfcHk0lio_IDW2ypYKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2rtw%253D%253D&md5=67886dc0b25717004f969569fc2fef8b</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604134%26sid%3Dliteratum%253Aachs%26aulast%3DBalin-Gauthier%26aufirst%3DD.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DPillaire%26aufirst%3DM.-J.%26aulast%3DRochaix%26aufirst%3DP.%26aulast%3DHoffman%26aufirst%3DJ.-S.%26aulast%3DBugat%26aufirst%3DR.%26aulast%3DCazaux%26aufirst%3DC.%26aulast%3DCanal%26aufirst%3DP.%26aulast%3DAllal%26aufirst%3DB.%2BC.%26atitle%3DCetuximab%2520potentiates%2520oxaliplatin%2520cytotoxic%2520effect%2520through%2520a%2520defect%2520in%2520NER%2520and%2520DNA%2520replication%2520initiation%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D120%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Siena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajetta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comandini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodoky, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hazel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devercelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amado, G. R.</span><span> </span><span class="NLM_article-title">Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18040272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=1469-1474&author=S.+Sienaauthor=M.+Peetersauthor=E.+van+Cutsemauthor=Y.+Humbletauthor=P.+Conteauthor=E.+Bajettaauthor=D.+Comandiniauthor=G.+Bodokyauthor=G.+van+Hazelauthor=T.+Salekauthor=M.+Wolfauthor=G.+Devercelliauthor=M.+Woolleyauthor=G.+R.+Amado&title=Association+of+progression-free+survival+with+patient-reported+outcomes+and+survival%3A+results+from+a+randomised+phase+3+trial+of+panitumumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab</span></div><div class="casAuthors">Siena, S.; Peeters, M.; Van Cutsem, E.; Humblet, Y.; Conte, P.; Bajetta, E.; Comandini, D.; Bodoky, G.; Van Hazel, G.; Salek, T.; Wolf, M.; Devercelli, G.; Woolley, M.; Amado, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1474</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC).  This anal. characterises the assocn. of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS).  CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment.  Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD).  Std. imputation methods were used to assign missing values.  Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC.  After excluding responders, a significant difference in PFS remained favoring panitumumab (HR=0.63, 95% CI=0.52-0.77; P<0.0001).  At week 8, lack of disease progression was assocd. with significantly and clin. meaningful lower CRC symptomatol. for both treatment groups and higher HRQoL for panitumumab patients only.  Overall survival favored no PD patients vs PD patients alive at week 8.  Lack of disease progression was assocd. with better symptom control, HRQoL, and OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxI4jb8PY5IrVg90H21EOLACvtfcHk0lio_IDW2ypYKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7vE&md5=1159205ed8fbfd609325645fc1f0e753</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604053%26sid%3Dliteratum%253Aachs%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3Dvan%2BCutsem%26aufirst%3DE.%26aulast%3DHumblet%26aufirst%3DY.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DBajetta%26aufirst%3DE.%26aulast%3DComandini%26aufirst%3DD.%26aulast%3DBodoky%26aufirst%3DG.%26aulast%3Dvan%2BHazel%26aufirst%3DG.%26aulast%3DSalek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DDevercelli%26aufirst%3DG.%26aulast%3DWoolley%26aufirst%3DM.%26aulast%3DAmado%26aufirst%3DG.%2BR.%26atitle%3DAssociation%2520of%2520progression-free%2520survival%2520with%2520patient-reported%2520outcomes%2520and%2520survival%253A%2520results%2520from%2520a%2520randomised%2520phase%25203%2520trial%2520of%2520panitumumab%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D1469%26epage%3D1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Berchuck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soper, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke-Pearson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, R. C.,  Jr.</span><span> </span><span class="NLM_article-title">Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4091</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=4087-4091&author=A.+Berchuckauthor=A.+Kamelauthor=R.+Whitakerauthor=B.+Kernsauthor=G.+Oltauthor=R.+Kinneyauthor=J.+T.+Soperauthor=R.+Dodgeauthor=D.+L.+Clarke-Pearsonauthor=P.+Marksauthor=S+McKenzieauthor=S.+Yinauthor=R.+C.+Bast&title=Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerchuck%26aufirst%3DA.%26aulast%3DKamel%26aufirst%3DA.%26aulast%3DWhitaker%26aufirst%3DR.%26aulast%3DKerns%26aufirst%3DB.%26aulast%3DOlt%26aufirst%3DG.%26aulast%3DKinney%26aufirst%3DR.%26aulast%3DSoper%26aufirst%3DJ.%2BT.%26aulast%3DDodge%26aufirst%3DR.%26aulast%3DClarke-Pearson%26aufirst%3DD.%2BL.%26aulast%3DMarks%26aufirst%3DP.%26aulast%3DMcKenzie%26aufirst%3DS%26aulast%3DYin%26aufirst%3DS.%26aulast%3DBast%26aufirst%3DR.%2BC.%26atitle%3DOverexpression%2520of%2520HER-2%252Fneu%2520is%2520associated%2520with%2520poor%2520survival%2520in%2520advanced%2520epithelial%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D4087%26epage%3D4091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, W. L.</span><span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2<b>/</b>neu oncogene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">235</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M.+Clarkauthor=S.+G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0lgIbvpn0GDoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lgIbvpn0GDoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span> </span><span class="NLM_article-title">Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=9661897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADyaK1cXksFCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2825-2831&author=J.+Baselgaauthor=L.+Nortonauthor=J.+Albanellauthor=Y.+Kimauthor=J.+Mendelsohn&title=Recombinant+humanized+anti-HER2+antibody+%28Herceptin%29+enhances+the+antitumor+activity+of+paclitaxel+and+doxorubicin+against+HER2%2Fneu+overexpressing+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span></div><div class="casAuthors">Baselga, Jose; Norton, Larry; Albanell, Joan; Kim, Young-Mee; Mendelsohn, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2825-2831</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast cancer cells overexpressing HER2 and has clin. activity.  We explored in preclin. models its capacity to enhance the tumoricidal effects of paclitaxel and doxorubicin.  In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel.  Treatment of well established BT-474 breast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-dependent antitumor activity.  In combination studies, treatment with paclitaxel and rhuMAb HER2 or doxorubicin and rhuMAb HER2 resulted in greater inhibition of growth than that obsd. with any agent alone.  The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone.  Clin. trials that are built on these results are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp43taV-JJAWbVg90H21EOLACvtfcHk0lgIbvpn0GDoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFCqt7g%253D&md5=580abe07d8f611d5b151418bc0e30d82</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DMendelsohn%26aufirst%3DJ.%26atitle%3DRecombinant%2520humanized%2520anti-HER2%2520antibody%2520%2528Herceptin%2529%2520enhances%2520the%2520antitumor%2520activity%2520of%2520paclitaxel%2520and%2520doxorubicin%2520against%2520HER2%252Fneu%2520overexpressing%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2825%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony-Servat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4744</span><span class="NLM_x">–</span> <span class="NLM_lpage">4749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4744-4749&author=M.+A.+Molinaauthor=J.+Codony-Servatauthor=J.+Albanellauthor=F.+Rojoauthor=J.+Arribasauthor=J.+Baselga&title=Trastuzumab+%28herceptin%29%2C+a+humanized+anti-Her2+receptor+monoclonal+antibody%2C+inhibits+basal+and+activated+Her2+ectodomain+cleavage+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTrastuzumab%2520%2528herceptin%2529%252C%2520a%2520humanized%2520anti-Her2%2520receptor%2520monoclonal%2520antibody%252C%2520inhibits%2520basal%2520and%2520activated%2520Her2%2520ectodomain%2520cleavage%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4744%26epage%3D4749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_contrib-group">Gennari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagnoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponchio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scelsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagliabue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglioni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magalotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliviero, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballardini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Prada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, A.</span><span> </span><span class="NLM_article-title">Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15355889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5650-5655&author=R.+Gennariauthor=S.+Menardauthor=F.+Fagnoniauthor=L.+Ponchioauthor=M.+Scelsiauthor=E.+Tagliabueauthor=F.+Castiglioniauthor=L.+Villaniauthor=C.+Magalottiauthor=N.+Gibelliauthor=B.+Olivieroauthor=B.+Ballardiniauthor=G.+Da+Pradaauthor=A.+Zambelliauthor=A.+Costa&title=Pilot+study+of+the+mechanism+of+action+of+preoperative+trastuzumab+in+patients+with+primary+operable+breast+tumors+overexpressing+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2</span></div><div class="casAuthors">Gennari, Roberto; Menard, Sylvie; Fagnoni, Francesco; Ponchio, Luisa; Scelsi, Mario; Tagliabue, Elda; Castiglioni, Fabio; Villani, Laura; Magalotti, Cesare; Gibelli, Nadia; Oliviero, Barbara; Ballardini, Bettina; Da Prada, Gian Antonio; Zambelli, Alberto; Costa, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5650-5655</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To elucidate the mechanism by which trastuzumab, a humanized monoclonal antibody against HER2 with proven survival benefit in women with HER2-pos. metastatic breast cancer, mediates its antitumor activity.  A pilot study including 11 patients with HER2-pos. tumors treated in a neo-adjuvant setting with trastuzumab was performed.  Trastuzumab was administered i.v. at a dose of 4 mg/kg followed by three weekly i.v. doses of 2 mg/kg.  The primary tumor was surgically removed 7 days after the last treatment.  Surgical samples, tumor biopsies, and lymphocytes from these patients were collected for biol. studies.  Clin. data indicated one complete pathol. remission and four partial remissions using RECIST (Response Evaluation Criteria in Solid Tumors).  Trastuzumab was well tolerated and neither serious adverse events nor changes in cardiac function were obsd. during this short-term treatment and after surgery.  The biol. data showed that, independent of response, (a) all patients showed high levels of circulating trastuzumab; (b) satg. level of trastuzumab was present in all of the tumors; (c) no down-modulation of HER2 was obsd. in any tumors; (d) no changes in vessel diam. was obsd. in any tumors; (e) no changes in proliferation was obsd. in any tumors; and (f) a strong infiltration by lymphoid cells was obsd. in all cases.  Patients with complete remission or partial remission were found to have a higher in situ infiltration of leukocytes and a higher capability to mediate in vitro antibody-dependent cellular cytotoxicity activity.  The results of this pilot study argue against trastuzumab activity in patients through down-modulation of HER2 but in favor of antibody-dependent cellular cytotoxicity guiding efforts to optimize the use of trastuzumab in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUt98GRSRn3LVg90H21EOLACvtfcHk0lgelObhFBGiFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlOqtb8%253D&md5=6476627d73af0e5549938eefbd6f6903</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0225%26sid%3Dliteratum%253Aachs%26aulast%3DGennari%26aufirst%3DR.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DFagnoni%26aufirst%3DF.%26aulast%3DPonchio%26aufirst%3DL.%26aulast%3DScelsi%26aufirst%3DM.%26aulast%3DTagliabue%26aufirst%3DE.%26aulast%3DCastiglioni%26aufirst%3DF.%26aulast%3DVillani%26aufirst%3DL.%26aulast%3DMagalotti%26aufirst%3DC.%26aulast%3DGibelli%26aufirst%3DN.%26aulast%3DOliviero%26aufirst%3DB.%26aulast%3DBallardini%26aufirst%3DB.%26aulast%3DDa%2BPrada%26aufirst%3DG.%26aulast%3DZambelli%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DA.%26atitle%3DPilot%2520study%2520of%2520the%2520mechanism%2520of%2520action%2520of%2520preoperative%2520trastuzumab%2520in%2520patients%2520with%2520primary%2520operable%2520breast%2520tumors%2520overexpressing%2520HER2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5650%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_contrib-group">Marty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cognetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraninchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauriac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubiana-Hulin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Extra, J. M.</span><span> </span><span class="NLM_article-title">Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1200%2FJCO.2005.04.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15911866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms12gs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4265-4274&author=M.+Martyauthor=F.+Cognettiauthor=D.+Maraninchiauthor=R.+Snyderauthor=L.+Mauriacauthor=M.+Tubiana-Hulinauthor=S.+Chanauthor=D.+Grimesauthor=A.+Antonauthor=A.+Lluchauthor=J.+Kennedyauthor=K.+O%E2%80%99Byrneauthor=P.+Conteauthor=M.+Greenauthor=C.+Wardauthor=K.+Mayneauthor=J.+M.+Extra&title=Efficacy+and+safety+of+trastuzumab+combined+with+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+administered+as+first-line+treatment%3A+results+of+a+randomized+phase+II+trial+by+the+M77001+Study+Group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group</span></div><div class="casAuthors">Marty, Michel; Cognetti, Francesco; Maraninchi, Dominique; Snyder, Ray; Mauriac, Louis; Tubiana-Hulin, Michele; Chan, Stephen; Grimes, David; Anton, Antonio; Lluch, Ana; Kennedy, John; O'Byrne, Kenneth; Conte, PierFranco; Green, Michael; Ward, Carol; Mayne, Karen; Extra, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4274</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel vs. docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -pos. metastatic breast cancer (MBC).  Patients and Methods: Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 wk, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression.  Results: A total of 186 patients received at least one dose of the study drug.  Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% vs. 34%; P = .0002), overall survival (median, 31.2 vs. 22.7 mo; P = .0325), time to disease progression (median, 11.7 vs. 6.1 mo; P = .0001), time to treatment failure (median, 9.8 vs. 5.3 mo; P = .0001), and duration of response (median, 11.7 vs. 5.7 mo; P = .009).  There was little difference in the no. and severity of adverse events between the arms.  Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%).  One patient in the combination arm experienced symptomatic heart failure (1%).  Another patient experienced symptomatic heart failure 5 mo after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 mo.  Conclusion Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-pos. MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqski_X7qpo7Vg90H21EOLACvtfcHk0lgelObhFBGiFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms12gs70%253D&md5=276e619038d9c9a81b51edadf542b176</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.173%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DM.%26aulast%3DCognetti%26aufirst%3DF.%26aulast%3DMaraninchi%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DMauriac%26aufirst%3DL.%26aulast%3DTubiana-Hulin%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DGrimes%26aufirst%3DD.%26aulast%3DAnton%26aufirst%3DA.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DC.%26aulast%3DMayne%26aufirst%3DK.%26aulast%3DExtra%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520trastuzumab%2520combined%2520with%2520docetaxel%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%2520administered%2520as%2520first-line%2520treatment%253A%2520results%2520of%2520a%2520randomized%2520phase%2520II%2520trial%2520by%2520the%2520M77001%2520Study%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4265%26epage%3D4274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10e"><span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hozumi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinkai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, S.</span><span> </span><span class="NLM_article-title">Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1007%2Fs10549-009-0498-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=19690954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2010&pages=127-136&author=K.+Inoueauthor=K.+Nakagamiauthor=M.+Mizutaniauthor=Y.+Hozumiauthor=Y.+Fujiwaraauthor=N.+Masudaauthor=F.+Tsukamotoauthor=M.+Saitoauthor=S.+Miuraauthor=K.+Eguchiauthor=T.+Shinkaiauthor=M.+Andoauthor=T.+Watanabeauthor=N.+Masudaauthor=Y.+Ohashiauthor=M.+Sanoauthor=S.+Noguchi&title=Randomized+phase+III+trial+of+trastuzumab+monotherapy+followed+by+trastuzumab+plus+docetaxel+versus+trastuzumab+plus+docetaxel+as+first-line+therapy+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group</span></div><div class="casAuthors">Inoue, Kenichi; Nakagami, Kazuhiko; Mizutani, Mitsuhiro; Hozumi, Yasuo; Fujiwara, Yasuhiro; Masuda, Norikazu; Tsukamoto, Fumine; Saito, Mitsue; Miura, Shigeto; Eguchi, Kenji; Shinkai, Tetsu; Ando, Masashi; Watanabe, Toru; Masuda, Noriyuki; Ohashi, Yasuo; Sano, Muneaki; Noguchi, Shinzaburo</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of sequential therapy with trastuzumab monotherapy (H-mono) followed by H plus docetaxel (D) after disease progression (H → H + D) vs. combination therapy with H + D as first-line therapy.  Patients with human epidermal growth factor receptor type 2 (HER2)-pos. metastatic breast cancer (MBC) and left ventricular ejection fraction >50% were randomly assigned to either (a) H → H + D [H, once weekly 2 mg/kg (loading dose, 4 mg/kg); D, once every 3 wk 60 mg/m2] or (b) H + D.  Primary endpoints were progression-free survival (PFS) for the H-mono stage of the H → H + D group and H + D group and overall survival (OS) for both groups.  Secondary endpoints were overall response rate, time to treatment failure, second PFS and safety.  The planned no. of patients was 160 patients in total.  Of 112 patients enrolled, 107 were eligible.  After 112 patients were enrolled, the Independent Data Monitoring Committee recommended stopping enrollment because PFS and OS were greater in the H + D group than the H → H + D group.  Median PFS was 445 days in the H + D group vs. 114 days for H-mono in the H → H + D group [hazard ratio (HR), 4.24; P < 0.01].  OS was significantly longer in the H + D group (HR, 2.72; P = 0.04).  H + D therapy is significantly superior to H → H + D therapy as first-line therapy in patients with HER2-pos. MBC, esp. in terms of OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMPCloYStTQbVg90H21EOLACvtfcHk0lhNBTTMqCMsgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtr3N&md5=489ff5af524faa1c757714a6f14d224e</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1007%2Fs10549-009-0498-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-009-0498-7%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DNakagami%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DM.%26aulast%3DHozumi%26aufirst%3DY.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DTsukamoto%26aufirst%3DF.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DShinkai%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DOhashi%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DNoguchi%26aufirst%3DS.%26atitle%3DRandomized%2520phase%2520III%2520trial%2520of%2520trastuzumab%2520monotherapy%2520followed%2520by%2520trastuzumab%2520plus%2520docetaxel%2520versus%2520trastuzumab%2520plus%2520docetaxel%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D119%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=K.+Glennonauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0lhNBTTMqCMsgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DGlennon%26aufirst%3DK.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+Unique+Structure+for+Epidermal+Growth+Factor+Receptor+Bound+to+GW572016+%28Lapatinib%29%3A+Relationships+among+Protein+Conformation%2C+Inhibitor+Off-Rate%2C+and+Receptor+Activity+in+Tumor+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lhNBTTMqCMsgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520Unique%2520Structure%2520for%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520Relationships%2520among%2520Protein%2520Conformation%252C%2520Inhibitor%2520Off-Rate%252C%2520and%2520Receptor%2520Activity%2520in%2520Tumor%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0lj8IRMQ8GwQQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span> <span class="citation_source-book">Package Insert Tykerb (Lapatinib)</span>; <span class="NLM_publisher-name">GlaxoSmithKline</span>: <span class="NLM_publisher-loc">Research Triangle Park, NC 27709 USA</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Package+Insert+Tykerb+%28Lapatinib%29%3B+GlaxoSmithKline%3A+Research+Triangle+Park%2C+NC+27709+USA%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DPackage%2520Insert%2520Tykerb%2520%2528Lapatinib%2529%26pub%3DGlaxoSmithKline%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11e"><span><span class="NLM_contrib-group">Iqbal, S.; Goldman, B.; Fenoglio-Preiser, C. M.; Lenz, H. J.; Zhang, W.; Danenberg, K. D.; Shibata, S. I.; Blanke, C. D.</span><span> </span><span class="NLM_article-title">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span>.  <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi: <span class="refDoi"> DOI: 10.1093/annonc/mdr021</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1093%2Fannonc%2Fmdr021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=21415234" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Iqbal&author=B.+Goldman&author=C.+M.+Fenoglio-Preiser&author=H.+J.+Lenz&author=W.+Zhang&author=K.+D.+Danenberg&author=S.+I.+Shibata&author=C.+D.+Blanke&title=Southwest+Oncology+Group+study+S0413%3A+a+phase+II+trial+of+lapatinib+%28GW572016%29+as+first-line+therapy+in+patients+with+advanced+or+metastatic+gastric+cancer&doi=10.1093%2Fannonc%2Fmdr021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr021%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26atitle%3DSouthwest%2520Oncology%2520Group%2520study%2520S0413%253A%2520a%2520phase%2520II%2520trial%2520of%2520lapatinib%2520%2528GW572016%2529%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26doi%3D10.1093%2Fannonc%2Fmdr021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11f"><span><span class="NLM_contrib-group">Whang, Y. E.; Armstrong, A. J.; Rathmell, W. K.; Godley, P. A.; Kim, W. Y.; Pruthi, R. S.; Wallen, E. M.; Crane, J. M.; Moore, D. T.; Grigson, G.; Morris, K.; Watkins, C. P.; George, D. J.</span><span> </span><span class="NLM_article-title">A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer</span>.  <span class="citation_source-journal">Urol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi:<span class="refDoi"> DOI: 10.1016/j.urolonc.2010.09.018</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2Fj.urolonc.2010.09.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+E.+Whang&author=A.+J.+Armstrong&author=W.+K.+Rathmell&author=P.+A.+Godley&author=W.+Y.+Kim&author=R.+S.+Pruthi&author=E.+M.+Wallen&author=J.+M.+Crane&author=D.+T.+Moore&author=G.+Grigson&author=K.+Morris&author=C.+P.+Watkins&author=D.+J.+George&title=A+phase+II+study+of+lapatinib%2C+a+dual+EGFR+and+HER-2+tyrosine+kinase+inhibitor%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urolonc.2010.09.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2010.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2010.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DY.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lapatinib%252C%2520a%2520dual%2520EGFR%2520and%2520HER-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrol.%2520Oncol.%26date%3D2011%26doi%3D10.1016%2Fj.urolonc.2010.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11g"><span><span class="NLM_contrib-group">Mimura, K.; Kono, K.; Maruyama, T.; Watanabe, M.; Izawa, S.; Shiba, S.; Mizukami, Y.; Kawaguchi, Y.; Inoue, M.; Kono, T.; Choudhury, A.; Kiessling, R.; Fujii, H.</span><span> </span><span class="NLM_article-title">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines</span>.  <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi: <span class="refDoi"> DOI: 10.1002/ijc.25896</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1002%2Fijc.25896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Mimura&author=K.+Kono&author=T.+Maruyama&author=M.+Watanabe&author=S.+Izawa&author=S.+Shiba&author=Y.+Mizukami&author=Y.+Kawaguchi&author=M.+Inoue&author=T.+Kono&author=A.+Choudhury&author=R.+Kiessling&author=H.+Fujii&title=Lapatinib+inhibits+receptor+phosphorylation+and+cell+growth+and+enhances+antibody+dependent+cellular+cytoxicity+%28ADCC%29+of+EGFR+and+HER2+over-expressing+esophageal+cancer+cell+lines&doi=10.1002%2Fijc.25896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1002%2Fijc.25896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25896%26sid%3Dliteratum%253Aachs%26aulast%3DMimura%26aufirst%3DK.%26atitle%3DLapatinib%2520inhibits%2520receptor%2520phosphorylation%2520and%2520cell%2520growth%2520and%2520enhances%2520antibody%2520dependent%2520cellular%2520cytoxicity%2520%2528ADCC%2529%2520of%2520EGFR%2520and%2520HER2%2520over-expressing%2520esophageal%2520cancer%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26doi%3D10.1002%2Fijc.25896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11h"><span><span class="NLM_contrib-group">Ross, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-08-3328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=20215545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1938-1949&author=H.+J.+Rossauthor=G.+R.+Blumenscheinauthor=J.+Aisnerauthor=N.+Damjanovauthor=A.+Dowlatiauthor=J.+Garstauthor=J.+R.+Rigasauthor=M.+Smylieauthor=H.+Hassaniauthor=K.+E.+Allenauthor=L.+Leopoldauthor=T.+Z.+Zaksauthor=F.+A.+Shepherd&title=Randomized+phase+II+multicenter+trial+of+two+schedules+of+lapatinib+as+first-+or+second-line+monotherapy+in+patients+with+advanced+or+metastatic+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11hR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Ross, Helen J.; Blumenschein, George R., Jr.; Aisner, Joseph; Damjanov, Nevena; Dowlati, Afshin; Garst, Jennifer; Rigas, James R.; Smylie, Michael; Hassani, Habib; Allen, Kimberly E.; Leopold, Lance; Zaks, Tal Z.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1938-1949</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.  Exptl. Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance.  Patients could have had a max. of one prior systemic therapy (chemotherapy or biol. therapy) for NSCLC.  Safety and activity were assessed every 4 and 8 wk, resp.  Tumors were analyzed for EGFR and HER2 mutations and/or amplifications.  RESULTS: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 wk.  No complete or partial responses were obsd. in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 wk.  No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification.  No mutations in HER2 were found.  One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed.  The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia.  Adverse events were similar across dosing regimens.  CONCLUSIONS: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups.  Lapatinib monotherapy did not induce a significant no. of tumor regressions in NSCLC.  Further studies may be warranted to det. whether lapatinib is active in combination with other agents in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-5ZsLpn50LrVg90H21EOLACvtfcHk0liiZrEd3mstXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D&md5=0bfa99df35f30bb9e9ef0b2addb23e28</span></div><a href="/servlet/linkout?suffix=cit11h&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3328%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DH.%2BJ.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAisner%26aufirst%3DJ.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DGarst%26aufirst%3DJ.%26aulast%3DRigas%26aufirst%3DJ.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DHassani%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DZaks%26aufirst%3DT.%2BZ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DRandomized%2520phase%2520II%2520multicenter%2520trial%2520of%2520two%2520schedules%2520of%2520lapatinib%2520as%2520first-%2520or%2520second-line%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D1938%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11i"><span><span class="NLM_contrib-group">Ooi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunitomo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobashi, Y.</span><span> </span><span class="NLM_article-title">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fmodpathol.3800137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15143334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=895-904&author=A.+Ooiauthor=T.+Takehanaauthor=X.+Liauthor=S.+Suzukiauthor=K.+Kunitomoauthor=H.+Iinoauthor=H.+Fujiiauthor=Y.+Takedaauthor=Y.+Dobashi&title=Protein+overexpression+and+gene+amplification+of+HER-2+and+EGFR+in+colorectal+cancers%3A+an+immunohistochemical+and+fluorescent+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11iR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span></div><div class="casAuthors">Ooi, Akishi; Takehana, Takuo; Li, Xiaoling; Suzuki, Shioto; Kunitomo, Kazuyoshi; Iino, Hiroshi; Fujii, Hideki; Takeda, Yasuhisa; Dobashi, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been obsd. in many cancers, sometimes accompanied by gene amplification.  To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examd. the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors.  We evaluated 244 colorectal cancers immunohistochem.  All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization.  Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, resp.  Gene amplification was obsd. in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, resp.  HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors.  EGFR amplification, obsd. as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was obsd. as a minor population within primary tumors, and found in variety of populations in metastatic tumors.  Overexpression of HER-2 and EGFR were obsd. in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps8JLiZoJAWbVg90H21EOLACvtfcHk0liiZrEd3mstXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D&md5=e073b560295b3ca3331a7f4fe11f59f7</span></div><a href="/servlet/linkout?suffix=cit11i&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3800137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3800137%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%26aulast%3DTakehana%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKunitomo%26aufirst%3DK.%26aulast%3DIino%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DDobashi%26aufirst%3DY.%26atitle%3DProtein%2520overexpression%2520and%2520gene%2520amplification%2520of%2520HER-2%2520and%2520EGFR%2520in%2520colorectal%2520cancers%253A%2520an%2520immunohistochemical%2520and%2520fluorescent%2520in%2520situ%2520hybridization%2520study%26jtitle%3DMod.%2520Pathol.%26date%3D2004%26volume%3D17%26spage%3D895%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-Disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+Orally+Active%2C+Irreversible+Inhibitors+of+Human+Epidermal+Growth+Factor+Receptor-2+Kinase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-Disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor-2%2520Kinase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.-C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+J%C3%A4nneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.-K.+Wong&title=Bronchial+and+Peripheral+Murine+Lung+Carcinomas+Induced+by+T790M-L858R+Mutant+EGFR+Respond+to+HKI-272+and+Rapamycin+Combination+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.-C.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBronchial%2520and%2520Peripheral%2520Murine%2520Lung%2520Carcinomas%2520Induced%2520by%2520T790M-L858R%2520Mutant%2520EGFR%2520Respond%2520to%2520HKI-272%2520and%2520Rapamycin%2520Combination%2520Therapy%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0lgDBA1hYQUNeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_contrib-group">Rall, W.; Soyka, R.; Kulinna, C.; Schnaubelt, J.; Sieger, P.</span><span> </span><span class="NLM_article-title">Method for the production of amino crotonyl compounds</span>. International Patent Application WO/2005/037824. PCT/EP2004/011378, <span class="NLM_month">April</span><span class="NLM_day">28</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=W.+Rall&author=R.+Soyka&author=C.+Kulinna&author=J.+Schnaubelt&author=P.+Sieger&title=Method+for+the+production+of+amino+crotonyl+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRall%26aufirst%3DW.%26atitle%3DMethod%2520for%2520the%2520production%2520of%2520amino%2520crotonyl%2520compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.-H.+Namauthor=J.+Heauthor=S.-J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_contrib-group">Bold, G.; Caprard, H.-G.; Caravatti, G.; Traxler, P.</span><span> </span><span class="NLM_article-title">4-Amino-6-phenyl-pyrrolo[2,3-<i>d</i>]pyrimidine Derivatives</span>. PCT Int. WO 03/013541, <span class="NLM_month">Feb</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=G.+Bold&author=H.-G.+Caprard&author=G.+Caravatti&author=P.+Traxler&title=4-Amino-6-phenyl-pyrrolo%5B2%2C3-d%5Dpyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3D4-Amino-6-phenyl-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lgadETZxYD5PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2036-2042&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=P.+Dextrazeauthor=B.+E.+Finkauthor=A.+Gavaiauthor=B.+Goyalauthor=W.-C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=E.+Ruedigerauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=New+C-5+substituted+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DRuediger%26aufirst%3DE.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNew%2520C-5%2520substituted%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2036%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2828</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2828-2833&author=H.+Mastalerzauthor=M.+Changauthor=A.+Gavaiauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=J.+Tarrant.author=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=Novel+C-5+aminomethyl+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DTarrant.%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNovel%2520C-5%2520aminomethyl%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2828%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4947-4954&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=B.+E.+Finkauthor=A.+Gavaiauthor=W+C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=K.+Leavittauthor=P.+Maratheauthor=D.+Norrisauthor=S.+Oppenheimerauthor=B.+Sleczkaauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=5-%28%284-Aminopiperidin-1-yl%29methyl%29pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW%2BC.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3D5-%2528%25284-Aminopiperidin-1-yl%2529methyl%2529pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4947%26epage%3D4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M. D.</span><span> </span><span class="NLM_article-title">Achieving selectivity between higly homologous tyrosine kinases anovel selective erbB2 inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=267-273&author=S.+K.+Bhattacharyaauthor=E.+D.+Coxauthor=J.+C.+Kathauthor=A.+M.+Mathiowetzauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=D.+T.+Richterauthor=C.+Suauthor=M.+D.+Wessel&title=Achieving+selectivity+between+higly+homologous+tyrosine+kinases+anovel+selective+erbB2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DAchieving%2520selectivity%2520between%2520higly%2520homologous%2520tyrosine%2520kinases%2520anovel%2520selective%2520erbB2%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D267%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span> </span><span class="NLM_article-title">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9887</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F0008-5472.CAN-06-3559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=17942920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9887-93&author=J.+P.+Janiauthor=R.+S.+Finnauthor=M.+Campbellauthor=K.+G.+Colemanauthor=R.+D.+Connellauthor=N.+Currierauthor=E.+O.+Emersonauthor=E.+Floydauthor=S.+Harrimanauthor=J.+C.+Kathauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=S.+Ralstonauthor=A.+M.+Rossiauthor=S.+J.+Steynauthor=L.+Wagnerauthor=S.+M.+Winterauthor=S.+K.+Bhattacharya&title=Discovery+and+Pharmacologic+Characterization+of+CP-724%2C714%2C+a+Selective+ErbB2+Tyrosine+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Jani, Jitesh P.; Finn, Richard S.; Campbell, Mary; Coleman, Kevin G.; Connell, Richard D.; Currier, Nicolas; Emerson, Erling O.; Floyd, Eugenia; Harriman, Shawn; Kath, John C.; Morris, Joel; Moyer, James D.; Pustilnik, Leslie R.; Rafidi, Kristina; Ralston, Sherry; Rossi, Ann Marie K.; Steyn, Stefanus J.; Wagner, Larry; Winter, Steven M.; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9887-9893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach.  It has been implicated in tumor growth, sensitivity to std. chemotherapy, prognosis of patients, and disease-free survival.  Although the clin. use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-mol. inhibitors.  CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clin. trials.  Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models.  CP-724,714 is selective for inhibiting growth of HER2-driven cell lines.  In addn., we show that it induces G1 cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice.  It induces a marked redn. of extracellular signal-regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3.  P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_a6qjvEZI-rVg90H21EOLACvtfcHk0ljQgB-ogvoW1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE&md5=21dc688108dd46aba15694d7e3159321</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3559%26sid%3Dliteratum%253Aachs%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DCurrier%26aufirst%3DN.%26aulast%3DEmerson%26aufirst%3DE.%2BO.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DS.%2BM.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520and%2520Pharmacologic%2520Characterization%2520of%2520CP-724%252C714%252C%2520a%2520Selective%2520ErbB2%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9887%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_contrib-group">Ripin, D. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourassa, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldi, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggon, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. M.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetelino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span> </span><span class="NLM_article-title">Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/doi/10.1021/op050039u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=440-450&author=D.+H.+B.+Ripinauthor=D.+E.+Bourassaauthor=T.+Brandtauthor=M.+J.+Castaldiauthor=H.+N.+Frostauthor=J.+Hawkinsauthor=P.+J.+Johnsonauthor=S.+S.+Massettauthor=K.+Neumannauthor=J.+Phillipsauthor=J.+W.+Raggonauthor=P.+R.+Roseauthor=J.+L.+Rutherfordauthor=B.+Sitterauthor=A.+M.+Stewartauthor=M.+G.+Vetelinoauthor=L.+Wei&title=Evaluation+of+Kilogram-Scale+Sonagashira%2C+Suzuki%2C+and+Heck+Coupling+Routes+to+Oncology+Candidate+CP-724%2C714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1021%2Fop050039u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop050039u%26sid%3Dliteratum%253Aachs%26aulast%3DRipin%26aufirst%3DD.%2BH.%2BB.%26aulast%3DBourassa%26aufirst%3DD.%2BE.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCastaldi%26aufirst%3DM.%2BJ.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%2BJ.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DNeumann%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DRaggon%26aufirst%3DJ.%2BW.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DRutherford%26aufirst%3DJ.%2BL.%26aulast%3DSitter%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DA.%2BM.%26aulast%3DVetelino%26aufirst%3DM.%2BG.%26aulast%3DWei%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520Kilogram-Scale%2520Sonagashira%252C%2520Suzuki%252C%2520and%2520Heck%2520Coupling%2520Routes%2520to%2520Oncology%2520Candidate%2520CP-724%252C714%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D440%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16d"><span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span> </span><span class="NLM_article-title">The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3081</span><span class="NLM_x">–</span> <span class="NLM_lpage">3086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3081-3086&author=B.+Lippaauthor=G.+S.+Kauffmanauthor=J.+Arcariauthor=T.+Kwanauthor=J.+Chenauthor=W.+Hungerfordauthor=S.+Bhattacharyaauthor=X.+Zhaoauthor=C.+Williamsauthor=J.+Xiaoauthor=L.+Pustilnikauthor=C.+Suauthor=J.+D.+Moyerauthor=L.+Maauthor=M.+Campbellauthor=S.+Steyn&title=The+discovery+of+highly+selective+erbB2+%28Her2%29+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DKauffman%26aufirst%3DG.%2BS.%26aulast%3DArcari%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DPustilnik%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DSteyn%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520highly%2520selective%2520erbB2%2520%2528Her2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3081%26epage%3D3086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Studies on nucleic acid antagonists. VII. Synthesis and characterization of 1,4,6-triazaindenes (5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidines)</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1964&pages=1030-1042&author=K.+Imai&title=Studies+on+nucleic+acid+antagonists.+VII.+Synthesis+and+characterization+of+1%2C4%2C6-triazaindenes+%285H-pyrrolo%5B3%2C2-d%5Dpyrimidines%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26atitle%3DStudies%2520on%2520nucleic%2520acid%2520antagonists.%2520VII.%2520Synthesis%2520and%2520characterization%2520of%25201%252C4%252C6-triazaindenes%2520%25285H-pyrrolo%255B3%252C2-d%255Dpyrimidines%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1964%26volume%3D12%26spage%3D1030%26epage%3D1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span> </span><span class="NLM_article-title">A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-overexpressing breast cancer</span>. <span class="NLM_contrib-group">Hayashi, A.; Tamura, T.; Yusa, T.; Takagi, S.; Ohta, Y.</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span>, <span class="NLM_issue">Suppl 1</span>, <div class="note"><p class="first last">Abstract 3143</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2008&issue=Suppl+1&author=A.+Hayashi&author=T.+Tamura&author=T.+Yusa&author=S.+Takagi&author=Y.+Ohta&title=A+novel+HER2+inhibitor+TAK-285+overcomes+trastuzumab+resistance+of+HER2-overexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520novel%2520HER2%2520inhibitor%2520TAK-285%2520overcomes%2520trastuzumab%2520resistance%2520of%2520HER2-overexpressing%2520breast%2520cancer%26aulast%3DHayashi%26aufirst%3DA.%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D69%26issue%3DSuppl%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span> </span><span class="NLM_article-title">Improved Syntheses of 3<i>H</i>,5<i>H</i>-Pyrrolo[3,2-<i>d</i>]pyrimidines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">8411</span><span class="NLM_x">–</span> <span class="NLM_lpage">8412</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo990903e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=8411-8412&author=R.+H.+Furneauxauthor=P.+C.+Tyler&title=Improved+Syntheses+of+3H%2C5H-Pyrrolo%5B3%2C2-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fjo990903e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990903e%26sid%3Dliteratum%253Aachs%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26atitle%3DImproved%2520Syntheses%2520of%25203H%252C5H-Pyrrolo%255B3%252C2-d%255Dpyrimidines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D8411%26epage%3D8412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_contrib-group">Evans, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kezar, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span> </span><span class="NLM_article-title">Addition of Lithiated 9-Deazapurine Derivatives to a Carbohydrate Cyclic Imine: Convergent Synthesis of the Aza-<i>C</i>-nucleoside Immucillins</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5723</span><span class="NLM_x">–</span> <span class="NLM_lpage">5730</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo0155613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=5723-5730&author=G.+B.+Evansauthor=R.+H.+Furneauxauthor=T.+L.+Hutchisonauthor=H.+S.+Kezarauthor=P.+E.+Morrisauthor=V.+L.+Schrammauthor=P.+C.+Tyler&title=Addition+of+Lithiated+9-Deazapurine+Derivatives+to+a+Carbohydrate+Cyclic+Imine%3A+Convergent+Synthesis+of+the+Aza-C-nucleoside+Immucillins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjo0155613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0155613%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DG.%2BB.%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DHutchison%26aufirst%3DT.%2BL.%26aulast%3DKezar%26aufirst%3DH.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BE.%26aulast%3DSchramm%26aufirst%3DV.%2BL.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26atitle%3DAddition%2520of%2520Lithiated%25209-Deazapurine%2520Derivatives%2520to%2520a%2520Carbohydrate%2520Cyclic%2520Imine%253A%2520Convergent%2520Synthesis%2520of%2520the%2520Aza-C-nucleoside%2520Immucillins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D5723%26epage%3D5730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_contrib-group">Furneaux, R. H.; Tyler, P. C.</span>PCT Int. WO 00/61783, <span class="NLM_month">Oct</span><span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Furneaux%2C+R.+H.%3B+Tyler%2C+P.+C.PCT+Int.+WO+00%2F61783%2C+Oct+2000."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yona, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yonaauthor=B.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYona%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RCD">3RCD</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e','cit11f','cit11g','cit11h','cit11i'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16a','cit16b','cit16c','cit16d'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 98 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tamer A. Elwaie, Safinaz E. Abbas, Enayat I. Aly, Riham F. George, Hamdy Ali, Nikolai Kraiouchkine, Khaldoun S. Abdelwahed, Tamer E. Fandy, Khalid A. El Sayed, Zakaria Y. Abd Elmageed, <span class="NLM_string-name hlFld-ContribAuthor">Hamed I. Ali</span>. </span><span class="cited-content_cbyCitation_article-title">HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15906-15945. <a href="https://doi.org/10.1021/acs.jmedchem.0c01647" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01647%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHER2%252BKinase-Targeted%252BBreast%252BCancer%252BTherapy%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BIn%252BVitro%252Band%252BIn%252BVivo%252BEvaluation%252Bof%252BNovel%252BLapatinib%252BCongeners%252Bas%252BSelective%252Band%252BPotent%252BHER2%252BInhibitors%252Bwith%252BFavorable%252BMetabolic%252BStability%26aulast%3DElwaie%26aufirst%3DTamer%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15906%26epage%3D15945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jonas Lategahn, Julia Hardick, Tobias Grabe, Janina Niggenaber, Kirujan Jeyakumar, Marina Keul, Hannah L. Tumbrink, Christian Becker, Luke Hodson, Tonia Kirschner, Philip Klövekorn, Julia Ketzer, Matthias Baumann, Susanne Terheyden, Anke Unger, Jörn Weisner, Matthias P. Müller, Willem A. L. van Otterlo, Sebastian Bauer, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11725-11755. <a href="https://doi.org/10.1021/acs.jmedchem.0c00870" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00870%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BHer2-insYVMA%252Bwith%252BCovalent%252BInhibitors%2525E2%252580%252594A%252BFocused%252BCompound%252BScreening%252Band%252BStructure-Based%252BDesign%252BApproach%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22052020%26date%3D30092020%26date%3D15092020%26volume%3D63%26issue%3D20%26spage%3D11725%26epage%3D11755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Julia Hardick, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 40-51. <a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BDefines%252BFunction%25253A%252BClinically%252BRelevant%252BMutations%252Bin%252BErbB%252BKinases%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D28082019%26date%3D15082019%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard Schroeder, Mary Sfondouris, Navneet Goyal, Rajesh Komati, Achira Weerathunga, Cory Gettridge, Cheryl L. Klein Stevens, Frank E. Jones, <span class="NLM_string-name hlFld-ContribAuthor">Jayalakshmi Sridhar</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (6)
                                     , 10610-10619. <a href="https://doi.org/10.1021/acsomega.9b00929" title="DOI URL">https://doi.org/10.1021/acsomega.9b00929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b00929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b00929%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DIdentification%252Bof%252BNew%252BMono%25252FDihydroxynaphthoquinone%252Bas%252BLead%252BAgents%252BThat%252BInhibit%252Bthe%252BGrowth%252Bof%252BRefractive%252Band%252BTriple-Negative%252BBreast%252BCancer%252BCell%252BLines%26aulast%3DSchroeder%26aufirst%3DRichard%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02042019%26date%3D15052019%26volume%3D4%26issue%3D6%26spage%3D10610%26epage%3D10619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>, <span class="hlFld-ContribAuthor ">Giorgio  Amendola</span>, <span class="hlFld-ContribAuthor ">Carminia Maria  Della Corte</span>, <span class="hlFld-ContribAuthor ">Chiara  Giacomelli</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Salvatore  Di Maro</span>, <span class="hlFld-ContribAuthor ">Anna  Messere</span>, <span class="hlFld-ContribAuthor ">Vincenza  Ciaramella</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Luciana  Marinelli</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Trincavelli</span>, <span class="hlFld-ContribAuthor ">Claudia  Martini</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, and <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (17)
                                     , 7447-7458. <a href="https://doi.org/10.1021/acs.jmedchem.7b00794" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00794%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BMET%252Band%252BSMO%252BNegative%252BModulators%252BOvercome%252BResistance%252Bto%252BEGFR%252BInhibitors%252Bin%252BHuman%252BNonsmall%252BCell%252BLung%252BCancer%26aulast%3DMorgillo%26aufirst%3DFloriana%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D31052017%26date%3D22082017%26date%3D14092017%26date%3D08082017%26volume%3D60%26issue%3D17%26spage%3D7447%26epage%3D7458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Yuqiong  Xu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7111-7124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00403" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructural%252BOptimization%252Bof%252BN5-Substituted%252B6%25252C7-Dioxo-6%25252C7-dihydropteridines%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26032016%26date%3D21072016%26date%3D11082016%26date%3D11072016%26volume%3D59%26issue%3D15%26spage%3D7111%26epage%3D7124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinde  Vidyacharan</span>, <span class="hlFld-ContribAuthor ">Arumugavel  Murugan</span>, and <span class="hlFld-ContribAuthor ">Duddu S.  Sharada</span>  . </span><span class="cited-content_cbyCitation_article-title">C(sp2)–H Functionalization of 2H-Indazoles at C3-Position via Palladium(II)-Catalyzed Isocyanide Insertion Strategy Leading to Diverse Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (7)
                                     , 2837-2848. <a href="https://doi.org/10.1021/acs.joc.6b00048" title="DOI URL">https://doi.org/10.1021/acs.joc.6b00048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b00048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b00048%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DC%252528sp2%252529%2525E2%252580%252593H%252BFunctionalization%252Bof%252B2H-Indazoles%252Bat%252BC3-Position%252Bvia%252BPalladium%252528II%252529-Catalyzed%252BIsocyanide%252BInsertion%252BStrategy%252BLeading%252Bto%252BDiverse%252BHeterocycles%26aulast%3DVidyacharan%26aufirst%3DShinde%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D19012016%26date%3D18032016%26date%3D01042016%26date%3D08032016%26volume%3D81%26issue%3D7%26spage%3D2837%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Hui  Peng</span>, <span class="hlFld-ContribAuthor ">Hui-Yi  Shiao</span>, <span class="hlFld-ContribAuthor ">Chih-Hsiang  Tu</span>, <span class="hlFld-ContribAuthor ">Pang-Min  Liu</span>, <span class="hlFld-ContribAuthor ">John Tsu-An  Hsu</span>, <span class="hlFld-ContribAuthor ">Prashanth Kumar  Amancha</span>, <span class="hlFld-ContribAuthor ">Jian-Sung  Wu</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>, <span class="hlFld-ContribAuthor ">Chun-Hwa  Chen</span>, <span class="hlFld-ContribAuthor ">Sing-Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Hsu-Yi  Sun</span>, <span class="hlFld-ContribAuthor ">Yu-Sheng  Chao</span>, <span class="hlFld-ContribAuthor ">Ping-Chiang  Lyu</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>, and <span class="hlFld-ContribAuthor ">Su-Ying  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (10)
                                     , 3889-3903. <a href="https://doi.org/10.1021/jm400072p" title="DOI URL">https://doi.org/10.1021/jm400072p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400072p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProtein%252BKinase%252BInhibitor%252BDesign%252Bby%252BTargeting%252Bthe%252BAsp-Phe-Gly%252B%252528DFG%252529%252BMotif%25253A%252BThe%252BRole%252Bof%252Bthe%252BDFG%252BMotif%252Bin%252Bthe%252BDesign%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%26aulast%3DPeng%26aufirst%3DYi-Hui%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D15012013%26date%3D10052013%26date%3D23052013%26date%3D23042013%26volume%3D56%26issue%3D10%26spage%3D3889%26epage%3D3903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Shigeru  Igaki</span>, <span class="hlFld-ContribAuthor ">Hidehisa  Iwata</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Cary</span>, <span class="hlFld-ContribAuthor ">Terufumi  Takagi</span>, <span class="hlFld-ContribAuthor ">Shinji  Takagi</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, and <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (2)
                                     , 201-205. <a href="https://doi.org/10.1021/ml300327z" title="DOI URL">https://doi.org/10.1021/ml300327z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml300327z%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-Based%252BApproach%252Bfor%252Bthe%252BDiscovery%252Bof%252BPyrrolo%25255B3%25252C2-d%25255Dpyrimidine-Based%252BEGFR%252BT790M%25252FL858R%252BMutant%252BInhibitors%26aulast%3DSogabe%26aufirst%3DSatoshi%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D10102012%26date%3D18122012%26date%3D21122012%26date%3D14022013%26date%3D18122012%26volume%3D4%26issue%3D2%26spage%3D201%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Jing-Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Ren-Lin  Zheng</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Pan  Ji</span>, <span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Xing-Dong  Lin</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (23)
                                     , 10685-10699. <a href="https://doi.org/10.1021/jm301365e" title="DOI URL">https://doi.org/10.1021/jm301365e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301365e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BOptimization%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BN2-%2525284-%2525284-Methylpiperazin-1-yl%252529phenyl%252529-N8-phenyl-9H-purine-2%25252C8-diamine%252BDerivatives%25252C%252Ba%252BNew%252BClass%252Bof%252BReversible%252BKinase%252BInhibitors%252BTargeting%252Bboth%252BEGFR-Activating%252Band%252BResistance%252BMutations%26aulast%3DYang%26aufirst%3DJiao%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D21092012%26date%3D16112012%26date%3D13122012%26date%3D01112012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Banno</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Ohashi</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tadashi  Yusa</span>, <span class="hlFld-ContribAuthor ">Akiko  Nakayama</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Hidehisa  Iwata</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Toshimasa  Tanaka</span>, <span class="hlFld-ContribAuthor ">Noriyuki  Habuka</span>, <span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, and <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (8)
                                     , 3975-3991. <a href="https://doi.org/10.1021/jm300185p" title="DOI URL">https://doi.org/10.1021/jm300185p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300185p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300185p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BPyrrolo%25255B3%25252C2-d%25255Dpyrimidine%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2%252B%252528HER2%252529%25252FEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BDual%252BInhibitors%25253A%252BExploration%252Bof%252BNovel%252BBack-Pocket%252BBinders%26aulast%3DKawakita%26aufirst%3DYouichi%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D10022012%26date%3D10042012%26date%3D26042012%26date%3D22032012%26volume%3D55%26issue%3D8%26spage%3D3975%26epage%3D3991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Jie  Zuo</span>, <span class="hlFld-ContribAuthor ">Xiao-Liang  Cheng</span>, <span class="hlFld-ContribAuthor ">Dong-Zheng  Liu</span>, <span class="hlFld-ContribAuthor ">Wei-Yi  Feng</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a validated LC-MS/MS method. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica</span><span> <strong>2021,</strong> <em>71 </em>
                                    (3)
                                     , 415-428. <a href="https://doi.org/10.2478/acph-2021-0024" title="DOI URL">https://doi.org/10.2478/acph-2021-0024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/acph-2021-0024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Facph-2021-0024%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%26atitle%3DQuantitative%252Banalysis%252Band%252Bpharmacokinetic%252Bstudy%252Bof%252Ba%252Bnovel%252Bdiarylurea%252BEGFR%252Binhibitor%252B%252528ZCJ14%252529%252Bin%252Brat%252Bplasma%252Busing%252Ba%252Bvalidated%252BLC-MS%25252FMS%252Bmethod%26aulast%3DZuo%26aufirst%3DSai-Jie%26date%3D2021%26date%3D2020%26volume%3D71%26issue%3D3%26spage%3D415%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter A.  Sidhom</span>, <span class="hlFld-ContribAuthor ">Eman  El-Bastawissy</span>, <span class="hlFld-ContribAuthor ">Abeer A.  Salama</span>, <span class="hlFld-ContribAuthor ">Tarek F.  El-Moselhy</span>. </span><span class="cited-content_cbyCitation_article-title">Revisiting ageless antiques; synthesis, biological evaluation, docking simulation and mechanistic insights of 1,4-Dihydropyridines as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105054. <a href="https://doi.org/10.1016/j.bioorg.2021.105054" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105054%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DRevisiting%252Bageless%252Bantiques%25253B%252Bsynthesis%25252C%252Bbiological%252Bevaluation%25252C%252Bdocking%252Bsimulation%252Band%252Bmechanistic%252Binsights%252Bof%252B1%25252C4-Dihydropyridines%252Bas%252Banticancer%252Bagents%26aulast%3DSidhom%26aufirst%3DPeter%2BA.%26date%3D2021%26volume%3D114%26spage%3D105054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Xiao‐jie  Jin</span>, <span class="hlFld-ContribAuthor ">Jia‐wei  Li</span>, <span class="hlFld-ContribAuthor ">Cheng‐hao  Li</span>, <span class="hlFld-ContribAuthor ">Shuang‐yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Jun‐jie  Li</span>, <span class="hlFld-ContribAuthor ">Cai‐qin  Feng</span>, <span class="hlFld-ContribAuthor ">Dong‐ling  Liu</span>, <span class="hlFld-ContribAuthor ">Yong‐qi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2021,</strong> <em>112 </em>
                                    (5)
                                     , 1772-1784. <a href="https://doi.org/10.1111/cas.14851" title="DOI URL">https://doi.org/10.1111/cas.14851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14851%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DSystematic%252Binsight%252Binto%252Bthe%252Bactive%252Bconstituents%252Band%252Bmechanism%252Bof%252BGuiqi%252BBaizhu%252Bfor%252Bthe%252Btreatment%252Bof%252Bgastric%252Bcancer%26aulast%3DLi%26aufirst%3DLing%26date%3D2021%26date%3D2021%26volume%3D112%26issue%3D5%26spage%3D1772%26epage%3D1784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akash Anand  Bansod</span>, <span class="hlFld-ContribAuthor ">Gnanam  Ramasamy</span>, <span class="hlFld-ContribAuthor ">Bharathi  Nathan</span>, <span class="hlFld-ContribAuthor ">Rajamani  Kandhasamy</span>, <span class="hlFld-ContribAuthor ">Meenakshisundaram  Palaniappan</span>, <span class="hlFld-ContribAuthor ">Santhanakrishnan  Vichangal Pridiuldi</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC. </span><span class="cited-content_cbyCitation_journal-name">3 Biotech</span><span> <strong>2021,</strong> <em>11 </em>
                                    (5)
                                     <a href="https://doi.org/10.1007/s13205-021-02768-x" title="DOI URL">https://doi.org/10.1007/s13205-021-02768-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13205-021-02768-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13205-021-02768-x%26sid%3Dliteratum%253Aachs%26jtitle%3D3%2520Biotech%26atitle%3DExploring%252Bthe%252Bendogenous%252Bpotential%252Bof%252BHemidesmus%252Bindicus%252Bagainst%252Bbreast%252Bcancer%252Busing%252Bin%252Bsilico%252Bstudies%252Band%252Bquantification%252Bof%252B2-hydroxy-4-methoxy%252Bbenzaldehyde%252Bthrough%252BRP-HPLC%26aulast%3DBansod%26aufirst%3DAkash%2BAnand%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louise  Pinet</span>, <span class="hlFld-ContribAuthor ">Ying-Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Célia  Deville</span>, <span class="hlFld-ContribAuthor ">Ewen  Lescop</span>, <span class="hlFld-ContribAuthor ">Françoise  Guerlesquin</span>, <span class="hlFld-ContribAuthor ">Ali  Badache</span>, <span class="hlFld-ContribAuthor ">François  Bontems</span>, <span class="hlFld-ContribAuthor ">Nelly  Morellet</span>, <span class="hlFld-ContribAuthor ">Dominique  Durand</span>, <span class="hlFld-ContribAuthor ">Nadine  Assrir</span>, <span class="hlFld-ContribAuthor ">Carine  van Heijenoort</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random. </span><span class="cited-content_cbyCitation_journal-name">Biophysical Journal</span><span> <strong>2021,</strong> <em>120 </em>
                                    (10)
                                     , 1869-1882. <a href="https://doi.org/10.1016/j.bpj.2021.03.005" title="DOI URL">https://doi.org/10.1016/j.bpj.2021.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bpj.2021.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bpj.2021.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBiophysical%2520Journal%26atitle%3DStructural%252Band%252Bdynamic%252Bcharacterization%252Bof%252Bthe%252BC-terminal%252Btail%252Bof%252BErbB2%25253A%252BDisordered%252Bbut%252Bnot%252Brandom%26aulast%3DPinet%26aufirst%3DLouise%26date%3D2021%26volume%3D120%26issue%3D10%26spage%3D1869%26epage%3D1882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bello  Martiniano</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2021,</strong> <em>27 </em>
                                    (4)
                                     <a href="https://doi.org/10.1007/s00894-021-04720-5" title="DOI URL">https://doi.org/10.1007/s00894-021-04720-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-021-04720-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-021-04720-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DMolecular%252Brecognition%252Bof%252Btak-285%252Band%252Blapatinib%252Bby%252Binactive%25252C%252Bactive%25252C%252Band%252Bmiddle%252Bactive-inactive%252BHER2%26aulast%3DMartiniano%26aufirst%3DBello%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denis  Schmidt</span>, <span class="hlFld-ContribAuthor ">Magdalena M.  Scharf</span>, <span class="hlFld-ContribAuthor ">Dominique  Sydow</span>, <span class="hlFld-ContribAuthor ">Eva  Aßmann</span>, <span class="hlFld-ContribAuthor ">Maria  Martí-Solano</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Andrea  Volkamer</span>, <span class="hlFld-ContribAuthor ">Peter  Kolb</span>. </span><span class="cited-content_cbyCitation_article-title">Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 629. <a href="https://doi.org/10.3390/molecules26030629" title="DOI URL">https://doi.org/10.3390/molecules26030629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030629%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAnalyzing%252BKinase%252BSimilarity%252Bin%252BSmall%252BMolecule%252Band%252BProtein%252BStructural%252BSpace%252Bto%252BExplore%252Bthe%252BLimits%252Bof%252BMulti-Target%252BScreening%26aulast%3DSchmidt%26aufirst%3DDenis%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nalinee  Pradubyat</span>, <span class="hlFld-ContribAuthor ">Athina  Giannoudis</span>, <span class="hlFld-ContribAuthor ">Taha  Elmetwali</span>, <span class="hlFld-ContribAuthor ">Panupong  Mahalapbutr</span>, <span class="hlFld-ContribAuthor ">Carlo  Palmieri</span>, <span class="hlFld-ContribAuthor ">Chalermchai  Mitrpant</span>, <span class="hlFld-ContribAuthor ">Wannarasmi  Ketchart</span>. </span><span class="cited-content_cbyCitation_article-title">1′-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Planta Medica</span><span> <strong>2021,</strong> <em>339 </em><a href="https://doi.org/10.1055/a-1307-3997" title="DOI URL">https://doi.org/10.1055/a-1307-3997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1307-3997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1307-3997%26sid%3Dliteratum%253Aachs%26jtitle%3DPlanta%2520Medica%26atitle%3D1%2525E2%252580%2525B2-Acetoxychavicol%252BAcetate%252Bfrom%252BAlpinia%252Bgalanga%252BRepresses%252BProliferation%252Band%252BInvasion%25252C%252Band%252BInduces%252BApoptosis%252Bvia%252BHER2-signaling%252Bin%252BEndocrine-Resistant%252BBreast%252BCancer%252BCells%26aulast%3DPradubyat%26aufirst%3DNalinee%26date%3D2021%26date%3D2021%26volume%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga  Cruz-López</span>, <span class="hlFld-ContribAuthor ">Matilde  Ner</span>, <span class="hlFld-ContribAuthor ">Francho  Nerín-Fonz</span>, <span class="hlFld-ContribAuthor ">Yaiza  Jiménez-Martínez</span>, <span class="hlFld-ContribAuthor ">David  Araripe</span>, <span class="hlFld-ContribAuthor ">Juan A.  Marchal</span>, <span class="hlFld-ContribAuthor ">Houria  Boulaiz</span>, <span class="hlFld-ContribAuthor ">Hugo  Gutiérrez-de-Terán</span>, <span class="hlFld-ContribAuthor ">Joaquín M.  Campos</span>, <span class="hlFld-ContribAuthor ">Ana  Conejo-García</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1553-1563. <a href="https://doi.org/10.1080/14756366.2021.1948841" title="DOI URL">https://doi.org/10.1080/14756366.2021.1948841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1948841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1948841%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252BHER2%252Binhibition%252Band%252Banticancer%252Bevaluation%252Bof%252Bnew%252Bsubstituted%252B1%25252C5-dihydro-4%25252C1-benzoxazepines%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1553%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alaa A.-M.  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Adel S.  El-Azab</span>, <span class="hlFld-ContribAuthor ">Nawaf A.  AlSaif</span>, <span class="hlFld-ContribAuthor ">Ahmad J.  Obaidullah</span>, <span class="hlFld-ContribAuthor ">Abdulrahman M.  Al-Obaid</span>, <span class="hlFld-ContribAuthor ">Ibrahim A.  Al-Suwaidan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1521-1539. <a href="https://doi.org/10.1080/14756366.2021.1924698" title="DOI URL">https://doi.org/10.1080/14756366.2021.1924698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1924698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1924698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpotential%252Bantitumor%252Bactivity%25252C%252Bcell%252Bcycle%252Banalysis%25252C%252Band%252Bmultitarget%252Bmechanisms%252Bof%252Bnovel%252Bhydrazones%252Bincorporating%252Ba%252B4-methylsulfonylbenzene%252Bscaffold%25253A%252Ba%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DAbdel-Aziz%26aufirst%3DAlaa%2BA.-M.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1521%26epage%3D1539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishtiaque  Ahammad</span>, <span class="hlFld-ContribAuthor ">Md. Rafiul Islam  Sarker</span>, <span class="hlFld-ContribAuthor ">Akib Mahmud  Khan</span>, <span class="hlFld-ContribAuthor ">Sohidul  Islam</span>, <span class="hlFld-ContribAuthor ">Mahmud  Hossain</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual Screening to Identify Novel Inhibitors of Pan ERBB Family of Proteins from Natural Products with Known Anti-tumorigenic Properties. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Peptide Research and Therapeutics</span><span> <strong>2020,</strong> <em>26 </em>
                                    (4)
                                     , 1923-1938. <a href="https://doi.org/10.1007/s10989-019-09992-3" title="DOI URL">https://doi.org/10.1007/s10989-019-09992-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10989-019-09992-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10989-019-09992-3%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Peptide%2520Research%2520and%2520Therapeutics%26atitle%3DVirtual%252BScreening%252Bto%252BIdentify%252BNovel%252BInhibitors%252Bof%252BPan%252BERBB%252BFamily%252Bof%252BProteins%252Bfrom%252BNatural%252BProducts%252Bwith%252BKnown%252BAnti-tumorigenic%252BProperties%26aulast%3DAhammad%26aufirst%3DIshtiaque%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D4%26spage%3D1923%26epage%3D1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelvin F.  Cho</span>, <span class="hlFld-ContribAuthor ">Taylur P.  Ma</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Rose</span>, <span class="hlFld-ContribAuthor ">Donald S.  Kirkpatrick</span>, <span class="hlFld-ContribAuthor ">Kebing  Yu</span>, <span class="hlFld-ContribAuthor ">Robert A.  Blake</span>. </span><span class="cited-content_cbyCitation_article-title">Chaperone mediated detection of small molecule target binding in cells. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-14033-0" title="DOI URL">https://doi.org/10.1038/s41467-019-14033-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-14033-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-14033-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DChaperone%252Bmediated%252Bdetection%252Bof%252Bsmall%252Bmolecule%252Btarget%252Bbinding%252Bin%252Bcells%26aulast%3DCho%26aufirst%3DKelvin%2BF.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nash D.  Rochman</span>, <span class="hlFld-ContribAuthor ">Yuri I.  Wolf</span>, <span class="hlFld-ContribAuthor ">Eugene V.  Koonin</span>. </span><span class="cited-content_cbyCitation_article-title">Deep phylogeny of cancer drivers and compensatory mutations. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-020-01276-7" title="DOI URL">https://doi.org/10.1038/s42003-020-01276-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-020-01276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-020-01276-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DDeep%252Bphylogeny%252Bof%252Bcancer%252Bdrivers%252Band%252Bcompensatory%252Bmutations%26aulast%3DRochman%26aufirst%3DNash%2BD.%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shailima  Rampogu</span>, <span class="hlFld-ContribAuthor ">Gihwan  Lee</span>, <span class="hlFld-ContribAuthor ">Ravinder  Doneti</span>, <span class="hlFld-ContribAuthor ">Keun  Woo Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Short communication for targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches- part 2. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2020,</strong> <em>87 </em>, 107242. <a href="https://doi.org/10.1016/j.compbiolchem.2020.107242" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2020.107242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2020.107242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2020.107242%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DShort%252Bcommunication%252Bfor%252Btargeting%252Bnatural%252Bcompounds%252Bagainst%252BHER2%252Bkinase%252Bdomain%252Bas%252Bpotential%252Banticancer%252Bdrugs%252Bapplying%252Bpharmacophore%252Bbased%252Bmolecular%252Bmodelling%252Bapproaches-%252Bpart%252B2%26aulast%3DRampogu%26aufirst%3DShailima%26date%3D2020%26volume%3D87%26spage%3D107242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xi  Ding</span>, <span class="hlFld-ContribAuthor ">Cheng  Tong</span>, <span class="hlFld-ContribAuthor ">Rong  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Wang</span>, <span class="hlFld-ContribAuthor ">Dongyun  Gao</span>, <span class="hlFld-ContribAuthor ">Lixia  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>96 </em>, 107526. <a href="https://doi.org/10.1016/j.jmgm.2019.107526" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.107526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.107526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.107526%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DSystematic%252Bmolecular%252Bprofiling%252Bof%252Binhibitor%252Bresponse%252Bto%252Bthe%252Bclinical%252Bmissense%252Bmutations%252Bof%252BErbB%252Bfamily%252Bkinases%252Bin%252Bhuman%252Bgastric%252Bcancer%26aulast%3DDing%26aufirst%3DXi%26date%3D2020%26volume%3D96%26spage%3D107526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuizhu  Wang</span>, <span class="hlFld-ContribAuthor ">Yuze  Yuan</span>, <span class="hlFld-ContribAuthor ">He  Pan</span>, <span class="hlFld-ContribAuthor ">Alan Chen-Yu  Hsu</span>, <span class="hlFld-ContribAuthor ">Jinluan  Chen</span>, <span class="hlFld-ContribAuthor ">Jinping  Liu</span>, <span class="hlFld-ContribAuthor ">Pingya  Li</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Protective Effect of Ocotillol, the Derivate of Ocotillol-Type Saponins in Panax Genus, against Acetic Acid-Induced Gastric Ulcer in Rats Based on Untargeted Metabolomics. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (7)
                                     , 2577. <a href="https://doi.org/10.3390/ijms21072577" title="DOI URL">https://doi.org/10.3390/ijms21072577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21072577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21072577%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DProtective%252BEffect%252Bof%252BOcotillol%25252C%252Bthe%252BDerivate%252Bof%252BOcotillol-Type%252BSaponins%252Bin%252BPanax%252BGenus%25252C%252Bagainst%252BAcetic%252BAcid-Induced%252BGastric%252BUlcer%252Bin%252BRats%252BBased%252Bon%252BUntargeted%252BMetabolomics%26aulast%3DWang%26aufirst%3DCuizhu%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D7%26spage%3D2577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Halil I.  CIFTCI</span>. </span><span class="cited-content_cbyCitation_article-title">α-Tomatin`nin Antiproliferatif Aktivitesi ve Moleküler Hedef Tanımlaması. </span><span class="cited-content_cbyCitation_journal-name">Türk Tarım ve Doğa Bilimleri Dergisi</span><span> <strong>2020,</strong> <em> </em>, 290-300. <a href="https://doi.org/10.30910/turkjans.706098" title="DOI URL">https://doi.org/10.30910/turkjans.706098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.30910/turkjans.706098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.30910%2Fturkjans.706098%26sid%3Dliteratum%253Aachs%26jtitle%3DT%25C3%25BCrk%2520Tar%25C4%25B1m%2520ve%2520Do%25C4%259Fa%2520Bilimleri%2520Dergisi%26atitle%3D%2525CE%2525B1-Tomatin%252560nin%252BAntiproliferatif%252BAktivitesi%252Bve%252BMolek%2525C3%2525BCler%252BHedef%252BTan%2525C4%2525B1mlamas%2525C4%2525B1%26aulast%3DCIFTCI%26aufirst%3DHalil%2BI.%26date%3D2020%26date%3D2020%26spage%3D290%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuju  Dong</span>, <span class="hlFld-ContribAuthor ">Pengfei  Yu</span>, <span class="hlFld-ContribAuthor ">Liang  Ye</span>, <span class="hlFld-ContribAuthor ">Jianzhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Fangxia  Zou</span>, <span class="hlFld-ContribAuthor ">Jingwei  Tian</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Kurihara</span>. </span><span class="cited-content_cbyCitation_article-title">PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-42245-3" title="DOI URL">https://doi.org/10.1038/s41598-019-42245-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-42245-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-42245-3%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPCC0208027%25252C%252Ba%252Bnovel%252Btyrosine%252Bkinase%252Binhibitor%25252C%252Binhibits%252Btumor%252Bgrowth%252Bof%252BNSCLC%252Bby%252Btargeting%252BEGFR%252Band%252BHER2%252Baberrations%26aulast%3DDong%26aufirst%3DQiuju%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janakiraman  Subramanian</span>, <span class="hlFld-ContribAuthor ">Archana  Katta</span>, <span class="hlFld-ContribAuthor ">Ashiq  Masood</span>, <span class="hlFld-ContribAuthor ">Dashavantha Reddy  Vudem</span>, <span class="hlFld-ContribAuthor ">Rama Krishna  Kancha</span>. </span><span class="cited-content_cbyCitation_article-title">Emergence of
              ERBB2
              Mutation as a Biomarker and an Actionable Target in Solid Cancers. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     <a href="https://doi.org/10.1634/theoncologist.2018-0845" title="DOI URL">https://doi.org/10.1634/theoncologist.2018-0845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2018-0845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2018-0845%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DEmergence%252Bof%252BERBB2%252BMutation%252Bas%252Ba%252BBiomarker%252Band%252Ban%252BActionable%252BTarget%252Bin%252BSolid%252BCancers%26aulast%3DSubramanian%26aufirst%3DJanakiraman%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishan I.  Panchal</span>, <span class="hlFld-ContribAuthor ">Ashish  Shah</span>, <span class="hlFld-ContribAuthor ">Animesh  Devgirkar</span>, <span class="hlFld-ContribAuthor ">Umang  Shah</span>, <span class="hlFld-ContribAuthor ">Ashish  Patel</span>, <span class="hlFld-ContribAuthor ">Alkesh  Patel</span>, <span class="hlFld-ContribAuthor ">Dhrubo J.  Sen</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Analysis and Molecular Docking Studies of Novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one Derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Cancer Therapy Reviews</span><span> <strong>2019,</strong> <em>15 </em>
                                    (3)
                                     , 235-247. <a href="https://doi.org/10.2174/1573394715666181129104528" title="DOI URL">https://doi.org/10.2174/1573394715666181129104528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573394715666181129104528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573394715666181129104528%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Cancer%2520Therapy%2520Reviews%26atitle%3DIn%252BSilico%252BAnalysis%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BNovel%252B6%25252C7-dihydropyrano%252B%25255B2%25252C3-d%25255D%252Bpyrimidin-5-one%252BDerivatives%252Bas%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2%252B%252528HER2%252529%252Band%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DPanchal%26aufirst%3DIshan%2BI.%26date%3D2019%26volume%3D15%26issue%3D3%26spage%3D235%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengxing  He</span>, <span class="hlFld-ContribAuthor ">Shenghui  Niu</span>, <span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Shi</span>, <span class="hlFld-ContribAuthor ">Siqi  Feng</span>, <span class="hlFld-ContribAuthor ">Linna  Du</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhilu  Ma</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hongmin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2019,</strong> <em>9 </em>
                                    (6)
                                     , 1193-1203. <a href="https://doi.org/10.1016/j.apsb.2019.06.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.06.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.06.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDiscovery%252Bof%252BWS-157%252Bas%252Ba%252Bhighly%252Bpotent%25252C%252Bselective%252Band%252Borally%252Bactive%252BEGFR%252Binhibitor%26aulast%3DHe%26aufirst%3DPengxing%26date%3D2019%26volume%3D9%26issue%3D6%26spage%3D1193%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Belgin  Sever</span>, <span class="hlFld-ContribAuthor ">Mehlika Dilek  Altıntop</span>, <span class="hlFld-ContribAuthor ">Mohamed O.  Radwan</span>, <span class="hlFld-ContribAuthor ">Ahmet  Özdemir</span>, <span class="hlFld-ContribAuthor ">Masami  Otsuka</span>, <span class="hlFld-ContribAuthor ">Mikako  Fujita</span>, <span class="hlFld-ContribAuthor ">Halil I.  Ciftci</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111648. <a href="https://doi.org/10.1016/j.ejmech.2019.111648" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111648%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnew%252Bseries%252Bof%252Bthiazolyl-pyrazolines%252Bas%252Bdual%252BEGFR%252Band%252BHER2%252Binhibitors%26aulast%3DSever%26aufirst%3DBelgin%26date%3D2019%26volume%3D182%26spage%3D111648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhao  Yang</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Gu</span>, <span class="hlFld-ContribAuthor ">Qiu-Ya  Ma</span>, <span class="hlFld-ContribAuthor ">Na  Xue</span>, <span class="hlFld-ContribAuthor ">Xiao-Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Ya-Bo  Wang</span>, <span class="hlFld-ContribAuthor ">De-Ying  Cao</span>, <span class="hlFld-ContribAuthor ">Ran  Guo</span>, <span class="hlFld-ContribAuthor ">Rui-Juan  Xing</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of aromatic urea-quinazolines. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (21)
                                     , 2821-2830. <a href="https://doi.org/10.4155/fmc-2019-0220" title="DOI URL">https://doi.org/10.4155/fmc-2019-0220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0220%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Baromatic%252Burea-quinazolines%26aulast%3DYang%26aufirst%3DZhao%26date%3D2019%26volume%3D11%26issue%3D21%26spage%3D2821%26epage%3D2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishan I.  Panchal</span>, <span class="hlFld-ContribAuthor ">Sandip N.  Badeliya</span>, <span class="hlFld-ContribAuthor ">Rakesh  Patel</span>, <span class="hlFld-ContribAuthor ">Ashish  Patel</span>, <span class="hlFld-ContribAuthor ">Animesh  Devaligar</span>. </span><span class="cited-content_cbyCitation_article-title">In silico Analysis and Molecular Docking Studies of Novel 4-Amino-3- (Isoquinolin-4-yl)-1H-Pyrazolo[3,4-d]Pyrimidine Derivatives as Dual PI3-K/mTOR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Discovery Technologies</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , 297-306. <a href="https://doi.org/10.2174/1568009618666181102144934" title="DOI URL">https://doi.org/10.2174/1568009618666181102144934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568009618666181102144934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568009618666181102144934%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Discovery%2520Technologies%26atitle%3DIn%252Bsilico%252BAnalysis%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BNovel%252B4-Amino-3-%252B%252528Isoquinolin-4-yl%252529-1H-Pyrazolo%25255B3%25252C4-d%25255DPyrimidine%252BDerivatives%252Bas%252BDual%252BPI3-K%25252FmTOR%252BInhibitors%26aulast%3DPanchal%26aufirst%3DIshan%2BI.%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3D297%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">Cuizhu  Wang</span>, <span class="hlFld-ContribAuthor ">Jiannan  Li</span>, <span class="hlFld-ContribAuthor ">Lingxin  Xiong</span>, <span class="hlFld-ContribAuthor ">Zhenzhou  Wang</span>, <span class="hlFld-ContribAuthor ">Jinping  Liu</span>, <span class="hlFld-ContribAuthor ">Pingya  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the gastroprotective effects of 20 (S)-ginsenoside Rg3 on gastric ulcer models in mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ginseng Research</span><span> <strong>2019,</strong> <em>43 </em>
                                    (4)
                                     , 550-561. <a href="https://doi.org/10.1016/j.jgr.2018.04.001" title="DOI URL">https://doi.org/10.1016/j.jgr.2018.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jgr.2018.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jgr.2018.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ginseng%2520Research%26atitle%3DEvaluation%252Bof%252Bthe%252Bgastroprotective%252Beffects%252Bof%252B20%252B%252528S%252529-ginsenoside%252BRg3%252Bon%252Bgastric%252Bulcer%252Bmodels%252Bin%252Bmice%26aulast%3DZhang%26aufirst%3DKai%26date%3D2019%26volume%3D43%26issue%3D4%26spage%3D550%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian M.  Cawrse</span>, <span class="hlFld-ContribAuthor ">Nia’mani M.  Robinson</span>, <span class="hlFld-ContribAuthor ">Nina C.  Lee</span>, <span class="hlFld-ContribAuthor ">Gerald M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Seley-Radtke</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and Biological Investigations for a Series of N-5 Substituted Pyrrolo[3,2-d]pyrimidines as Potential Anti-Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (14)
                                     , 2656. <a href="https://doi.org/10.3390/molecules24142656" title="DOI URL">https://doi.org/10.3390/molecules24142656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24142656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24142656%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStructural%252Band%252BBiological%252BInvestigations%252Bfor%252Ba%252BSeries%252Bof%252BN-5%252BSubstituted%252BPyrrolo%25255B3%25252C2-d%25255Dpyrimidines%252Bas%252BPotential%252BAnti-Cancer%252BTherapeutics%26aulast%3DCawrse%26aufirst%3DBrian%2BM.%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D14%26spage%3D2656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring structural features of EGFR–HER2 dual inhibitors as anti-cancer agents using G-QSAR approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 243-252. <a href="https://doi.org/10.1080/10799893.2019.1660896" title="DOI URL">https://doi.org/10.1080/10799893.2019.1660896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2019.1660896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2019.1660896%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DExploring%252Bstructural%252Bfeatures%252Bof%252BEGFR%2525E2%252580%252593HER2%252Bdual%252Binhibitors%252Bas%252Banti-cancer%252Bagents%252Busing%252BG-QSAR%252Bapproach%26aulast%3DFatima%26aufirst%3DShehnaz%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D3%26spage%3D243%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nazia  Ikram</span>, <span class="hlFld-ContribAuthor ">Muhammad Usman  Mirza</span>, <span class="hlFld-ContribAuthor ">Michiel  Vanmeert</span>, <span class="hlFld-ContribAuthor ">Matheus  Froeyen</span>, <span class="hlFld-ContribAuthor ">Outi M. H.  Salo-Ahen</span>, <span class="hlFld-ContribAuthor ">Muhammad  Tahir</span>, <span class="hlFld-ContribAuthor ">Aamer  Qazi</span>, <span class="hlFld-ContribAuthor ">Sarfraz  Ahmad</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (4)
                                     , 124. <a href="https://doi.org/10.3390/biom9040124" title="DOI URL">https://doi.org/10.3390/biom9040124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9040124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9040124%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DInhibition%252Bof%252BOncogenic%252BKinases%25253A%252BAn%252BIn%252BVitro%252BValidated%252BComputational%252BApproach%252BIdentified%252BPotential%252BMulti-Target%252BAnticancer%252BCompounds%26aulast%3DIkram%26aufirst%3DNazia%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D4%26spage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md. Moshfekus  Saleh-e-In</span>, <span class="hlFld-ContribAuthor ">Ayan  Roy</span>, <span class="hlFld-ContribAuthor ">Muhammad Abdullah  Al-Mansur</span>, <span class="hlFld-ContribAuthor ">Choudhury  Mahmood Hasan</span>, <span class="hlFld-ContribAuthor ">Md. Matiur  Rahim</span>, <span class="hlFld-ContribAuthor ">Nasim  Sultana</span>, <span class="hlFld-ContribAuthor ">Shamim  Ahmed</span>, <span class="hlFld-ContribAuthor ">Md. Rabiul  Islam</span>, <span class="hlFld-ContribAuthor ">Johannes  van Staden</span>. </span><span class="cited-content_cbyCitation_article-title">Isolation and in silico prediction of potential drug-like compounds from Anethum sowa L. root extracts targeted towards cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>78 </em>, 242-259. <a href="https://doi.org/10.1016/j.compbiolchem.2018.11.025" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.11.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.11.025%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DIsolation%252Band%252Bin%252Bsilico%252Bprediction%252Bof%252Bpotential%252Bdrug-like%252Bcompounds%252Bfrom%252BAnethum%252Bsowa%252BL.%252Broot%252Bextracts%252Btargeted%252Btowards%252Bcancer%252Btherapy%26aulast%3DSaleh-e-In%26aufirst%3DMd.%2BMoshfekus%26date%3D2019%26volume%3D78%26spage%3D242%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiten M.  Soliman</span>, <span class="hlFld-ContribAuthor ">Ali S.  Alqahtani</span>, <span class="hlFld-ContribAuthor ">Mostafa M.  Ghorab</span>. </span><span class="cited-content_cbyCitation_article-title">Novel sulfonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1030-1040. <a href="https://doi.org/10.1080/14756366.2019.1609469" title="DOI URL">https://doi.org/10.1080/14756366.2019.1609469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1609469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1609469%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bsulfonamide%252Bbenzoquinazolinones%252Bas%252Bdual%252BEGFR%25252FHER2%252Binhibitors%25252C%252Bapoptosis%252Binducers%252Band%252Bradiosensitizers%26aulast%3DSoliman%26aufirst%3DAiten%2BM.%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1030%26epage%3D1040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbao  Ye</span>, <span class="hlFld-ContribAuthor ">Tao  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenjun  Du</span>, <span class="hlFld-ContribAuthor ">Anhu  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Jingrong  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1233-1246. <a href="https://doi.org/10.1080/14756366.2019.1634704" title="DOI URL">https://doi.org/10.1080/14756366.2019.1634704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1634704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1634704%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Baminopyridine-containing%252Bspiro%252Bderivatives%252Bas%252BEGFR%252Bmutations%252Binhibitors%26aulast%3DYe%26aufirst%3DLianbao%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1233%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai  Adel</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>81 </em>, 612-629. <a href="https://doi.org/10.1016/j.bioorg.2018.09.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnew%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bpotent%252BVEGFR-2%252Btyrosine%252Bkinase%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%26aulast%3DAdel%26aufirst%3DMai%26date%3D2018%26volume%3D81%26spage%3D612%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafaela  de Angelo</span>, <span class="hlFld-ContribAuthor ">Michell  Almeida</span>, <span class="hlFld-ContribAuthor ">Heberth  de Paula</span>, <span class="hlFld-ContribAuthor ">Kathia  Honorio</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on the Dual Activity of EGFR and HER-2 Inhibitors Using Structure-Based Drug Design Techniques. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (12)
                                     , 3728. <a href="https://doi.org/10.3390/ijms19123728" title="DOI URL">https://doi.org/10.3390/ijms19123728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19123728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19123728%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStudies%252Bon%252Bthe%252BDual%252BActivity%252Bof%252BEGFR%252Band%252BHER-2%252BInhibitors%252BUsing%252BStructure-Based%252BDrug%252BDesign%252BTechniques%26aulast%3Dde%2BAngelo%26aufirst%3DRafaela%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D3728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangfang  Yan</span>, <span class="hlFld-ContribAuthor ">Xinguo  Liu</span>, <span class="hlFld-ContribAuthor ">Shaolong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Su</span>, <span class="hlFld-ContribAuthor ">Qinggang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (70)
                                     , 39797-39810. <a href="https://doi.org/10.1039/C8RA06844E" title="DOI URL">https://doi.org/10.1039/C8RA06844E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA06844E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA06844E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DEffect%252Bof%252Bdouble%252Bmutations%252BT790M%25252FL858R%252Bon%252Bconformation%252Band%252Bdrug-resistant%252Bmechanism%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bexplored%252Bby%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DYan%26aufirst%3DFangfang%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D70%26spage%3D39797%26epage%3D39810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun  Patel</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Iqrar  Ansari</span>, <span class="hlFld-ContribAuthor ">Harsha  Jadhav</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5-6)
                                     , 393-412. <a href="https://doi.org/10.1080/10799893.2018.1557207" title="DOI URL">https://doi.org/10.1080/10799893.2018.1557207</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2018.1557207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2018.1557207%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252B2%25252C4-disubstituted%252Baminopyrimidines%25253A%252Breversible%252Bnon-covalent%252BT790M%252BEGFR%252Binhibitors%26aulast%3DPatel%26aufirst%3DHarun%26date%3D2018%26date%3D2019%26volume%3D38%26issue%3D5-6%26spage%3D393%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingmin  Ding</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Chunrong  Qu</span>, <span class="hlFld-ContribAuthor ">Fuchun  Xu</span>, <span class="hlFld-ContribAuthor ">Yingmin  Zhu</span>, <span class="hlFld-ContribAuthor ">Guangyao  Lv</span>, <span class="hlFld-ContribAuthor ">Yungang  Lu</span>, <span class="hlFld-ContribAuthor ">Qingjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Hui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Zeng</span>, <span class="hlFld-ContribAuthor ">Jingwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunhong  Yan</span>, <span class="hlFld-ContribAuthor ">Jiacheng  Lin</span>, <span class="hlFld-ContribAuthor ">Huai-Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Zixing  Deng</span>, <span class="hlFld-ContribAuthor ">Yuling  Xiao</span>, <span class="hlFld-ContribAuthor ">Jinbin  Tian</span>, <span class="hlFld-ContribAuthor ">Michael X.  Zhu</span>, <span class="hlFld-ContribAuthor ">Xuechuan  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2018,</strong> <em>432 </em>, 47-55. <a href="https://doi.org/10.1016/j.canlet.2018.05.041" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.05.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.05.041%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252BTRPC6%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bgastric%252Bcancer%26aulast%3DDing%26aufirst%3DMingmin%26date%3D2018%26volume%3D432%26spage%3D47%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding  Liu</span>, <span class="hlFld-ContribAuthor ">Yan-peng  Li</span>, <span class="hlFld-ContribAuthor ">Hong-xiu  Shen</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Qi-zhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun-mei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anti-tumor activities of novel 7-O-amino acids chrysin derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chinese Herbal Medicines</span><span> <strong>2018,</strong> <em>10 </em>
                                    (3)
                                     , 323-330. <a href="https://doi.org/10.1016/j.chmed.2018.07.002" title="DOI URL">https://doi.org/10.1016/j.chmed.2018.07.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chmed.2018.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chmed.2018.07.002%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Herbal%2520Medicines%26atitle%3DSynthesis%252Band%252Banti-tumor%252Bactivities%252Bof%252Bnovel%252B7-O-amino%252Bacids%252Bchrysin%252Bderivatives%26aulast%3DLiu%26aufirst%3DDing%26date%3D2018%26volume%3D10%26issue%3D3%26spage%3D323%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Amal Kamal  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Saverio  Minucci</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 316-336. <a href="https://doi.org/10.1016/j.ejmech.2018.06.011" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSurmounting%252Bthe%252Bresistance%252Bagainst%252BEGFR%252Binhibitors%252Bthrough%252Bthe%252Bdevelopment%252Bof%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine-based%252Bdual%252BEGFR%25252FHER2%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2018%26volume%3D155%26spage%3D316%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanae  Gamo</span>, <span class="hlFld-ContribAuthor ">Yuumi  Okuzono</span>, <span class="hlFld-ContribAuthor ">Masato  Yabuki</span>, <span class="hlFld-ContribAuthor ">Takashi  Ochi</span>, <span class="hlFld-ContribAuthor ">Kyoko  Sugimura</span>, <span class="hlFld-ContribAuthor ">Yosuke  Sato</span>, <span class="hlFld-ContribAuthor ">Masaki  Sagara</span>, <span class="hlFld-ContribAuthor ">Hiroki  Hayashi</span>, <span class="hlFld-ContribAuthor ">Yoshimasa  Ishimura</span>, <span class="hlFld-ContribAuthor ">Yutaka  Nishimoto</span>, <span class="hlFld-ContribAuthor ">Yusuke  Murakawa</span>, <span class="hlFld-ContribAuthor ">Zenyu  Shiokawa</span>, <span class="hlFld-ContribAuthor ">Masayuki  Gotoh</span>, <span class="hlFld-ContribAuthor ">Takahiro  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Yukihiko  Ebisuno</span>. </span><span class="cited-content_cbyCitation_article-title">Gene Signature–Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2018,</strong> <em>24 </em>
                                    (6)
                                     , 1251-1265. <a href="https://doi.org/10.1093/ibd/izy079" title="DOI URL">https://doi.org/10.1093/ibd/izy079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izy079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizy079%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DGene%252BSignature%2525E2%252580%252593Based%252BApproach%252BIdentified%252BMEK1%25252F2%252Bas%252Ba%252BPotential%252BTarget%252BAssociated%252BWith%252BRelapse%252BAfter%252BAnti-TNF%2525CE%2525B1%252BTreatment%252Bfor%252BCrohn%2525E2%252580%252599s%252BDisease%26aulast%3DGamo%26aufirst%3DKanae%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D6%26spage%3D1251%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martiniano  Bello</span>, <span class="hlFld-ContribAuthor ">Lucia  Saldaña-Rivero</span>, <span class="hlFld-ContribAuthor ">José  Correa-Basurto</span>, <span class="hlFld-ContribAuthor ">Benjamín  García</span>, <span class="hlFld-ContribAuthor ">Victor Armando  Sánchez-Espinosa</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2018,</strong> <em>111 </em>, 569-586. <a href="https://doi.org/10.1016/j.ijbiomac.2017.12.162" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2017.12.162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2017.12.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2017.12.162%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DStructural%252Band%252Benergetic%252Bbasis%252Bfor%252Bthe%252Bmolecular%252Brecognition%252Bof%252Bdual%252Bsynthetic%252Bvs.%252Bnatural%252Binhibitors%252Bof%252BEGFR%25252FHER2%26aulast%3DBello%26aufirst%3DMartiniano%26date%3D2018%26volume%3D111%26spage%3D569%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian M.  Cawrse</span>, <span class="hlFld-ContribAuthor ">Rena S.  Lapidus</span>, <span class="hlFld-ContribAuthor ">Brandon  Cooper</span>, <span class="hlFld-ContribAuthor ">Eun Yong  Choi</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Seley-Radtke</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Properties of Halogenated Pyrrolo[3,2-
              d
              ]pyrimidines with Decreased Toxicity via N5 Substitution. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (2)
                                     , 178-185. <a href="https://doi.org/10.1002/cmdc.201700641" title="DOI URL">https://doi.org/10.1002/cmdc.201700641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700641%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAnticancer%252BProperties%252Bof%252BHalogenated%252BPyrrolo%25255B3%25252C2-%252Bd%252B%25255Dpyrimidines%252Bwith%252BDecreased%252BToxicity%252Bvia%252BN5%252BSubstitution%26aulast%3DCawrse%26aufirst%3DBrian%2BM.%26date%3D2018%26date%3D2017%26volume%3D13%26issue%3D2%26spage%3D178%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nulgumnalli Manjunathaiah  Raghavendra</span>, <span class="hlFld-ContribAuthor ">Divya  Pingili</span>, <span class="hlFld-ContribAuthor ">Sundeep  Kadasi</span>, <span class="hlFld-ContribAuthor ">Akhila  Mettu</span>, <span class="hlFld-ContribAuthor ">S.V.U.M.  Prasad</span>. </span><span class="cited-content_cbyCitation_article-title">Dual or multi-targeting inhibitors: The next generation anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1277-1300. <a href="https://doi.org/10.1016/j.ejmech.2017.10.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bor%252Bmulti-targeting%252Binhibitors%25253A%252BThe%252Bnext%252Bgeneration%252Banticancer%252Bagents%26aulast%3DRaghavendra%26aufirst%3DNulgumnalli%2BManjunathaiah%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 131-151. <a href="https://doi.org/10.1016/j.ejmech.2017.07.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252Bto%252Btrain%252Byour%252Binhibitor%25253A%252BDesign%252Bstrategies%252Bto%252Bovercome%252Bresistance%252Bto%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2017%26volume%3D142%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mansour S.  Alsaid</span>, <span class="hlFld-ContribAuthor ">Abdullah A.  Al-Mishari</span>, <span class="hlFld-ContribAuthor ">Aiten M.  Soliman</span>, <span class="hlFld-ContribAuthor ">Fatma A.  Ragab</span>, <span class="hlFld-ContribAuthor ">Mostafa M.  Ghorab</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 84-91. <a href="https://doi.org/10.1016/j.ejmech.2017.09.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBenzo%25255Bg%25255Dquinazolin%252Bbenzenesulfonamide%252Bderivatives%252Bas%252Bdual%252BEGFR%25252FHER2%252Binhibitors%26aulast%3DAlsaid%26aufirst%3DMansour%2BS.%26date%3D2017%26volume%3D141%26spage%3D84%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Chang</span>, <span class="hlFld-ContribAuthor ">Hongyu  Ren</span>, <span class="hlFld-ContribAuthor ">Mingxia  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Chong</span>, <span class="hlFld-ContribAuthor ">Wenwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Yong  He</span>, <span class="hlFld-ContribAuthor ">Yunling  Zhao</span>, <span class="hlFld-ContribAuthor ">Huabei  Zhang</span>, <span class="hlFld-ContribAuthor ">Chuanmin  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 669-688. <a href="https://doi.org/10.1016/j.ejmech.2017.07.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252Bseries%252Bof%252Bnovel%252B4-anlinoquinazoline%252Bderivatives%252Bpossessing%252Bquinazoline%252Bskeleton%25253A%252BDesign%25252C%252Bsynthesis%25252C%252BEGFR%252Bkinase%252Binhibitory%252Befficacy%25252C%252Band%252Bevaluation%252Bof%252Banticancer%252Bactivities%252Bin%2525C2%2525A0vitro%26aulast%3DChang%26aufirst%3DJin%26date%3D2017%26volume%3D138%26spage%3D669%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. G.  Lyapunova</span>, <span class="hlFld-ContribAuthor ">A. S.  D’yachenko</span>, <span class="hlFld-ContribAuthor ">N. A.  Danilkina</span>. </span><span class="cited-content_cbyCitation_article-title">Potassium fluoride for one-pot desilylation and the Sonogashira coupling of ethynylsilanes and buta-1,3-diynylsilanes. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>53 </em>
                                    (5)
                                     , 800-804. <a href="https://doi.org/10.1134/S1070428017050268" title="DOI URL">https://doi.org/10.1134/S1070428017050268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428017050268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428017050268%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPotassium%252Bfluoride%252Bfor%252Bone-pot%252Bdesilylation%252Band%252Bthe%252BSonogashira%252Bcoupling%252Bof%252Bethynylsilanes%252Band%252Bbuta-1%25252C3-diynylsilanes%26aulast%3DLyapunova%26aufirst%3DA.%2BG.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D5%26spage%3D800%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (2)
                                     , 314-367. <a href="https://doi.org/10.1002/med.21409" title="DOI URL">https://doi.org/10.1002/med.21409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21409%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DApproved%252Band%252BExperimental%252BSmall-Molecule%252BOncology%252BKinase%252BInhibitor%252BDrugs%25253A%252BA%252BMid-2016%252BOverview%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D2%26spage%3D314%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Qu</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>, <span class="hlFld-ContribAuthor ">J. S.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 111-132. <a href="https://doi.org/10.1080/1062936X.2017.1284898" title="DOI URL">https://doi.org/10.1080/1062936X.2017.1284898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2017.1284898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2017.1284898%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DSAR%252Band%252BQSAR%252Bstudy%252Bon%252Bthe%252Bbioactivities%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor-2%252B%252528HER2%252529%252Binhibitors%26aulast%3DQu%26aufirst%3DD.%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Tsui</span>, <span class="hlFld-ContribAuthor ">Q.  Zeng</span>, <span class="hlFld-ContribAuthor ">K.  Chen</span>, <span class="hlFld-ContribAuthor ">X.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting Kinases in the CNS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 408-446. <a href="https://doi.org/10.1016/B978-0-12-409547-2.13815-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.13815-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.13815-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.13815-6%26sid%3Dliteratum%253Aachs%26atitle%3DInhibiting%252BKinases%252Bin%252Bthe%252BCNS%26aulast%3DTsui%26aufirst%3DH.%26date%3D2017%26spage%3D408%26epage%3D446%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Osamu  Yabe</span>, <span class="hlFld-ContribAuthor ">Akihiro  Suzuki</span>, <span class="hlFld-ContribAuthor ">Tomomi  Ikemoto</span>. </span><span class="cited-content_cbyCitation_article-title">A Convergent Scale-up Synthesis of A HER2/EGRF Dual Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2017,</strong> <em>94 </em>
                                    (4)
                                     , 702. <a href="https://doi.org/10.3987/COM-17-13663" title="DOI URL">https://doi.org/10.3987/COM-17-13663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-17-13663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-17-13663%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DA%252BConvergent%252BScale-up%252BSynthesis%252Bof%252BA%252BHER2%25252FEGRF%252BDual%252BKinase%252BInhibitor%26aulast%3DYabe%26aufirst%3DOsamu%26date%3D2017%26volume%3D94%26issue%3D4%26spage%3D702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soha R.  Abd El Hadi</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Mahmoud A.  Hassan</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of 4-Anilinothieno[2,3-
              d
              ]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2016,</strong> <em>349 </em>
                                    (11)
                                     , 827-847. <a href="https://doi.org/10.1002/ardp.201600197" title="DOI URL">https://doi.org/10.1002/ardp.201600197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201600197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201600197%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252B4-Anilinothieno%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine-Based%252BCompounds%252Bas%252BDual%252BEGFR%25252FHER-2%252BInhibitors%26aulast%3DAbd%2BEl%2BHadi%26aufirst%3DSoha%2BR.%26date%3D2016%26date%3D2016%26volume%3D349%26issue%3D11%26spage%3D827%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Ying  Hu</span>, <span class="hlFld-ContribAuthor ">Huixin  Wan</span>, <span class="hlFld-ContribAuthor ">Yanwei  Hu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Chen</span>, <span class="hlFld-ContribAuthor ">Shilei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yinan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient synthesis of 4,6-substituted pyrrolo[3,2-d]pyrimidines by silver-catalyzed cyclization of acetylene amine. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2016,</strong> <em>57 </em>
                                    (22)
                                     , 2418-2421. <a href="https://doi.org/10.1016/j.tetlet.2016.04.077" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.04.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.04.077%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAn%252Befficient%252Bsynthesis%252Bof%252B4%25252C6-substituted%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidines%252Bby%252Bsilver-catalyzed%252Bcyclization%252Bof%252Bacetylene%252Bamine%26aulast%3DXie%26aufirst%3DRui%26date%3D2016%26volume%3D57%26issue%3D22%26spage%3D2418%26epage%3D2421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Jie  Zuo</span>, <span class="hlFld-ContribAuthor ">Sai  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xie</span>, <span class="hlFld-ContribAuthor ">Xue  Xiao</span>, <span class="hlFld-ContribAuthor ">Min-Hnag  Xin</span>, <span class="hlFld-ContribAuthor ">Wei  Xuan</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  He</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (2)
                                     , 179-190. <a href="https://doi.org/10.1016/j.bmc.2015.12.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DCombination%252Bof%252B4-anilinoquinazoline%25252C%252Barylurea%252Band%252Btertiary%252Bamine%252Bmoiety%252Bto%252Bdiscover%252Bnovel%252Banticancer%252Bagents%26aulast%3DZuo%26aufirst%3DSai-Jie%26date%3D2016%26volume%3D24%26issue%3D2%26spage%3D179%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Journal of Pharmaceutical Sciences</span><span> <strong>2015,</strong> <em>1 </em>
                                    (2)
                                     , 33-41. <a href="https://doi.org/10.1016/j.fjps.2015.09.001" title="DOI URL">https://doi.org/10.1016/j.fjps.2015.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fjps.2015.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fjps.2015.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DThieno%25255B2%25252C3-d%25255Dpyrimidine%252Bbased%252Bderivatives%252Bas%252Bkinase%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DElrazaz%26aufirst%3DEman%2BZ.%26date%3D2015%26volume%3D1%26issue%3D2%26spage%3D33%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Ahmed Karam  Farag</span>, <span class="hlFld-ContribAuthor ">Ambily Nath Indu  Viswanath</span>, <span class="hlFld-ContribAuthor ">Tarek M.  Bedair</span>, <span class="hlFld-ContribAuthor ">Dong Gyu  Leem</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (22)
                                     , 5147-5154. <a href="https://doi.org/10.1016/j.bmcl.2015.10.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTargeting%252BEGFR%25252FHER2%252Btyrosine%252Bkinases%252Bwith%252Ba%252Bnew%252Bpotent%252Bseries%252Bof%252B6-substituted%252B4-anilinoquinazoline%252Bhybrids%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bkinase%252Bassay%25252C%252Bcell-based%252Bassay%25252C%252Band%252Bmolecular%252Bdocking%26aulast%3DElkamhawy%26aufirst%3DAhmed%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5147%26epage%3D5154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kartik W.  Temburnikar</span>, <span class="hlFld-ContribAuthor ">Christina R.  Ross</span>, <span class="hlFld-ContribAuthor ">Gerald M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Brian M.  Cawrse</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Seley-Radtke</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4354-4363. <a href="https://doi.org/10.1016/j.bmc.2015.06.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAntiproliferative%252Bactivities%252Bof%252Bhalogenated%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidines%26aulast%3DTemburnikar%26aufirst%3DKartik%2BW.%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4354%26epage%3D4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siyuan  Yin</span>, <span class="hlFld-ContribAuthor ">Liliang  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Lin</span>, <span class="hlFld-ContribAuthor ">Lingjing  Xue</span>, <span class="hlFld-ContribAuthor ">Can  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activities of novel oxazolo[4,5- g ]quinazolin-2(1H)-one derivatives as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 462-475. <a href="https://doi.org/10.1016/j.ejmech.2015.07.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivities%252Bof%252Bnovel%252Boxazolo%25255B4%25252C5-%252Bg%252B%25255Dquinazolin-2%2525281H%252529-one%252Bderivatives%252Bas%252BEGFR%252Binhibitors%26aulast%3DYin%26aufirst%3DSiyuan%26date%3D2015%26volume%3D101%26spage%3D462%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arumugam  Sudha</span>, <span class="hlFld-ContribAuthor ">Pappu  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Palanivel  Rameshthangam</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2015,</strong> <em>35 </em>
                                    (2)
                                     , 137-148. <a href="https://doi.org/10.3109/10799893.2014.942461" title="DOI URL">https://doi.org/10.3109/10799893.2014.942461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/10799893.2014.942461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F10799893.2014.942461%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DExploration%252Bof%252Bpotential%252BEGFR%252Binhibitors%25253A%252Ba%252Bcombination%252Bof%252Bpharmacophore-based%252Bvirtual%252Bscreening%25252C%252Batom-based%252B3D-QSAR%252Band%252Bmolecular%252Bdocking%252Banalysis%26aulast%3DSudha%26aufirst%3DArumugam%26date%3D2015%26date%3D2014%26volume%3D35%26issue%3D2%26spage%3D137%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samia A.  Elseginy</span>, <span class="hlFld-ContribAuthor ">Glorianne  Lazaro</span>, <span class="hlFld-ContribAuthor ">Galal A.M.  Nawwar</span>, <span class="hlFld-ContribAuthor ">Kamilia M.  Amin</span>, <span class="hlFld-ContribAuthor ">Stephen  Hiscox</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 758-762. <a href="https://doi.org/10.1016/j.bmcl.2014.12.095" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.095%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComputer-aided%252Bidentification%252Bof%252Bnovel%252Banticancer%252Bcompounds%252Bwith%252Ba%252Bpossible%252Bdual%252BHER1%25252FHER2%252Binhibition%252Bmechanism%26aulast%3DElseginy%26aufirst%3DSamia%2BA.%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D758%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed  Akl</span>, <span class="hlFld-ContribAuthor ">Nehad  Ayoub</span>, <span class="hlFld-ContribAuthor ">Hassan  Ebrahim</span>, <span class="hlFld-ContribAuthor ">Mohamed  Mohyeldin</span>, <span class="hlFld-ContribAuthor ">Khaled  Orabi</span>, <span class="hlFld-ContribAuthor ">Ahmed  Foudah</span>, <span class="hlFld-ContribAuthor ">Khalid  Sayed</span>. </span><span class="cited-content_cbyCitation_article-title">Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2015,</strong> <em>13 </em>
                                    (1)
                                     , 288-311. <a href="https://doi.org/10.3390/md13010288" title="DOI URL">https://doi.org/10.3390/md13010288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md13010288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd13010288%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DAraguspongine%252BC%252BInduces%252BAutophagic%252BDeath%252Bin%252BBreast%252BCancer%252BCells%252Bthrough%252BSuppression%252Bof%252Bc-Met%252Band%252BHER2%252BReceptor%252BTyrosine%252BKinase%252BSignaling%26aulast%3DAkl%26aufirst%3DMohamed%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D1%26spage%3D288%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gennadiy  Tenin</span>, <span class="hlFld-ContribAuthor ">Christopher  Clowes</span>, <span class="hlFld-ContribAuthor ">Kathryn  Wolton</span>, <span class="hlFld-ContribAuthor ">Eliska  Krejci</span>, <span class="hlFld-ContribAuthor ">Jayne A.  Wright</span>, <span class="hlFld-ContribAuthor ">Simon C.  Lovell</span>, <span class="hlFld-ContribAuthor ">David  Sedmera</span>, <span class="hlFld-ContribAuthor ">Kathryn E.  Hentges</span>, . </span><span class="cited-content_cbyCitation_article-title">Erbb2 Is Required for Cardiac Atrial Electrical Activity during Development. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (9)
                                     , e107041. <a href="https://doi.org/10.1371/journal.pone.0107041" title="DOI URL">https://doi.org/10.1371/journal.pone.0107041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0107041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0107041%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DErbb2%252BIs%252BRequired%252Bfor%252BCardiac%252BAtrial%252BElectrical%252BActivity%252Bduring%252BDevelopment%26aulast%3DTenin%26aufirst%3DGennadiy%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D9%26spage%3De107041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Schroeder</span>, <span class="hlFld-ContribAuthor ">Cheryl  Stevens</span>, <span class="hlFld-ContribAuthor ">Jayalakshmi  Sridhar</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (9)
                                     , 15196-15212. <a href="https://doi.org/10.3390/molecules190915196" title="DOI URL">https://doi.org/10.3390/molecules190915196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules190915196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules190915196%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSmall%252BMolecule%252BTyrosine%252BKinase%252BInhibitors%252Bof%252BErbB2%25252FHER2%25252FNeu%252Bin%252Bthe%252BTreatment%252Bof%252BAggressive%252BBreast%252BCancer%26aulast%3DSchroeder%26aufirst%3DRichard%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D9%26spage%3D15196%26epage%3D15212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiu L.  Yang</span>, <span class="hlFld-ContribAuthor ">Tian C.  Wang</span>, <span class="hlFld-ContribAuthor ">Sen  Lin</span>, <span class="hlFld-ContribAuthor ">Hou X.  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Irreversible Inhibitors of the Epidermal Growth Factor Receptor: Thienopyrimidine Core with α,β-Unsaturated Amide Side Chain. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2014,</strong> <em>347 </em>
                                    (8)
                                     , 552-558. <a href="https://doi.org/10.1002/ardp.201400098" title="DOI URL">https://doi.org/10.1002/ardp.201400098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201400098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201400098%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%25253A%252BThienopyrimidine%252BCore%252Bwith%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BAmide%252BSide%252BChain%26aulast%3DYang%26aufirst%3DXiu%2BL.%26date%3D2014%26date%3D2014%26volume%3D347%26issue%3D8%26spage%3D552%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xun  Ji</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (7)
                                     , 2366-2378. <a href="https://doi.org/10.1016/j.bmc.2014.01.035" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B6-alkenylamides%252Bsubstituted%252Bof%252B4-anilinothieno%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Birreversible%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%26aulast%3DJi%26aufirst%3DXun%26date%3D2014%26volume%3D22%26issue%3D7%26spage%3D2366%26epage%3D2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinji  Takagi</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Banno</span>, <span class="hlFld-ContribAuthor ">Akira  Hayashi</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>. </span><span class="cited-content_cbyCitation_article-title">HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. </span><span class="cited-content_cbyCitation_journal-name">Oncoscience</span><span> <strong>2014,</strong> <em>1 </em>
                                    (3)
                                     , 196-204. <a href="https://doi.org/10.18632/oncoscience.23" title="DOI URL">https://doi.org/10.18632/oncoscience.23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncoscience.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncoscience.23%26sid%3Dliteratum%253Aachs%26jtitle%3DOncoscience%26atitle%3DHER2%252Band%252BHER3%252Bcooperatively%252Bregulate%252Bcancer%252Bcell%252Bgrowth%252Band%252Bdetermine%252Bsensitivity%252Bto%252Bthe%252Bnovel%252Binvestigational%252BEGFR%25252FHER2%252Bkinase%252Binhibitor%252BTAK-285%26aulast%3DTakagi%26aufirst%3DShinji%26date%3D2014%26volume%3D1%26issue%3D3%26spage%3D196%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia  LoRusso</span>, <span class="hlFld-ContribAuthor ">Karthik  Venkatakrishnan</span>, <span class="hlFld-ContribAuthor ">E. Gabriela  Chiorean</span>, <span class="hlFld-ContribAuthor ">Dennis  Noe</span>, <span class="hlFld-ContribAuthor ">Jing-Tao  Wu</span>, <span class="hlFld-ContribAuthor ">Serap  Sankoh</span>, <span class="hlFld-ContribAuthor ">Maria  Corvez</span>, <span class="hlFld-ContribAuthor ">Edward A.  Sausville</span>. </span><span class="cited-content_cbyCitation_article-title">Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2014,</strong> <em>32 </em>
                                    (1)
                                     , 160-170. <a href="https://doi.org/10.1007/s10637-013-9988-x" title="DOI URL">https://doi.org/10.1007/s10637-013-9988-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-013-9988-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-013-9988-x%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DPhase%252B1%252Bdose-escalation%25252C%252Bpharmacokinetic%25252C%252Band%252Bcerebrospinal%252Bfluid%252Bdistribution%252Bstudy%252Bof%252BTAK-285%25252C%252Ban%252Binvestigational%252Binhibitor%252Bof%252BEGFR%252Band%252BHER2%26aulast%3DLoRusso%26aufirst%3DPatricia%26date%3D2014%26date%3D2013%26volume%3D32%26issue%3D1%26spage%3D160%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayalakshmi  Sridhar</span>, <span class="hlFld-ContribAuthor ">Mary E.  Sfondouris</span>, <span class="hlFld-ContribAuthor ">Melyssa R.  Bratton</span>, <span class="hlFld-ContribAuthor ">Thuy-Linh K.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Ian  Townley</span>, <span class="hlFld-ContribAuthor ">Cheryl L.  Klein Stevens</span>, <span class="hlFld-ContribAuthor ">Frank E.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (1)
                                     , 126-131. <a href="https://doi.org/10.1016/j.bmcl.2013.11.064" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.11.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.11.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.11.064%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Bquinones%252Bas%252BHER2%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Btrastuzumab%252Bresistant%252Bbreast%252Bcancer%26aulast%3DSridhar%26aufirst%3DJayalakshmi%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D126%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Letícia de Castro  Barbosa</span>, <span class="hlFld-ContribAuthor ">Lídia Moreira  Lima</span>, <span class="hlFld-ContribAuthor ">Roberta  Tesch</span>, <span class="hlFld-ContribAuthor ">Carlos Mauricio R.  Sant'Anna</span>, <span class="hlFld-ContribAuthor ">Frank  Totzke</span>, <span class="hlFld-ContribAuthor ">Michael H.G.  Kubbutat</span>, <span class="hlFld-ContribAuthor ">Christoph  Schächtele</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>71 </em>, 1-14. <a href="https://doi.org/10.1016/j.ejmech.2013.10.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.10.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.10.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.10.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B2-chloro-4-anilino-quinazoline%252Bderivatives%252Bas%252BEGFR%252Band%252BVEGFR-2%252Bdual%252Binhibitors%26aulast%3DBarbosa%26aufirst%3DMaria%2BLet%25C3%25ADcia%2Bde%2BCastro%26date%3D2014%26volume%3D71%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kei  Yamaura</span>, <span class="hlFld-ContribAuthor ">Keiko  Kuwata</span>, <span class="hlFld-ContribAuthor ">Tomonori  Tamura</span>, <span class="hlFld-ContribAuthor ">Yoshiyuki  Kioi</span>, <span class="hlFld-ContribAuthor ">Yousuke  Takaoka</span>, <span class="hlFld-ContribAuthor ">Shigeki  Kiyonaka</span>, <span class="hlFld-ContribAuthor ">Itaru  Hamachi</span>. </span><span class="cited-content_cbyCitation_article-title">Live cell off-target identification of lapatinib using ligand-directed tosyl chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chem. Commun.</span><span> <strong>2014,</strong> <em>50 </em>
                                    (91)
                                     , 14097-14100. <a href="https://doi.org/10.1039/C4CC05885B" title="DOI URL">https://doi.org/10.1039/C4CC05885B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4CC05885B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4CC05885B%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Commun.%26atitle%3DLive%252Bcell%252Boff-target%252Bidentification%252Bof%252Blapatinib%252Busing%252Bligand-directed%252Btosyl%252Bchemistry%26aulast%3DYamaura%26aufirst%3DKei%26date%3D2014%26date%3D2014%26volume%3D50%26issue%3D91%26spage%3D14097%26epage%3D14100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">MEI HONG  ZHANG</span>, <span class="hlFld-ContribAuthor ">HONG TAO  MAN</span>, <span class="hlFld-ContribAuthor ">XIAO DAN  ZHAO</span>, <span class="hlFld-ContribAuthor ">NI  DONG</span>, <span class="hlFld-ContribAuthor ">SHI LIANG  MA</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). </span><span class="cited-content_cbyCitation_journal-name">Biomedical Reports</span><span> <strong>2014,</strong> <em>2 </em>
                                    (1)
                                     , 41-52. <a href="https://doi.org/10.3892/br.2013.187" title="DOI URL">https://doi.org/10.3892/br.2013.187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/br.2013.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fbr.2013.187%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Reports%26atitle%3DEstrogen%252Breceptor-positive%252Bbreast%252Bcancer%252Bmolecular%252Bsignatures%252Band%252Btherapeutic%252Bpotentials%252B%252528Review%252529%26aulast%3DZHANG%26aufirst%3DMEI%2BHONG%26date%3D2014%26date%3D2013%26volume%3D2%26issue%3D1%26spage%3D41%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Xun  Ji</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Zeng  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (24)
                                     , 7988-7998. <a href="https://doi.org/10.1016/j.bmc.2013.09.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.09.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.09.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-anilinoquinazolines%252Bwith%252BC-6%252Burea-linked%252Bside%252Bchains%252Bas%252Binhibitors%252Bof%252Bthe%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DZhang%26aufirst%3DXu%26date%3D2013%26volume%3D21%26issue%3D24%26spage%3D7988%26epage%3D7998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo-Rui  Kang</span>, <span class="hlFld-ContribAuthor ">Ai-Lin  Shan</span>, <span class="hlFld-ContribAuthor ">Yi-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Xu</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (22)
                                     , 6956-6964. <a href="https://doi.org/10.1016/j.bmc.2013.09.027" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.09.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.09.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-aryl-8-hydroxy%252B%252528or%252Bmethoxy%252529-isoquinolin-1%2525282H%252529-ones%252Bas%252Bnovel%252BEGFR%252Binhibitor%252Bby%252Bscaffold%252Bhopping%26aulast%3DKang%26aufirst%3DBo-Rui%26date%3D2013%26volume%3D21%26issue%3D22%26spage%3D6956%26epage%3D6964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Jost</span>, <span class="hlFld-ContribAuthor ">Johannes  Schilling</span>, <span class="hlFld-ContribAuthor ">Rastislav  Tamaskovic</span>, <span class="hlFld-ContribAuthor ">Martin  Schwill</span>, <span class="hlFld-ContribAuthor ">Annemarie  Honegger</span>, <span class="hlFld-ContribAuthor ">Andreas  Plückthun</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2013,</strong> <em>21 </em>
                                    (11)
                                     , 1979-1991. <a href="https://doi.org/10.1016/j.str.2013.08.020" title="DOI URL">https://doi.org/10.1016/j.str.2013.08.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2013.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2013.08.020%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DStructural%252BBasis%252Bfor%252BEliciting%252Ba%252BCytotoxic%252BEffect%252Bin%252BHER2-Overexpressing%252BCancer%252BCells%252Bvia%252BBinding%252Bto%252Bthe%252BExtracellular%252BDomain%252Bof%252BHER2%26aulast%3DJost%26aufirst%3DChristian%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D1979%26epage%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo-Han  Su</span>, <span class="hlFld-ContribAuthor ">Yi-Syuan  Huang</span>, <span class="hlFld-ContribAuthor ">Chia-Yun  Chang</span>, <span class="hlFld-ContribAuthor ">Yi-Shu  Tu</span>, <span class="hlFld-ContribAuthor ">Yufeng  Tseng</span>. </span><span class="cited-content_cbyCitation_article-title">Template-Based de Novo Design for Type II Kinase Inhibitors and Its Extended Application to Acetylcholinesterase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2013,</strong> <em>18 </em>
                                    (11)
                                     , 13487-13509. <a href="https://doi.org/10.3390/molecules181113487" title="DOI URL">https://doi.org/10.3390/molecules181113487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules181113487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules181113487%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTemplate-Based%252Bde%252BNovo%252BDesign%252Bfor%252BType%252BII%252BKinase%252BInhibitors%252Band%252BIts%252BExtended%252BApplication%252Bto%252BAcetylcholinesterase%252BInhibitors%26aulast%3DSu%26aufirst%3DBo-Han%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D11%26spage%3D13487%26epage%3D13509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brindaban C.  Ranu</span>, <span class="hlFld-ContribAuthor ">Debasree  Saha</span>, <span class="hlFld-ContribAuthor ">Debasish  Kundu</span>, <span class="hlFld-ContribAuthor ">Nirmalya  Mukherjee</span>. </span><span class="cited-content_cbyCitation_article-title">Aryl Carbon-Heteroatom Coupling Reactions Using Nanometal Catalyst. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 189-220. <a href="https://doi.org/10.1002/9781118609811.ch6" title="DOI URL">https://doi.org/10.1002/9781118609811.ch6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118609811.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118609811.ch6%26sid%3Dliteratum%253Aachs%26atitle%3DAryl%252BCarbon-Heteroatom%252BCoupling%252BReactions%252BUsing%252BNanometal%252BCatalyst%26aulast%3DRanu%26aufirst%3DBrindaban%2BC.%26date%3D2013%26date%3D2013%26spage%3D189%26epage%3D220%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DNanocatalysis%252BSynthesis%252Band%252BApplications%26aulast%3DPolshettiwar%26aufirst%3DVivek%26date%3D2013%26volume%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Jing-Ran  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Fang</span>, <span class="hlFld-ContribAuthor ">Qian-Ru  Du</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Gong</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>, . </span><span class="cited-content_cbyCitation_article-title">Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2013,</strong> <em>8 </em>
                                    (8)
                                     , e69427. <a href="https://doi.org/10.1371/journal.pone.0069427" title="DOI URL">https://doi.org/10.1371/journal.pone.0069427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0069427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0069427%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DOptimization%252Bof%252BSubstituted%252B6-Salicyl-4-Anilinoquinazoline%252BDerivatives%252Bas%252BDual%252BEGFR%25252FHER2%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DLi%26aufirst%3DDong-Dong%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3De69427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Masaki  Seto</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Ohashi</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tadashi  Yusa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Hidehisa  Iwata</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Toshimasa  Tanaka</span>, <span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel pyrimido[4,5- b ]azepine derivatives as HER2/EGFR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (8)
                                     , 2250-2261. <a href="https://doi.org/10.1016/j.bmc.2013.02.014" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bpyrimido%25255B4%25252C5-%252Bb%252B%25255Dazepine%252Bderivatives%252Bas%252BHER2%25252FEGFR%252Bdual%252Binhibitors%26aulast%3DKawakita%26aufirst%3DYouichi%26date%3D2013%26volume%3D21%26issue%3D8%26spage%3D2250%26epage%3D2261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lorenzo  Palmieri</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">αC helix displacement as a general approach for allosteric modulation of protein kinases. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2013,</strong> <em>18 </em>
                                    (7-8)
                                     , 407-414. <a href="https://doi.org/10.1016/j.drudis.2012.11.009" title="DOI URL">https://doi.org/10.1016/j.drudis.2012.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3D%2525CE%2525B1C%252Bhelix%252Bdisplacement%252Bas%252Ba%252Bgeneral%252Bapproach%252Bfor%252Ballosteric%252Bmodulation%252Bof%252Bprotein%252Bkinases%26aulast%3DPalmieri%26aufirst%3DLorenzo%26date%3D2013%26volume%3D18%26issue%3D7-8%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjay  Saha</span>, <span class="hlFld-ContribAuthor ">Ch.  Venkata Ramana Reddy</span>, <span class="hlFld-ContribAuthor ">T.  Chiranjeevi</span>, <span class="hlFld-ContribAuthor ">Uma  Addepally</span>, <span class="hlFld-ContribAuthor ">T.S.  Chinta Rao</span>, <span class="hlFld-ContribAuthor ">Balaram  Patro</span>. </span><span class="cited-content_cbyCitation_article-title">The first total synthesis and biological evaluation of marine natural products ma’edamines A and B. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (4)
                                     , 1013-1016. <a href="https://doi.org/10.1016/j.bmcl.2012.12.033" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.12.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.12.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bfirst%252Btotal%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bmarine%252Bnatural%252Bproducts%252Bma%2525E2%252580%252599edamines%252BA%252Band%252BB%26aulast%3DSaha%26aufirst%3DSanjay%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D1013%26epage%3D1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ron  Bose</span>, <span class="hlFld-ContribAuthor ">Shyam M.  Kavuri</span>, <span class="hlFld-ContribAuthor ">Adam C.  Searleman</span>, <span class="hlFld-ContribAuthor ">Wei  Shen</span>, <span class="hlFld-ContribAuthor ">Dong  Shen</span>, <span class="hlFld-ContribAuthor ">Daniel C.  Koboldt</span>, <span class="hlFld-ContribAuthor ">John  Monsey</span>, <span class="hlFld-ContribAuthor ">Nicholas  Goel</span>, <span class="hlFld-ContribAuthor ">Adam B.  Aronson</span>, <span class="hlFld-ContribAuthor ">Shunqiang  Li</span>, <span class="hlFld-ContribAuthor ">Cynthia X.  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Ding</span>, <span class="hlFld-ContribAuthor ">Elaine R.  Mardis</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Ellis</span>. </span><span class="cited-content_cbyCitation_article-title">Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2013,</strong> <em>3 </em>
                                    (2)
                                     , 224-237. <a href="https://doi.org/10.1158/2159-8290.CD-12-0349" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-12-0349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-12-0349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-12-0349%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DActivating%252BHER2%252BMutations%252Bin%252BHER2%252BGene%252BAmplification%252BNegative%252BBreast%252BCancer%26aulast%3DBose%26aufirst%3DRon%26date%3D2013%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D224%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youichi  Kawakita</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Miwa</span>, <span class="hlFld-ContribAuthor ">Masaki  Seto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Banno</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Ohta</span>, <span class="hlFld-ContribAuthor ">Toshiya  Tamura</span>, <span class="hlFld-ContribAuthor ">Tadashi  Yusa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Miki</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Ikeda</span>, <span class="hlFld-ContribAuthor ">Toshimasa  Tanaka</span>, <span class="hlFld-ContribAuthor ">Keiji  Kamiyama</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (20)
                                     , 6171-6180. <a href="https://doi.org/10.1016/j.bmc.2012.08.002" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpyrrolo%25255B3%25252C2-d%25255Dpyrimidine%252BHER2%25252FEGFR%252Bdual%252Binhibitors%25253A%252BImprovement%252Bof%252Bthe%252Bphysicochemical%252Band%252Bpharmacokinetic%252Bprofiles%252Bfor%252Bpotent%252Bin%252Bvivo%252Banti-tumor%252Befficacy%26aulast%3DKawakita%26aufirst%3DYouichi%26date%3D2012%26volume%3D20%26issue%3D20%26spage%3D6171%26epage%3D6180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium(II)-Catalyzed Cycloamidination via C(sp2)H Activation and Isocyanide Insertion. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2012,</strong> <em>354 </em>
                                    (10)
                                     , 1902-1908. <a href="https://doi.org/10.1002/adsc.201200106" title="DOI URL">https://doi.org/10.1002/adsc.201200106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201200106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201200106%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DPalladium%252528II%252529-Catalyzed%252BCycloamidination%252Bvia%252BC%252528sp2%252529%2525EF%2525A3%2525BFH%252BActivation%252Band%252BIsocyanide%252BInsertion%26aulast%3DWang%26aufirst%3DYong%26date%3D2012%26date%3D2012%26volume%3D354%26issue%3D10%26spage%3D1902%26epage%3D1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miao  Zuo</span>, <span class="hlFld-ContribAuthor ">Yue-Wen  Zheng</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (14)
                                     , 4405-4412. <a href="https://doi.org/10.1016/j.bmc.2012.05.034" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.05.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.05.034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BN-aryl%252Bsalicylamides%252Bwith%252Ba%252Bhydroxamic%252Bacid%252Bmoiety%252Bat%252B5-position%252Bas%252Bnovel%252BHDAC%2525E2%252580%252593EGFR%252Bdual%252Binhibitors%26aulast%3DZuo%26aufirst%3DMiao%26date%3D2012%26volume%3D20%26issue%3D14%26spage%3D4405%26epage%3D4412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Larry  Yet</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 393-420. <a href="https://doi.org/10.1016/B978-0-08-096807-0.00013-0" title="DOI URL">https://doi.org/10.1016/B978-0-08-096807-0.00013-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-096807-0.00013-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-096807-0.00013-0%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%26aulast%3DYet%26aufirst%3DLarry%26date%3D2012%26spage%3D393%26epage%3D420%26pub%3DElsevier%26date%3D2012%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0016.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of EGFR and/or HER2 small molecule inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0017.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of pyrrolo[3,2-<i>d</i>]pyrimidine scaffold as HER2 kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0022.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives <b>6a</b>–<b>n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>2a</b>–<b>n</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 2 h; (b) H<sub>2</sub>, Pt–C, AcOEt, rt, 2 h, or Fe, CaCl<sub>2</sub>, EtOH, 100 °C, 15 h, 56–99% for 2 steps; (c) <b>5</b>, NMP, 100 °C, 3 h, 31–83%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives <b>6o</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>4o</b>–<b>4q</b>, NMP, 100 °C, 3 h, 66–80%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>8</b>, <b>10</b>, and <b>12</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) iodomethane, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 3 h, 93%; (b) aniline <b>4e</b> or <b>4j</b> or <b>4l</b>, NMP, 140 °C, 4 h, 75–92%; (c) 2-iodoethyl benzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 70%; (d) (i) aniline <b>4e</b> or <b>4j</b> or <b>4</b>l NMP, 140 °C, 2.5 h, (ii) 1N NaOH, MeOH, rt, 46–72%; (e) 2-(2-iodoethoxy)ethyl benzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 55%; (f) (i) 2,3-dichloro-5-nitropyridine, NaH, THF, rt, 2.5 h, (ii) Fe, CaCl<sub>2</sub>, EtOH, 80 °C, 8 h, 39% from <b>2j</b>.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-5 Hydroxypentyl Pyrrolo[3,2-<i>d</i>]pyrimidine derivative <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 5-chloropentyl acetate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 69%; (b) <b>4j</b>, 2-PrOH, 80 °C, 14 h; (c) 1N NaOH, rt, 1 h, MeOH, 79% for 2 steps.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of a <i>N</i>-5 Hydroxyethylaminoethyl Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-bromo-1,1-diethoxyethane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4.5 h, 72%; (b) PhOH, K<sub>2</sub>CO<sub>3</sub>, NMP, 140 °C, 6 h, 95%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 91%; (d) 2-aminoethanol, NaB(OAc)<sub>3</sub>H, AcOH, DMF, rt, 16 h, 52%; (e) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 16 h, 19%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of a <i>N</i>-5 Sulfur-Containing Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>28</b>, <b>29</b>, and <b>30</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>iso</i>-Pr<sub>2</sub>EtN, 40 °C, 3 days, 77%; (b) PPh<sub>3</sub>, CBr<sub>4</sub>, rt, 3 days, 76%; (c) <b>5</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 15 h, 80%; (d) <b>4j</b>, 2-PrOH, 80 °C, 15 h; (e) 1N NaOH, MeOH, rt, 1 h, 59% for 2 steps; (f) <i>m</i>CPBA, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 1 h, 85%; (g) <i>tert</i>-BuO<sub>2</sub>H, Ti(O<sup><i>iso</i></sup>Pr)<sub>4</sub>, MeOH, H<sub>2</sub>O, rt, 2 days, 74%.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of a <i>N</i>-5 Carboxamido Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives (<b>34a</b> and <b>34c</b>–<b>34e</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>tert</i>-butyl (2-bromoethyl)carbamate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 71%; (b) <b>4j</b>, 2-PrOH, 80 °C, 12 h, 85%; (c) 2N HCl, THF, 60 °C, 20 h, quant; (d) WSC, HOBt, Et<sub>3</sub>N, carboxylic acid, DMF, 3 days, 74–86%; (e) MsOH, AcOEt, rt, 2 h, 25% from <b>33a</b>.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0007.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of a <i>N</i>-5 Carboxamido Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>34b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-[(<i>tert</i>-butoxycarbonyl)(methyl)amino]ethyl methanesulfonate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 4 days, 33%; (b) <b>4j</b>, 2-PrOH, 80 °C, 12 h, 76%; (c) 2N HCl, THF, 60 °C, 20 h, 91%; (d) WSC, HOBt, Et<sub>3</sub>N, hydroxyacetic acid, DMF, 3 days, 62%.</p></p></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0008.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of a <i>C</i>-6 Methyl Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) trimethyl(prop-1-yn-1-yl)silane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, KF, DMF, Et<sub>3</sub>N, 60 °C, 16 h, 73%; (b) <i>tert</i>-BuOK, THF, 0 °C, 40 min, 67%; (c) 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 21 h, 93%; (d) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 17 h, 58%; (e) 1N NaOH, MeOH, rt, 2 h, 90%.</p></p></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0009.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of a <i>C</i>-6 Cyano Pyrrolo[3,2-<i>d</i>]pyrimidine Derivative <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 3,3-diethoxyprop-1-yne, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, MeCN, Et<sub>3</sub>N, rt, 16.5 h, 89%; (b) <i>tert</i>-BuOK, THF, rt, 1.5 h, 51%; (c) 1N HCl, THF, rt, 2 h, 90%; (d) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, DMSO, H<sub>2</sub>O, rt, 2 h, quant; (e) (i) SOCl<sub>2</sub>, 75 °C, 2 h, (ii) NH<sub>3</sub>, THF, 0 °C, 92%; (f) POCl<sub>3</sub>, 70 °C, 1.5 h, 61%; (g) 2-{2-[(methylsulfonyl)oxy]ethoxy}ethyl benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 7 h, 61%; (h) <b>4j</b>, pyridinium chloride, phenol, 140 °C, 17 h, 74%; (i) 1N NaOH, MeOH, rt, 1 h, 61%.</p></p></figure><figure data-id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0018.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor efficacy of <b>34e</b> in 4–1ST xenograft models in mice. Dose levels 50 and 100 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0019.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor efficacy of <b>34e</b> in 4–1ST xenograft models in rats. (A) Dose levels 6.25 mg/kg and 12.5 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test). (B) Dose levels 25 and 50 mg/kg; <i>P</i> ≤ 0.025 vs control at day 14 (one-tailed Shirley–Williams test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0020.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Concentration of <b>34e</b> in tumor (μg/g) and plasma (μg/mL) in rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/medium/jm-2011-008634_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0021.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray cocrystal structures of compound <b>34e</b> (TAK-285) with HER2 (A) and EGFR (B), together with that of compound <b>12r</b> with HER2 (C).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-23/jm2008634/production/images/large/jm-2011-008634_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2008634&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77222" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77222" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 21 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyajima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ooi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoshima, K.</span><span> </span><span class="NLM_article-title">The erbB gene of avian erythroblastosis virus is a member of the <i>src</i> gene family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1983&pages=71-78&author=T.+Yamamotoauthor=T.+Nishidaauthor=N.+Miyajimaauthor=S.+Kawaiauthor=T.+Ooiauthor=K.+Toyoshima&title=The+erbB+gene+of+avian+erythroblastosis+virus+is+a+member+of+the+src+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%26aulast%3DOoi%26aufirst%3DT.%26aulast%3DToyoshima%26aufirst%3DK.%26atitle%3DThe%2520erbB%2520gene%2520of%2520avian%2520erythroblastosis%2520virus%2520is%2520a%2520member%2520of%2520the%2520src%2520gene%2520family%26jtitle%3DCell%26date%3D1983%26volume%3D35%26spage%3D71%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as targets in cancer therapy—successes and failures</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1517%2F14728222.7.2.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12667099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=215-234&author=P.+Traxler&title=Tyrosine+kinases+as+targets+in+cancer+therapy%E2%80%94successes+and+failures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets in cancer therapy - successes and failures</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-234</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction and also in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth-related kinases, esp. Tyr kinases, might therefore provide new therapies for diseases such as cancer.  Due to the enormous progress that was made in the past few years in the identification of the human genome, in mol. and cell biol. technologies, in structural biol. and in bioinformatics, the no. of receptor and non-receptor Tyr kinases that were identified as valuable mol. targets has greatly increased.  Currently, > 20 different Tyr kinase targets are under evaluation in drug discovery projects in oncol.  The progress made in the crystn. of protein kinases, in most cases complexed with ATP-site-directed inhibitors, has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for rational drug design; > 20 ATP-competitive, low mol. wt. inhibitors are in various phases of clin. evaluation.  Meanwhile, clin. proof-of-concept (POC) was achieved with several antibodies and small mols. targeted against Tyr kinases.  With Herceptin, Glivec, and Iressa (registered in Japan), the 1st kinase drugs have entered the market.  This review describes the preclin. and clin. status of low mol. wt. drugs targeted against different Tyr kinases (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Kit, Fms-like Tyr kinase [Flt]-3), briefly describes new targets, and provides a crit. anal. of the current situation in the area of Tyr kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyxUqnX26eLVg90H21EOLACvtfcHk0liBL8REFgnv2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVGrt7w%253D&md5=aac69b84205b6525b0acb4ab2a43f219</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1517%2F14728222.7.2.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.7.2.215%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinases%2520as%2520targets%2520in%2520cancer%2520therapy%25E2%2580%2594successes%2520and%2520failures%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2003%26volume%3D7%26spage%3D215%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0liBL8REFgnv2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Burgess, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">An Open-and-Shut Case? Recent Insights into the Activation of EGF/erbB2 Receptors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=541-552&author=A.+W.+Burgessauthor=H.+S.+Choauthor=C.+Eigenbrotauthor=K.+M.+Fergusonauthor=T.+P.+Garrettauthor=D.+J.+Leahyauthor=M.+A.+Lemmonauthor=M.+X.+Sliwkowskiauthor=C.+W.+Wardauthor=S.+Yokoyama&title=An+Open-and-Shut+Case%3F+Recent+Insights+into+the+Activation+of+EGF%2FerbB2+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DK.%2BM.%26aulast%3DGarrett%26aufirst%3DT.%2BP.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DWard%26aufirst%3DC.%2BW.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DAn%2520Open-and-Shut%2520Case%253F%2520Recent%2520Insights%2520into%2520the%2520Activation%2520of%2520EGF%252FerbB2%2520Receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D12%26spage%3D541%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0liGVhI7RdCeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, D. F.</span><span> </span><span class="NLM_article-title">The biology of erbB-2/neu/HER-2 and its role in cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">1198</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1198&publication_year=1994&pages=165-184&author=N.+E.+Hynesauthor=D.+F.+Stern&title=The+biology+of+erbB-2%2Fneu%2FHER-2+and+its+role+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DStern%26aufirst%3DD.%2BF.%26atitle%3DThe%2520biology%2520of%2520erbB-2%252Fneu%252FHER-2%2520and%2520its%2520role%2520in%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1994%26volume%3D1198%26spage%3D165%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthom, L. R.</span><span> </span><span class="NLM_article-title">#4251 ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=633&author=J.+R.+Woodburnauthor=A.+J.+Barkerauthor=K.+H.+Gilsonauthor=S.+E.+Ashtonauthor=A.+E.+Wakelingauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+R.+Henthom&title=%234251+ZD+1839%2C+an+epidermal+growth+factor+tyrosine+kinase+inhibitor+selected+for+clinical+trial+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGilson%26aufirst%3DK.%2BH.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthom%26aufirst%3DL.%2BR.%26atitle%3D%25234251%2520ZD%25201839%252C%2520an%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitor%2520selected%2520for%2520clinical%2520trial%2520development%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D1997%26volume%3D38%26spage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+Leading+to+the+Identification+of+ZD1839+%28Iressa%29%3A+An+Orally+Active%2C+Selective+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Targeted+to+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0liGVhI7RdCeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520Leading%2520to%2520the%2520Identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520An%2520Orally%2520Active%252C%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Targeted%2520to%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, K. H.</span><span> </span><span class="NLM_article-title">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12384534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gilson&title=ZD1839+%28Iressa%29%3A+An+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span></div><div class="casAuthors">Wakeling, Alan E.; Guy, Simon P.; Woodburn, Jim R.; Ashton, Susan E.; Curry, Brenda J.; Barker, Andrew J.; Gibson, Keith H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5749-5754</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy.  We have developed a low-mol.-wt. EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa).  ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC50 = 0.033 μM) that selectively inhibits EGF-stimulated tumor cell growth (IC50 = 0.054 μM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells.  In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner.  The level of expression of EGFR did not det. xenograft tumor sensitivity to ZD1839.  Long-term ZD1839 (>3 mo) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors.  No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal.  These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkoHZ9zL06abVg90H21EOLACvtfcHk0liGVhI7RdCeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D&md5=f5f86c652786db476a2d23b5bbd1a9e9</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGilson%26aufirst%3DK.%2BH.%26atitle%3DZD1839%2520%2528Iressa%2529%253A%2520An%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_contrib-group">Matar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Bueno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosimo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">6487</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15475436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1OitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=6487-6501&author=P.+Matarauthor=F.+Rojoauthor=R.+Cassiaauthor=G.+Moreno-Buenoauthor=S.+D.+Cosimoauthor=J.+Taberneroauthor=M.+Guzmanauthor=S.+Rodriguezauthor=J.+Arribasauthor=J.+Palaciosauthor=J.+Baselga&title=Combined+epidermal+growth+factor+receptor+targeting+with+the+tyrosine+kinase+inhibitor+gefitinib+%28ZD1839%29+and+the+monoclonal+antibody+cetuximab+%28IMC-C225%29%3A+superiority+over+single-agent+receptor+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting</span></div><div class="casAuthors">Matar, Pablo; Rojo, Federico; Cassia, Raul; Moreno-Bueno, Gema; Di Cosimo, Serena; Tabernero, Jose; Guzman, Marta; Rodriguez, Sonia; Arribas, Joaquin; Palacios, Jose; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6487-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and low-mol.-wt. tyrosine kinase inhibitors, have shown antitumor activity in patients.  Because these two classes of antireceptor agents target the EGFR at different sites, we decided to explore whether the combined administration of gefitinib, a tyrosine kinase inhibitor, and cetuximab, a monoclonal antibody, had superior antitumor activity than either agent given alone.  We studied the effects of the combination of gefitinib and cetuximab in a panel of human cancer cell lines and in an EGFR-dependent human tumor xenograft model (A431).  The effects of these two agents on EGFR signaling, proliferation, apoptosis, and vascularization were evaluated.  In addn., we analyzed, with cDNA arrays, changes in gene expression profiles induced by both agents.  The combined treatment with gefitinib and cetuximab resulted in a synergistic effect on cell proliferation and in superior inhibition of EGFR-dependent signaling and induction of apoptosis.  In a series of in vivo expts., single-agent gefitinib or cetuximab resulted in transient complete tumor remission only at the highest doses.  In contrast, suboptimal doses of gefitinib and cetuximab given together resulted in a complete and permanent regression of large tumors.  In the combination-treated tumors, there was a superior inhibition of EGFR, mitogen-activated protein kinase, and Akt phosphorylation, as well as greater inhibition of cell proliferation and vascularization and enhanced apoptosis.  Using cDNA arrays, we found 59 genes that were coregulated and 45 genes differentially regulated, including genes related to cell proliferation and differentiation, transcription, DNA synthesis and repair, angiogenesis, signaling mols., cytoskeleton organization, and tumor invasion and metastasis.  Our findings suggest both shared and complementary mechanisms of action with gefitinib and cetuximab and support combined EGFR targeting as a clin. exploitable strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXVcoupyARorVg90H21EOLACvtfcHk0lhB7_dC_OeTjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1OitbY%253D&md5=b62bd5319dfbf9a453324158c1ae6122</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0870%26sid%3Dliteratum%253Aachs%26aulast%3DMatar%26aufirst%3DP.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DCassia%26aufirst%3DR.%26aulast%3DMoreno-Bueno%26aufirst%3DG.%26aulast%3DCosimo%26aufirst%3DS.%2BD.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DPalacios%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DCombined%2520epidermal%2520growth%2520factor%2520receptor%2520targeting%2520with%2520the%2520tyrosine%2520kinase%2520inhibitor%2520gefitinib%2520%2528ZD1839%2529%2520and%2520the%2520monoclonal%2520antibody%2520cetuximab%2520%2528IMC-C225%2529%253A%2520superiority%2520over%2520single-agent%2520receptor%2520targeting%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D6487%26epage%3D6501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramukai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, M.</span><span> </span><span class="NLM_article-title">Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer—a retrospective analysis: JMTO LC03–02</span> <span class="citation_source-journal">BMC Res. Notes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1186%2F1756-0500-2-157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=19656374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A280%3ADC%252BD1MrpsF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=157&author=M.+Nakagawaauthor=T.+Nishimuraauthor=S.+Teramukaiauthor=H.+Tadaauthor=F.+Tanakaauthor=K.+Yanagiharaauthor=K.+Furuseauthor=H.+Wadaauthor=M.+Fukushima&title=Interstitial+lung+disease+in+gefitinib-treated+Japanese+patients+with+non-small+cell+lung+cancer%E2%80%94a+retrospective+analysis%3A+JMTO+LC03%E2%80%9302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02</span></div><div class="casAuthors">Nakagawa Masatsugu; Nishimura Tsutomu; Teramukai Satoshi; Tada Harue; Tanaka Fumihiro; Yanagihara Kazuhiro; Furuse Kiyoyuki; Wada Hiromi; Fukushima Masanori</div><div class="citationInfo"><span class="NLM_cas:title">BMC research notes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC).  We investigated the efficacy of gefitinib, the incidence of ILD and risk factors for ILD in these patients.  FINDINGS:  We obtained patient data retrospectively using questionnaires sent to 22 institutions.  We asked for demographic and clinical data on NSCLC patients for whom gefitinib treatment had begun between July 2002 and February 2003.  Data from a total of 526 patients were analyzed.  The patient characteristics were as follows: 64% male, 69% with adenocarcinoma, 61% with a performance score of 0-1, and 5% with concurrent interstitial pneumonitis.  The objective response proportion was 80/439 (18.2%; 95% CI: 14.7-22.0).  ILD developed in 17 patients (3.2%; 95% CI 1.9-5.1%), of whom 7 died.  According to multivariate analysis, female sex, history of prior chemotherapy, low absolute neutrophil count before gefitinib treatment, and adenocarcinoma histology were associated with response to gefitinib treatment.  None of the factors we evaluated were associated with the development of ILD.  CONCLUSION:  The results of this study are consistent with previously published values for treatment response proportions and incidence of ILD during gefitinib treatment in Japanese patients.  Future studies should be aimed at identifying factors indicating that a patient has a high probability of receiving benefit from gefitinib and a low risk of developing ILD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjgPlh7Q_C477NkxioyDXTfW6udTcc2eYsxouDkBZXarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrpsF2hsQ%253D%253D&md5=44854536d62576b45cd5b34fa87cddfc</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1186%2F1756-0500-2-157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-0500-2-157%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DTeramukai%26aufirst%3DS.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DF.%26aulast%3DYanagihara%26aufirst%3DK.%26aulast%3DFuruse%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DM.%26atitle%3DInterstitial%2520lung%2520disease%2520in%2520gefitinib-treated%2520Japanese%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%25E2%2580%2594a%2520retrospective%2520analysis%253A%2520JMTO%2520LC03%25E2%2580%259302%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2009%26volume%3D2%26spage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+EGF+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520EGF%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_contrib-group">Sorbera, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestre, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayes, M.</span><span> </span><span class="NLM_article-title">Erlotinib Hydrochloride</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1358%2Fdof.2002.027.10.697002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=923&author=L.+A.+Sorberaauthor=J.+Casta%C3%B1erauthor=J.+S.+Silvestreauthor=M.+Bayes&title=Erlotinib+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib hydrochloride: oncolytic EGF receptor inhibitor</span></div><div class="casAuthors">Sorbera, L. A.; Castaner, J.; Silvestre, J. S.; Bayes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">923-934</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a type 1 receptor tyrosine kinase that is involved in the modulation of cellular differentiation and is overexpressed in many types of human cancers such as lung, pancreatic, ovarian, renal cell, gastric, hepatocellular and breast.  Overexpression of EGFR is frequently correlated with increased tumor grade, increased metastatic potential and poor prognosis.  Thus, inhibition of EGFR signaling is an attractive therapeutic option for the treatment of cancer.  One method that can interfere with EGFR is the direct inhibition of EGFR tyrosine kinase activity.  Several tyrosine kinase inhibitors have been developed and evaluated over the past 10 yr of which the majority are reversible competitors with ATP for binding to the intracellular catalytic domain of the tyrosine kinase.  One such EGFR tyrosine kinase inhibitor that has shown excellent antitumor activity is erlotinib hydrochloride, an oral quinazoline deriv. that reversibly and selectively inhibits tyrosine kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHlS4LhWq4u7Vg90H21EOLACvtfcHk0lhB7_dC_OeTjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFelsg%253D%253D&md5=e2fe2bf52a2521acebd6ea695aadfa0c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.10.697002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.10.697002%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DJ.%26aulast%3DSilvestre%26aufirst%3DJ.%2BS.%26aulast%3DBayes%26aufirst%3DM.%26atitle%3DErlotinib%2520Hydrochloride%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroog, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Soler, R.</span><span> </span><span class="NLM_article-title">Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1572</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15746062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1572-1578&author=Q.+Daiauthor=Y.-H.+Lingauthor=M.+Lieauthor=Y.-Y.+Zouauthor=G.+Kroogauthor=K.+K.+Iwataauthor=R.+Perez-Soler&title=Enhanced+Sensitivity+to+the+HER1%2FEpidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+Erlotinib+Hydrochloride+in+Chemotherapy-Resistant+Tumor+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines</span></div><div class="casAuthors">Dai, Qun; Ling, Yi-He; Lia, Marie; Zou, Yi-Yu; Kroog, Glenn; Iwata, Kenneth K.; Perez-Soler, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1572-1578</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the HER1/epidermal growth factor receptor (EGFR) tyrosine kinase.  In phase II clin. studies, oral erlotinib monotherapy has shown antitumor activity in patients with advanced non-small cell lung cancer, head and neck cancer, and ovarian cancer after the failure of std. chemotherapy.  We hypothesized that some tumors treated with multiple cytotoxic therapies may become more dependent on the HER1/EGFR signaling pathways for survival.  The growth-inhibitory effect of erlotinib was tested on 10 pairs of chemosensitive, parental, and chemoresistant tumor cell lines.  Enhanced sensitivity to erlotinib was obsd. in the doxorubicin-resistant human breast cancer cell line MCF-7, paclitaxel-resistant human ovarian carcinoma cell line A2780, and cisplatin-resistant human cervical carcinoma cell line ME180.  The IC50 values of erlotinib in the resistant cell lines were 2- to 20-fold lower than those in the corresponding parental cell lines.  This enhanced sensitivity to erlotinib correlated with higher HER1/EGFR and phospho-HER1/EGFR expression when compared with the corresponding parental cell lines.  Acquired resistance to cytotoxic agents was not assocd. with cross-resistance to erlotinib.  AE-ME180/CDDP-resistant xenografts showed greater sensitivity to erlotinib than parental ME180 xenografts did.  Our findings suggest that acquired resistance to cytotoxic therapy in some tumors is assocd. with enhanced sensitivity to HER1/EGFR inhibitors, which correlates with increased HER1/EGFR expression.  These data may explain some of the obsd. clin. activity of HER1/EGFR inhibitors in patients previously treated with multiple therapies.  HER1/EGFR tyrosine kinase inhibitors may be more effective as second- or third-line treatment for certain patients with tumors that were previously treated with multiple chemotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeXCdcqp21VrVg90H21EOLACvtfcHk0lji0a3VF4dozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVSrtrs%253D&md5=eb368294959fdf32f666cf5bdf8b4c5a</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0993%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DLing%26aufirst%3DY.-H.%26aulast%3DLie%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DY.-Y.%26aulast%3DKroog%26aufirst%3DG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DEnhanced%2520Sensitivity%2520to%2520the%2520HER1%252FEpidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520Erlotinib%2520Hydrochloride%2520in%2520Chemotherapy-Resistant%2520Tumor%2520Cell%2520Lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D1572%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_contrib-group">Melosky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agulnik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assi, H.</span><span> </span><span class="NLM_article-title">Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=279-285&author=B.+Meloskyauthor=J.+Agulnikauthor=H.+Assi&title=Retrospective+practice+review+of+treatment+of+metastatic+non-small-cell+lung+cancer+with+second-line+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelosky%26aufirst%3DB.%26aulast%3DAgulnik%26aufirst%3DJ.%26aulast%3DAssi%26aufirst%3DH.%26atitle%3DRetrospective%2520practice%2520review%2520of%2520treatment%2520of%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520with%2520second-line%2520erlotinib%26jtitle%3DCurr.%2520Oncol.%26date%3D2008%26volume%3D6%26spage%3D279%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasser, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekele, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, N. J.</span><span> </span><span class="NLM_article-title">Cetuximab and Irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-05-1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=16428506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=600-607&author=S.+Kimauthor=N.+C.+Prichardauthor=N.+M.+Younesauthor=D.+Y.+Yaziciauthor=A.+S.+Jasserauthor=N.+B.+Bekeleauthor=N.+J.+Myers&title=Cetuximab+and+Irinotecan+interact+synergistically+to+inhibit+the+growth+of+orthotopic+anaplastic+thyroid+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice</span></div><div class="casAuthors">Kim, Seungwon; Prichard, Christopher N.; Younes, Maher N.; Yazici, Yasemin D.; Jasser, Samar A.; Bekele, B. Nebiyou; Myers, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">600-607</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers.  Targeted mol. therapy with cetuximab, a monoclonal antibody against epidermal growth factor receptor, offers new treatment potentials for patient with ATC.  Cetuximab has also been reported to have synergistic effects when combined with irinotecan, a topoisomerase inhibitor.  Therefore, we hypothesized that cetuximab and irinotecan would be effective in inhibiting the growth and progression of ATC in a murine orthotopic model.  Exptl. Design: The in vitro antiproliferative effects of cetuximab and irinotecan on ATC cell line ARO were examd.  We also studied the in vivo effects of cetuximab and irinotecan on the growth, invasion, and metastasis of orthotopic ATC tumors in nude mice.  The in vivo antitumor efficacy of cetuximab/irinotecan combination was also compared with that of doxorubicin.  Results: Cetuximab alone did not show any antiproliferative or proapoptotic effect on this cell line.  However, when combined with irinotecan, cetuximab potentiated the in vitro antiproliferative and proapoptotic effect of irinotecan.  Cetuximab, irinotecan, and cetuximab/irinotecan combination resulted in 77%, 79%, and 93% in vivo inhibition of tumor growth, resp.  Incidences of lymph node metastasis, laryngeal invasion, and tumor microvessel d. were also significantly decreased in these treatment groups.  Furthermore, the cetuximab/irinotecan combination was significantly more effective than doxorubicin in inhibiting the growth of orthotopic ATC xenografts.  Conclusions: Combination therapy with cetuximab/irinotecan inhibits the growth and progression of orthotopic ATC xenografts in nude mice.  Given the lack of curative options for patients with ATC, combination therapy with cetuximab and irinotecan treatment warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsHzVhsFHwebVg90H21EOLACvtfcHk0lji0a3VF4dozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D&md5=90f0a52d3c65268632c168a4cb4b633c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1325%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPrichard%26aufirst%3DN.%2BC.%26aulast%3DYounes%26aufirst%3DN.%2BM.%26aulast%3DYazici%26aufirst%3DD.%2BY.%26aulast%3DJasser%26aufirst%3DA.%2BS.%26aulast%3DBekele%26aufirst%3DN.%2BB.%26aulast%3DMyers%26aufirst%3DN.%2BJ.%26atitle%3DCetuximab%2520and%2520Irinotecan%2520interact%2520synergistically%2520to%2520inhibit%2520the%2520growth%2520of%2520orthotopic%2520anaplastic%2520thyroid%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group">Balin-Gauthier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delord, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillaire, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochaix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugat, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allal, B. C.</span><span> </span><span class="NLM_article-title">Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18182978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=120-128&author=D.+Balin-Gauthierauthor=J.-P.+Delordauthor=M.-J.+Pillaireauthor=P.+Rochaixauthor=J.-S.+Hoffmanauthor=R.+Bugatauthor=C.+Cazauxauthor=P.+Canalauthor=B.+C.+Allal&title=Cetuximab+potentiates+oxaliplatin+cytotoxic+effect+through+a+defect+in+NER+and+DNA+replication+initiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation</span></div><div class="casAuthors">Balin-Gauthier, D.; Delord, J.-P.; Pillaire, M.-J.; Rochaix, P.; Hoffman, J.-S.; Bugat, R.; Cazaux, C.; Canal, P.; Allal, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-128</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Preclin. studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum deriv., is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors.  To explore the mechanism of this synergistic benefit, we used HCT-8 and HCT-116, two human colon cancer cell lines, resp., responsive and non-responsive to the oxaliplatin/cetuximab combination.  We examd. the effect of drug exposure on glutathione-S-transferase-mediated oxaliplatin detoxification, DNA-platinum adducts formation, cell cycle distribution, apoptosis, and the expression of multiple targets involved in DNA replication, recombination, and repair.  The major changes we found in HCT-8 were a stimulation of oxaliplatin-DNA adduct formation assocd. with reduced expression of the key enzyme (excision repair cross complementation group 1: ERCC1) in the key repair process of oxaliplatin-DNA platinum adduct, the nucleotide excision repair (NER), both at the mRNA and protein levels.  We also obsd. a reduced expression of factors involved in DNA replication initiation, which correlates with an enrichment of cells in the G1 phase of the cell cycle as well as an acceleration of apoptosis.  None of these changes occurred in the non-responsive HCT-116 cell that we used as a neg. control.  These findings support the fact that cetuximab potentiates the oxaliplatin-mediated cytotoxic effect as the result of inhibition of NER and also DNA replication initiation.  British Journal of Cancer (2008) 98, 120-128. doi:10.1038/sj.bjc.6604134 www.bjcancer.com Published online 8 Jan. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbmecY6u2Qz7Vg90H21EOLACvtfcHk0ljrjaRUMXCeBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2rtw%253D%253D&md5=67886dc0b25717004f969569fc2fef8b</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604134%26sid%3Dliteratum%253Aachs%26aulast%3DBalin-Gauthier%26aufirst%3DD.%26aulast%3DDelord%26aufirst%3DJ.-P.%26aulast%3DPillaire%26aufirst%3DM.-J.%26aulast%3DRochaix%26aufirst%3DP.%26aulast%3DHoffman%26aufirst%3DJ.-S.%26aulast%3DBugat%26aufirst%3DR.%26aulast%3DCazaux%26aufirst%3DC.%26aulast%3DCanal%26aufirst%3DP.%26aulast%3DAllal%26aufirst%3DB.%2BC.%26atitle%3DCetuximab%2520potentiates%2520oxaliplatin%2520cytotoxic%2520effect%2520through%2520a%2520defect%2520in%2520NER%2520and%2520DNA%2520replication%2520initiation%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D120%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Siena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajetta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comandini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodoky, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hazel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devercelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amado, G. R.</span><span> </span><span class="NLM_article-title">Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18040272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=1469-1474&author=S.+Sienaauthor=M.+Peetersauthor=E.+van+Cutsemauthor=Y.+Humbletauthor=P.+Conteauthor=E.+Bajettaauthor=D.+Comandiniauthor=G.+Bodokyauthor=G.+van+Hazelauthor=T.+Salekauthor=M.+Wolfauthor=G.+Devercelliauthor=M.+Woolleyauthor=G.+R.+Amado&title=Association+of+progression-free+survival+with+patient-reported+outcomes+and+survival%3A+results+from+a+randomised+phase+3+trial+of+panitumumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab</span></div><div class="casAuthors">Siena, S.; Peeters, M.; Van Cutsem, E.; Humblet, Y.; Conte, P.; Bajetta, E.; Comandini, D.; Bodoky, G.; Van Hazel, G.; Salek, T.; Wolf, M.; Devercelli, G.; Woolley, M.; Amado, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1474</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC).  This anal. characterises the assocn. of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS).  CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment.  Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD).  Std. imputation methods were used to assign missing values.  Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC.  After excluding responders, a significant difference in PFS remained favoring panitumumab (HR=0.63, 95% CI=0.52-0.77; P<0.0001).  At week 8, lack of disease progression was assocd. with significantly and clin. meaningful lower CRC symptomatol. for both treatment groups and higher HRQoL for panitumumab patients only.  Overall survival favored no PD patients vs PD patients alive at week 8.  Lack of disease progression was assocd. with better symptom control, HRQoL, and OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxI4jb8PY5IrVg90H21EOLACvtfcHk0ljrjaRUMXCeBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7vE&md5=1159205ed8fbfd609325645fc1f0e753</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604053%26sid%3Dliteratum%253Aachs%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3Dvan%2BCutsem%26aufirst%3DE.%26aulast%3DHumblet%26aufirst%3DY.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DBajetta%26aufirst%3DE.%26aulast%3DComandini%26aufirst%3DD.%26aulast%3DBodoky%26aufirst%3DG.%26aulast%3Dvan%2BHazel%26aufirst%3DG.%26aulast%3DSalek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DDevercelli%26aufirst%3DG.%26aulast%3DWoolley%26aufirst%3DM.%26aulast%3DAmado%26aufirst%3DG.%2BR.%26atitle%3DAssociation%2520of%2520progression-free%2520survival%2520with%2520patient-reported%2520outcomes%2520and%2520survival%253A%2520results%2520from%2520a%2520randomised%2520phase%25203%2520trial%2520of%2520panitumumab%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D1469%26epage%3D1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Berchuck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soper, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke-Pearson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, R. C.,  Jr.</span><span> </span><span class="NLM_article-title">Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4091</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=4087-4091&author=A.+Berchuckauthor=A.+Kamelauthor=R.+Whitakerauthor=B.+Kernsauthor=G.+Oltauthor=R.+Kinneyauthor=J.+T.+Soperauthor=R.+Dodgeauthor=D.+L.+Clarke-Pearsonauthor=P.+Marksauthor=S+McKenzieauthor=S.+Yinauthor=R.+C.+Bast&title=Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerchuck%26aufirst%3DA.%26aulast%3DKamel%26aufirst%3DA.%26aulast%3DWhitaker%26aufirst%3DR.%26aulast%3DKerns%26aufirst%3DB.%26aulast%3DOlt%26aufirst%3DG.%26aulast%3DKinney%26aufirst%3DR.%26aulast%3DSoper%26aufirst%3DJ.%2BT.%26aulast%3DDodge%26aufirst%3DR.%26aulast%3DClarke-Pearson%26aufirst%3DD.%2BL.%26aulast%3DMarks%26aufirst%3DP.%26aulast%3DMcKenzie%26aufirst%3DS%26aulast%3DYin%26aufirst%3DS.%26aulast%3DBast%26aufirst%3DR.%2BC.%26atitle%3DOverexpression%2520of%2520HER-2%252Fneu%2520is%2520associated%2520with%2520poor%2520survival%2520in%2520advanced%2520epithelial%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D4087%26epage%3D4091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, W. L.</span><span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2<b>/</b>neu oncogene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">235</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M.+Clarkauthor=S.+G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0ljrjaRUMXCeBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0ljXiiyZp8Ve7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span> </span><span class="NLM_article-title">Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=9661897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADyaK1cXksFCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2825-2831&author=J.+Baselgaauthor=L.+Nortonauthor=J.+Albanellauthor=Y.+Kimauthor=J.+Mendelsohn&title=Recombinant+humanized+anti-HER2+antibody+%28Herceptin%29+enhances+the+antitumor+activity+of+paclitaxel+and+doxorubicin+against+HER2%2Fneu+overexpressing+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span></div><div class="casAuthors">Baselga, Jose; Norton, Larry; Albanell, Joan; Kim, Young-Mee; Mendelsohn, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2825-2831</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast cancer cells overexpressing HER2 and has clin. activity.  We explored in preclin. models its capacity to enhance the tumoricidal effects of paclitaxel and doxorubicin.  In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel.  Treatment of well established BT-474 breast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-dependent antitumor activity.  In combination studies, treatment with paclitaxel and rhuMAb HER2 or doxorubicin and rhuMAb HER2 resulted in greater inhibition of growth than that obsd. with any agent alone.  The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone.  Clin. trials that are built on these results are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp43taV-JJAWbVg90H21EOLACvtfcHk0ljXiiyZp8Ve7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFCqt7g%253D&md5=580abe07d8f611d5b151418bc0e30d82</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DMendelsohn%26aufirst%3DJ.%26atitle%3DRecombinant%2520humanized%2520anti-HER2%2520antibody%2520%2528Herceptin%2529%2520enhances%2520the%2520antitumor%2520activity%2520of%2520paclitaxel%2520and%2520doxorubicin%2520against%2520HER2%252Fneu%2520overexpressing%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2825%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony-Servat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4744</span><span class="NLM_x">–</span> <span class="NLM_lpage">4749</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4744-4749&author=M.+A.+Molinaauthor=J.+Codony-Servatauthor=J.+Albanellauthor=F.+Rojoauthor=J.+Arribasauthor=J.+Baselga&title=Trastuzumab+%28herceptin%29%2C+a+humanized+anti-Her2+receptor+monoclonal+antibody%2C+inhibits+basal+and+activated+Her2+ectodomain+cleavage+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DCodony-Servat%26aufirst%3DJ.%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTrastuzumab%2520%2528herceptin%2529%252C%2520a%2520humanized%2520anti-Her2%2520receptor%2520monoclonal%2520antibody%252C%2520inhibits%2520basal%2520and%2520activated%2520Her2%2520ectodomain%2520cleavage%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4744%26epage%3D4749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_contrib-group">Gennari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagnoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponchio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scelsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagliabue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castiglioni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magalotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliviero, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballardini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Prada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, A.</span><span> </span><span class="NLM_article-title">Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-04-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15355889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5650-5655&author=R.+Gennariauthor=S.+Menardauthor=F.+Fagnoniauthor=L.+Ponchioauthor=M.+Scelsiauthor=E.+Tagliabueauthor=F.+Castiglioniauthor=L.+Villaniauthor=C.+Magalottiauthor=N.+Gibelliauthor=B.+Olivieroauthor=B.+Ballardiniauthor=G.+Da+Pradaauthor=A.+Zambelliauthor=A.+Costa&title=Pilot+study+of+the+mechanism+of+action+of+preoperative+trastuzumab+in+patients+with+primary+operable+breast+tumors+overexpressing+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2</span></div><div class="casAuthors">Gennari, Roberto; Menard, Sylvie; Fagnoni, Francesco; Ponchio, Luisa; Scelsi, Mario; Tagliabue, Elda; Castiglioni, Fabio; Villani, Laura; Magalotti, Cesare; Gibelli, Nadia; Oliviero, Barbara; Ballardini, Bettina; Da Prada, Gian Antonio; Zambelli, Alberto; Costa, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5650-5655</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To elucidate the mechanism by which trastuzumab, a humanized monoclonal antibody against HER2 with proven survival benefit in women with HER2-pos. metastatic breast cancer, mediates its antitumor activity.  A pilot study including 11 patients with HER2-pos. tumors treated in a neo-adjuvant setting with trastuzumab was performed.  Trastuzumab was administered i.v. at a dose of 4 mg/kg followed by three weekly i.v. doses of 2 mg/kg.  The primary tumor was surgically removed 7 days after the last treatment.  Surgical samples, tumor biopsies, and lymphocytes from these patients were collected for biol. studies.  Clin. data indicated one complete pathol. remission and four partial remissions using RECIST (Response Evaluation Criteria in Solid Tumors).  Trastuzumab was well tolerated and neither serious adverse events nor changes in cardiac function were obsd. during this short-term treatment and after surgery.  The biol. data showed that, independent of response, (a) all patients showed high levels of circulating trastuzumab; (b) satg. level of trastuzumab was present in all of the tumors; (c) no down-modulation of HER2 was obsd. in any tumors; (d) no changes in vessel diam. was obsd. in any tumors; (e) no changes in proliferation was obsd. in any tumors; and (f) a strong infiltration by lymphoid cells was obsd. in all cases.  Patients with complete remission or partial remission were found to have a higher in situ infiltration of leukocytes and a higher capability to mediate in vitro antibody-dependent cellular cytotoxicity activity.  The results of this pilot study argue against trastuzumab activity in patients through down-modulation of HER2 but in favor of antibody-dependent cellular cytotoxicity guiding efforts to optimize the use of trastuzumab in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUt98GRSRn3LVg90H21EOLACvtfcHk0ljXiiyZp8Ve7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlOqtb8%253D&md5=6476627d73af0e5549938eefbd6f6903</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0225%26sid%3Dliteratum%253Aachs%26aulast%3DGennari%26aufirst%3DR.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DFagnoni%26aufirst%3DF.%26aulast%3DPonchio%26aufirst%3DL.%26aulast%3DScelsi%26aufirst%3DM.%26aulast%3DTagliabue%26aufirst%3DE.%26aulast%3DCastiglioni%26aufirst%3DF.%26aulast%3DVillani%26aufirst%3DL.%26aulast%3DMagalotti%26aufirst%3DC.%26aulast%3DGibelli%26aufirst%3DN.%26aulast%3DOliviero%26aufirst%3DB.%26aulast%3DBallardini%26aufirst%3DB.%26aulast%3DDa%2BPrada%26aufirst%3DG.%26aulast%3DZambelli%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DA.%26atitle%3DPilot%2520study%2520of%2520the%2520mechanism%2520of%2520action%2520of%2520preoperative%2520trastuzumab%2520in%2520patients%2520with%2520primary%2520operable%2520breast%2520tumors%2520overexpressing%2520HER2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5650%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_contrib-group">Marty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cognetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraninchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauriac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubiana-Hulin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Extra, J. M.</span><span> </span><span class="NLM_article-title">Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1200%2FJCO.2005.04.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15911866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms12gs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4265-4274&author=M.+Martyauthor=F.+Cognettiauthor=D.+Maraninchiauthor=R.+Snyderauthor=L.+Mauriacauthor=M.+Tubiana-Hulinauthor=S.+Chanauthor=D.+Grimesauthor=A.+Antonauthor=A.+Lluchauthor=J.+Kennedyauthor=K.+O%E2%80%99Byrneauthor=P.+Conteauthor=M.+Greenauthor=C.+Wardauthor=K.+Mayneauthor=J.+M.+Extra&title=Efficacy+and+safety+of+trastuzumab+combined+with+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+administered+as+first-line+treatment%3A+results+of+a+randomized+phase+II+trial+by+the+M77001+Study+Group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group</span></div><div class="casAuthors">Marty, Michel; Cognetti, Francesco; Maraninchi, Dominique; Snyder, Ray; Mauriac, Louis; Tubiana-Hulin, Michele; Chan, Stephen; Grimes, David; Anton, Antonio; Lluch, Ana; Kennedy, John; O'Byrne, Kenneth; Conte, PierFranco; Green, Michael; Ward, Carol; Mayne, Karen; Extra, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4274</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel vs. docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -pos. metastatic breast cancer (MBC).  Patients and Methods: Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 wk, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression.  Results: A total of 186 patients received at least one dose of the study drug.  Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% vs. 34%; P = .0002), overall survival (median, 31.2 vs. 22.7 mo; P = .0325), time to disease progression (median, 11.7 vs. 6.1 mo; P = .0001), time to treatment failure (median, 9.8 vs. 5.3 mo; P = .0001), and duration of response (median, 11.7 vs. 5.7 mo; P = .009).  There was little difference in the no. and severity of adverse events between the arms.  Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%).  One patient in the combination arm experienced symptomatic heart failure (1%).  Another patient experienced symptomatic heart failure 5 mo after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 mo.  Conclusion Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-pos. MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqski_X7qpo7Vg90H21EOLACvtfcHk0lg8ZapTTjG6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms12gs70%253D&md5=276e619038d9c9a81b51edadf542b176</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.173%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DM.%26aulast%3DCognetti%26aufirst%3DF.%26aulast%3DMaraninchi%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DMauriac%26aufirst%3DL.%26aulast%3DTubiana-Hulin%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DGrimes%26aufirst%3DD.%26aulast%3DAnton%26aufirst%3DA.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DC.%26aulast%3DMayne%26aufirst%3DK.%26aulast%3DExtra%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520trastuzumab%2520combined%2520with%2520docetaxel%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%2520administered%2520as%2520first-line%2520treatment%253A%2520results%2520of%2520a%2520randomized%2520phase%2520II%2520trial%2520by%2520the%2520M77001%2520Study%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4265%26epage%3D4274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hozumi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinkai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, S.</span><span> </span><span class="NLM_article-title">Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1007%2Fs10549-009-0498-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=19690954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2010&pages=127-136&author=K.+Inoueauthor=K.+Nakagamiauthor=M.+Mizutaniauthor=Y.+Hozumiauthor=Y.+Fujiwaraauthor=N.+Masudaauthor=F.+Tsukamotoauthor=M.+Saitoauthor=S.+Miuraauthor=K.+Eguchiauthor=T.+Shinkaiauthor=M.+Andoauthor=T.+Watanabeauthor=N.+Masudaauthor=Y.+Ohashiauthor=M.+Sanoauthor=S.+Noguchi&title=Randomized+phase+III+trial+of+trastuzumab+monotherapy+followed+by+trastuzumab+plus+docetaxel+versus+trastuzumab+plus+docetaxel+as+first-line+therapy+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group</span></div><div class="casAuthors">Inoue, Kenichi; Nakagami, Kazuhiko; Mizutani, Mitsuhiro; Hozumi, Yasuo; Fujiwara, Yasuhiro; Masuda, Norikazu; Tsukamoto, Fumine; Saito, Mitsue; Miura, Shigeto; Eguchi, Kenji; Shinkai, Tetsu; Ando, Masashi; Watanabe, Toru; Masuda, Noriyuki; Ohashi, Yasuo; Sano, Muneaki; Noguchi, Shinzaburo</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of sequential therapy with trastuzumab monotherapy (H-mono) followed by H plus docetaxel (D) after disease progression (H → H + D) vs. combination therapy with H + D as first-line therapy.  Patients with human epidermal growth factor receptor type 2 (HER2)-pos. metastatic breast cancer (MBC) and left ventricular ejection fraction >50% were randomly assigned to either (a) H → H + D [H, once weekly 2 mg/kg (loading dose, 4 mg/kg); D, once every 3 wk 60 mg/m2] or (b) H + D.  Primary endpoints were progression-free survival (PFS) for the H-mono stage of the H → H + D group and H + D group and overall survival (OS) for both groups.  Secondary endpoints were overall response rate, time to treatment failure, second PFS and safety.  The planned no. of patients was 160 patients in total.  Of 112 patients enrolled, 107 were eligible.  After 112 patients were enrolled, the Independent Data Monitoring Committee recommended stopping enrollment because PFS and OS were greater in the H + D group than the H → H + D group.  Median PFS was 445 days in the H + D group vs. 114 days for H-mono in the H → H + D group [hazard ratio (HR), 4.24; P < 0.01].  OS was significantly longer in the H + D group (HR, 2.72; P = 0.04).  H + D therapy is significantly superior to H → H + D therapy as first-line therapy in patients with HER2-pos. MBC, esp. in terms of OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMPCloYStTQbVg90H21EOLACvtfcHk0lg8ZapTTjG6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtr3N&md5=489ff5af524faa1c757714a6f14d224e</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1007%2Fs10549-009-0498-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-009-0498-7%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DNakagami%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DM.%26aulast%3DHozumi%26aufirst%3DY.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DTsukamoto%26aufirst%3DF.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DShinkai%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DOhashi%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DNoguchi%26aufirst%3DS.%26atitle%3DRandomized%2520phase%2520III%2520trial%2520of%2520trastuzumab%2520monotherapy%2520followed%2520by%2520trastuzumab%2520plus%2520docetaxel%2520versus%2520trastuzumab%2520plus%2520docetaxel%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D119%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=K.+Glennonauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0lg8ZapTTjG6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DGlennon%26aufirst%3DK.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+Unique+Structure+for+Epidermal+Growth+Factor+Receptor+Bound+to+GW572016+%28Lapatinib%29%3A+Relationships+among+Protein+Conformation%2C+Inhibitor+Off-Rate%2C+and+Receptor+Activity+in+Tumor+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lhxAJRv9mav5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520Unique%2520Structure%2520for%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520Relationships%2520among%2520Protein%2520Conformation%252C%2520Inhibitor%2520Off-Rate%252C%2520and%2520Receptor%2520Activity%2520in%2520Tumor%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0lhxAJRv9mav5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span> <span class="citation_source-book">Package Insert Tykerb (Lapatinib)</span>; <span class="NLM_publisher-name">GlaxoSmithKline</span>: <span class="NLM_publisher-loc">Research Triangle Park, NC 27709 USA</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Package+Insert+Tykerb+%28Lapatinib%29%3B+GlaxoSmithKline%3A+Research+Triangle+Park%2C+NC+27709+USA%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DPackage%2520Insert%2520Tykerb%2520%2528Lapatinib%2529%26pub%3DGlaxoSmithKline%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_contrib-group">Iqbal, S.; Goldman, B.; Fenoglio-Preiser, C. M.; Lenz, H. J.; Zhang, W.; Danenberg, K. D.; Shibata, S. I.; Blanke, C. D.</span><span> </span><span class="NLM_article-title">Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer</span>.  <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi: <span class="refDoi"> DOI: 10.1093/annonc/mdr021</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1093%2Fannonc%2Fmdr021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=21415234" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Iqbal&author=B.+Goldman&author=C.+M.+Fenoglio-Preiser&author=H.+J.+Lenz&author=W.+Zhang&author=K.+D.+Danenberg&author=S.+I.+Shibata&author=C.+D.+Blanke&title=Southwest+Oncology+Group+study+S0413%3A+a+phase+II+trial+of+lapatinib+%28GW572016%29+as+first-line+therapy+in+patients+with+advanced+or+metastatic+gastric+cancer&doi=10.1093%2Fannonc%2Fmdr021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr021%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26atitle%3DSouthwest%2520Oncology%2520Group%2520study%2520S0413%253A%2520a%2520phase%2520II%2520trial%2520of%2520lapatinib%2520%2528GW572016%2529%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26doi%3D10.1093%2Fannonc%2Fmdr021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11f"><span><span class="NLM_contrib-group">Whang, Y. E.; Armstrong, A. J.; Rathmell, W. K.; Godley, P. A.; Kim, W. Y.; Pruthi, R. S.; Wallen, E. M.; Crane, J. M.; Moore, D. T.; Grigson, G.; Morris, K.; Watkins, C. P.; George, D. J.</span><span> </span><span class="NLM_article-title">A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer</span>.  <span class="citation_source-journal">Urol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi:<span class="refDoi"> DOI: 10.1016/j.urolonc.2010.09.018</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1016%2Fj.urolonc.2010.09.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+E.+Whang&author=A.+J.+Armstrong&author=W.+K.+Rathmell&author=P.+A.+Godley&author=W.+Y.+Kim&author=R.+S.+Pruthi&author=E.+M.+Wallen&author=J.+M.+Crane&author=D.+T.+Moore&author=G.+Grigson&author=K.+Morris&author=C.+P.+Watkins&author=D.+J.+George&title=A+phase+II+study+of+lapatinib%2C+a+dual+EGFR+and+HER-2+tyrosine+kinase+inhibitor%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urolonc.2010.09.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2010.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2010.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DY.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lapatinib%252C%2520a%2520dual%2520EGFR%2520and%2520HER-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrol.%2520Oncol.%26date%3D2011%26doi%3D10.1016%2Fj.urolonc.2010.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11g"><span><span class="NLM_contrib-group">Mimura, K.; Kono, K.; Maruyama, T.; Watanabe, M.; Izawa, S.; Shiba, S.; Mizukami, Y.; Kawaguchi, Y.; Inoue, M.; Kono, T.; Choudhury, A.; Kiessling, R.; Fujii, H.</span><span> </span><span class="NLM_article-title">Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines</span>.  <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span>Epub ahead of print; doi: <span class="refDoi"> DOI: 10.1002/ijc.25896</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1002%2Fijc.25896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Mimura&author=K.+Kono&author=T.+Maruyama&author=M.+Watanabe&author=S.+Izawa&author=S.+Shiba&author=Y.+Mizukami&author=Y.+Kawaguchi&author=M.+Inoue&author=T.+Kono&author=A.+Choudhury&author=R.+Kiessling&author=H.+Fujii&title=Lapatinib+inhibits+receptor+phosphorylation+and+cell+growth+and+enhances+antibody+dependent+cellular+cytoxicity+%28ADCC%29+of+EGFR+and+HER2+over-expressing+esophageal+cancer+cell+lines&doi=10.1002%2Fijc.25896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1002%2Fijc.25896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25896%26sid%3Dliteratum%253Aachs%26aulast%3DMimura%26aufirst%3DK.%26atitle%3DLapatinib%2520inhibits%2520receptor%2520phosphorylation%2520and%2520cell%2520growth%2520and%2520enhances%2520antibody%2520dependent%2520cellular%2520cytoxicity%2520%2528ADCC%2529%2520of%2520EGFR%2520and%2520HER2%2520over-expressing%2520esophageal%2520cancer%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26doi%3D10.1002%2Fijc.25896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11h"><span><span class="NLM_contrib-group">Ross, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-08-3328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=20215545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1938-1949&author=H.+J.+Rossauthor=G.+R.+Blumenscheinauthor=J.+Aisnerauthor=N.+Damjanovauthor=A.+Dowlatiauthor=J.+Garstauthor=J.+R.+Rigasauthor=M.+Smylieauthor=H.+Hassaniauthor=K.+E.+Allenauthor=L.+Leopoldauthor=T.+Z.+Zaksauthor=F.+A.+Shepherd&title=Randomized+phase+II+multicenter+trial+of+two+schedules+of+lapatinib+as+first-+or+second-line+monotherapy+in+patients+with+advanced+or+metastatic+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11hR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Ross, Helen J.; Blumenschein, George R., Jr.; Aisner, Joseph; Damjanov, Nevena; Dowlati, Afshin; Garst, Jennifer; Rigas, James R.; Smylie, Michael; Hassani, Habib; Allen, Kimberly E.; Leopold, Lance; Zaks, Tal Z.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1938-1949</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.  Exptl. Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance.  Patients could have had a max. of one prior systemic therapy (chemotherapy or biol. therapy) for NSCLC.  Safety and activity were assessed every 4 and 8 wk, resp.  Tumors were analyzed for EGFR and HER2 mutations and/or amplifications.  RESULTS: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 wk.  No complete or partial responses were obsd. in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 wk.  No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification.  No mutations in HER2 were found.  One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed.  The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia.  Adverse events were similar across dosing regimens.  CONCLUSIONS: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups.  Lapatinib monotherapy did not induce a significant no. of tumor regressions in NSCLC.  Further studies may be warranted to det. whether lapatinib is active in combination with other agents in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-5ZsLpn50LrVg90H21EOLACvtfcHk0lj4lGbW8lXjiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyhurY%253D&md5=0bfa99df35f30bb9e9ef0b2addb23e28</span></div><a href="/servlet/linkout?suffix=cit11h&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3328%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DH.%2BJ.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DAisner%26aufirst%3DJ.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DGarst%26aufirst%3DJ.%26aulast%3DRigas%26aufirst%3DJ.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DHassani%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DZaks%26aufirst%3DT.%2BZ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DRandomized%2520phase%2520II%2520multicenter%2520trial%2520of%2520two%2520schedules%2520of%2520lapatinib%2520as%2520first-%2520or%2520second-line%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D1938%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11i"><span><span class="NLM_contrib-group">Ooi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunitomo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobashi, Y.</span><span> </span><span class="NLM_article-title">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fmodpathol.3800137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=15143334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11i&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=895-904&author=A.+Ooiauthor=T.+Takehanaauthor=X.+Liauthor=S.+Suzukiauthor=K.+Kunitomoauthor=H.+Iinoauthor=H.+Fujiiauthor=Y.+Takedaauthor=Y.+Dobashi&title=Protein+overexpression+and+gene+amplification+of+HER-2+and+EGFR+in+colorectal+cancers%3A+an+immunohistochemical+and+fluorescent+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11iR"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study</span></div><div class="casAuthors">Ooi, Akishi; Takehana, Takuo; Li, Xiaoling; Suzuki, Shioto; Kunitomo, Kazuyoshi; Iino, Hiroshi; Fujii, Hideki; Takeda, Yasuhisa; Dobashi, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been obsd. in many cancers, sometimes accompanied by gene amplification.  To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examd. the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors.  We evaluated 244 colorectal cancers immunohistochem.  All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization.  Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, resp.  Gene amplification was obsd. in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, resp.  HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors.  EGFR amplification, obsd. as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was obsd. as a minor population within primary tumors, and found in variety of populations in metastatic tumors.  Overexpression of HER-2 and EGFR were obsd. in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps8JLiZoJAWbVg90H21EOLACvtfcHk0lj4lGbW8lXjiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOltrk%253D&md5=e073b560295b3ca3331a7f4fe11f59f7</span></div><a href="/servlet/linkout?suffix=cit11i&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3800137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3800137%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%26aulast%3DTakehana%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKunitomo%26aufirst%3DK.%26aulast%3DIino%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DDobashi%26aufirst%3DY.%26atitle%3DProtein%2520overexpression%2520and%2520gene%2520amplification%2520of%2520HER-2%2520and%2520EGFR%2520in%2520colorectal%2520cancers%253A%2520an%2520immunohistochemical%2520and%2520fluorescent%2520in%2520situ%2520hybridization%2520study%26jtitle%3DMod.%2520Pathol.%26date%3D2004%26volume%3D17%26spage%3D895%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-Disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+Orally+Active%2C+Irreversible+Inhibitors+of+Human+Epidermal+Growth+Factor+Receptor-2+Kinase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-Disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520Human%2520Epidermal%2520Growth%2520Factor%2520Receptor-2%2520Kinase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.-C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+J%C3%A4nneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.-K.+Wong&title=Bronchial+and+Peripheral+Murine+Lung+Carcinomas+Induced+by+T790M-L858R+Mutant+EGFR+Respond+to+HKI-272+and+Rapamycin+Combination+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.-C.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBronchial%2520and%2520Peripheral%2520Murine%2520Lung%2520Carcinomas%2520Induced%2520by%2520T790M-L858R%2520Mutant%2520EGFR%2520Respond%2520to%2520HKI-272%2520and%2520Rapamycin%2520Combination%2520Therapy%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0ljof9O8ztl98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_contrib-group">Rall, W.; Soyka, R.; Kulinna, C.; Schnaubelt, J.; Sieger, P.</span><span> </span><span class="NLM_article-title">Method for the production of amino crotonyl compounds</span>. International Patent Application WO/2005/037824. PCT/EP2004/011378, <span class="NLM_month">April</span><span class="NLM_day">28</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=W.+Rall&author=R.+Soyka&author=C.+Kulinna&author=J.+Schnaubelt&author=P.+Sieger&title=Method+for+the+production+of+amino+crotonyl+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRall%26aufirst%3DW.%26atitle%3DMethod%2520for%2520the%2520production%2520of%2520amino%2520crotonyl%2520compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.-H.+Namauthor=J.+Heauthor=S.-J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_contrib-group">Bold, G.; Caprard, H.-G.; Caravatti, G.; Traxler, P.</span><span> </span><span class="NLM_article-title">4-Amino-6-phenyl-pyrrolo[2,3-<i>d</i>]pyrimidine Derivatives</span>. PCT Int. WO 03/013541, <span class="NLM_month">Feb</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=G.+Bold&author=H.-G.+Caprard&author=G.+Caravatti&author=P.+Traxler&title=4-Amino-6-phenyl-pyrrolo%5B2%2C3-d%5Dpyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3D4-Amino-6-phenyl-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0li931JvlleS2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2036-2042&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=P.+Dextrazeauthor=B.+E.+Finkauthor=A.+Gavaiauthor=B.+Goyalauthor=W.-C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=E.+Ruedigerauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=New+C-5+substituted+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DRuediger%26aufirst%3DE.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNew%2520C-5%2520substituted%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2036%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2828</span><span class="NLM_x">–</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2828-2833&author=H.+Mastalerzauthor=M.+Changauthor=A.+Gavaiauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=P.+Maratheauthor=A.+Mathurauthor=S.+Oppenheimerauthor=J.+Tarrant.author=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=Novel+C-5+aminomethyl+pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DTarrant.%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DNovel%2520C-5%2520aminomethyl%2520pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2828%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleczka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span> </span><span class="NLM_article-title">5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4947-4954&author=H.+Mastalerzauthor=M.+Changauthor=P.+Chenauthor=B.+E.+Finkauthor=A.+Gavaiauthor=W+C.+Hanauthor=W.+Johnsonauthor=D.+Langleyauthor=F.+Y.+Leeauthor=K.+Leavittauthor=P.+Maratheauthor=D.+Norrisauthor=S.+Oppenheimerauthor=B.+Sleczkaauthor=J.+Tarrantauthor=J.+S.+Tokarskiauthor=G.+D.+Viteauthor=D.+M.+Vyasauthor=H.+Wongauthor=T.+W.+Wongauthor=H.+Zhangauthor=G.+Zhang&title=5-%28%284-Aminopiperidin-1-yl%29methyl%29pyrrolotriazine+dual+inhibitors+of+EGFR+and+HER2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DGavai%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DW%2BC.%26aulast%3DJohnson%26aufirst%3DW.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3D5-%2528%25284-Aminopiperidin-1-yl%2529methyl%2529pyrrolotriazine%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520HER2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4947%26epage%3D4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessel, M. D.</span><span> </span><span class="NLM_article-title">Achieving selectivity between higly homologous tyrosine kinases anovel selective erbB2 inhibitor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=267-273&author=S.+K.+Bhattacharyaauthor=E.+D.+Coxauthor=J.+C.+Kathauthor=A.+M.+Mathiowetzauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=D.+T.+Richterauthor=C.+Suauthor=M.+D.+Wessel&title=Achieving+selectivity+between+higly+homologous+tyrosine+kinases+anovel+selective+erbB2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DAchieving%2520selectivity%2520between%2520higly%2520homologous%2520tyrosine%2520kinases%2520anovel%2520selective%2520erbB2%2520inhibitor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D267%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafidi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span> </span><span class="NLM_article-title">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9887</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm2008634&amp;key=10.1158%2F0008-5472.CAN-06-3559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm2008634&amp;key=17942920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm2008634&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9887-93&author=J.+P.+Janiauthor=R.+S.+Finnauthor=M.+Campbellauthor=K.+G.+Colemanauthor=R.+D.+Connellauthor=N.+Currierauthor=E.+O.+Emersonauthor=E.+Floydauthor=S.+Harrimanauthor=J.+C.+Kathauthor=J.+Morrisauthor=J.+D.+Moyerauthor=L.+R.+Pustilnikauthor=K.+Rafidiauthor=S.+Ralstonauthor=A.+M.+Rossiauthor=S.+J.+Steynauthor=L.+Wagnerauthor=S.+M.+Winterauthor=S.+K.+Bhattacharya&title=Discovery+and+Pharmacologic+Characterization+of+CP-724%2C714%2C+a+Selective+ErbB2+Tyrosine+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Jani, Jitesh P.; Finn, Richard S.; Campbell, Mary; Coleman, Kevin G.; Connell, Richard D.; Currier, Nicolas; Emerson, Erling O.; Floyd, Eugenia; Harriman, Shawn; Kath, John C.; Morris, Joel; Moyer, James D.; Pustilnik, Leslie R.; Rafidi, Kristina; Ralston, Sherry; Rossi, Ann Marie K.; Steyn, Stefanus J.; Wagner, Larry; Winter, Steven M.; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9887-9893</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach.  It has been implicated in tumor growth, sensitivity to std. chemotherapy, prognosis of patients, and disease-free survival.  Although the clin. use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-mol. inhibitors.  CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clin. trials.  Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models.  CP-724,714 is selective for inhibiting growth of HER2-driven cell lines.  In addn., we show that it induces G1 cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice.  It induces a marked redn. of extracellular signal-regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3.  P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_a6qjvEZI-rVg90H21EOLACvtfcHk0lipQ4ueAuP4ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOnsbvE&md5=21dc688108dd46aba15694d7e3159321</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3559%26sid%3Dliteratum%253Aachs%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DK.%2BG.%26aulast%3DConnell%26aufirst%3DR.%2BD.%26aulast%3DCurrier%26aufirst%3DN.%26aulast%3DEmerson%26aufirst%3DE.%2BO.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRafidi%26aufirst%3DK.%26aulast%3DRalston%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DS.%2BM.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520and%2520Pharmacologic%2520Characterization%2520of%2520CP-724%252C714%252C%2520a%2520Selective%2520ErbB2%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9887%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_contrib-group">Ripin, D. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourassa, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldi, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massett, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raggon, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. M.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetelino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span> </span><span class="NLM_article-title">Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/doi/10.1021/op050039u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=440-450&author=D.+H.+B.+Ripinauthor=D.+E.+Bourassaauthor=T.+Brandtauthor=M.+J.+Castaldiauthor=H.+N.+Frostauthor=J.+Hawkinsauthor=P.+J.+Johnsonauthor=S.+S.+Massettauthor=K.+Neumannauthor=J.+Phillipsauthor=J.+W.+Raggonauthor=P.+R.+Roseauthor=J.+L.+Rutherfordauthor=B.+Sitterauthor=A.+M.+Stewartauthor=M.+G.+Vetelinoauthor=L.+Wei&title=Evaluation+of+Kilogram-Scale+Sonagashira%2C+Suzuki%2C+and+Heck+Coupling+Routes+to+Oncology+Candidate+CP-724%2C714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1021%2Fop050039u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop050039u%26sid%3Dliteratum%253Aachs%26aulast%3DRipin%26aufirst%3DD.%2BH.%2BB.%26aulast%3DBourassa%26aufirst%3DD.%2BE.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCastaldi%26aufirst%3DM.%2BJ.%26aulast%3DFrost%26aufirst%3DH.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%2BJ.%26aulast%3DMassett%26aufirst%3DS.%2BS.%26aulast%3DNeumann%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DJ.%26aulast%3DRaggon%26aufirst%3DJ.%2BW.%26aulast%3DRose%26aufirst%3DP.%2BR.%26aulast%3DRutherford%26aufirst%3DJ.%2BL.%26aulast%3DSitter%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DA.%2BM.%26aulast%3DVetelino%26aufirst%3DM.%2BG.%26aulast%3DWei%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520Kilogram-Scale%2520Sonagashira%252C%2520Suzuki%252C%2520and%2520Heck%2520Coupling%2520Routes%2520to%2520Oncology%2520Candidate%2520CP-724%252C714%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D440%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span> </span><span class="NLM_article-title">The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3081</span><span class="NLM_x">–</span> <span class="NLM_lpage">3086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3081-3086&author=B.+Lippaauthor=G.+S.+Kauffmanauthor=J.+Arcariauthor=T.+Kwanauthor=J.+Chenauthor=W.+Hungerfordauthor=S.+Bhattacharyaauthor=X.+Zhaoauthor=C.+Williamsauthor=J.+Xiaoauthor=L.+Pustilnikauthor=C.+Suauthor=J.+D.+Moyerauthor=L.+Maauthor=M.+Campbellauthor=S.+Steyn&title=The+discovery+of+highly+selective+erbB2+%28Her2%29+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DKauffman%26aufirst%3DG.%2BS.%26aulast%3DArcari%26aufirst%3DJ.%26aulast%3DKwan%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DPustilnik%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DSteyn%26aufirst%3DS.%26atitle%3DThe%2520discovery%2520of%2520highly%2520selective%2520erbB2%2520%2528Her2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3081%26epage%3D3086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Studies on nucleic acid antagonists. VII. Synthesis and characterization of 1,4,6-triazaindenes (5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidines)</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1964&pages=1030-1042&author=K.+Imai&title=Studies+on+nucleic+acid+antagonists.+VII.+Synthesis+and+characterization+of+1%2C4%2C6-triazaindenes+%285H-pyrrolo%5B3%2C2-d%5Dpyrimidines%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26atitle%3DStudies%2520on%2520nucleic%2520acid%2520antagonists.%2520VII.%2520Synthesis%2520and%2520characterization%2520of%25201%252C4%252C6-triazaindenes%2520%25285H-pyrrolo%255B3%252C2-d%255Dpyrimidines%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1964%26volume%3D12%26spage%3D1030%26epage%3D1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span> </span><span class="NLM_article-title">A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-overexpressing breast cancer</span>. <span class="NLM_contrib-group">Hayashi, A.; Tamura, T.; Yusa, T.; Takagi, S.; Ohta, Y.</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span>, <span class="NLM_issue">Suppl 1</span>, <div class="note"><p class="first last">Abstract 3143</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2008&issue=Suppl+1&author=A.+Hayashi&author=T.+Tamura&author=T.+Yusa&author=S.+Takagi&author=Y.+Ohta&title=A+novel+HER2+inhibitor+TAK-285+overcomes+trastuzumab+resistance+of+HER2-overexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520novel%2520HER2%2520inhibitor%2520TAK-285%2520overcomes%2520trastuzumab%2520resistance%2520of%2520HER2-overexpressing%2520breast%2520cancer%26aulast%3DHayashi%26aufirst%3DA.%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D69%26issue%3DSuppl%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span> </span><span class="NLM_article-title">Improved Syntheses of 3<i>H</i>,5<i>H</i>-Pyrrolo[3,2-<i>d</i>]pyrimidines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">8411</span><span class="NLM_x">–</span> <span class="NLM_lpage">8412</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo990903e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=8411-8412&author=R.+H.+Furneauxauthor=P.+C.+Tyler&title=Improved+Syntheses+of+3H%2C5H-Pyrrolo%5B3%2C2-d%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fjo990903e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990903e%26sid%3Dliteratum%253Aachs%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26atitle%3DImproved%2520Syntheses%2520of%25203H%252C5H-Pyrrolo%255B3%252C2-d%255Dpyrimidines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D8411%26epage%3D8412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_contrib-group">Evans, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kezar, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, P. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span> </span><span class="NLM_article-title">Addition of Lithiated 9-Deazapurine Derivatives to a Carbohydrate Cyclic Imine: Convergent Synthesis of the Aza-<i>C</i>-nucleoside Immucillins</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5723</span><span class="NLM_x">–</span> <span class="NLM_lpage">5730</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo0155613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=5723-5730&author=G.+B.+Evansauthor=R.+H.+Furneauxauthor=T.+L.+Hutchisonauthor=H.+S.+Kezarauthor=P.+E.+Morrisauthor=V.+L.+Schrammauthor=P.+C.+Tyler&title=Addition+of+Lithiated+9-Deazapurine+Derivatives+to+a+Carbohydrate+Cyclic+Imine%3A+Convergent+Synthesis+of+the+Aza-C-nucleoside+Immucillins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjo0155613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0155613%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DG.%2BB.%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DHutchison%26aufirst%3DT.%2BL.%26aulast%3DKezar%26aufirst%3DH.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BE.%26aulast%3DSchramm%26aufirst%3DV.%2BL.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26atitle%3DAddition%2520of%2520Lithiated%25209-Deazapurine%2520Derivatives%2520to%2520a%2520Carbohydrate%2520Cyclic%2520Imine%253A%2520Convergent%2520Synthesis%2520of%2520the%2520Aza-C-nucleoside%2520Immucillins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D5723%26epage%3D5730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_contrib-group">Furneaux, R. H.; Tyler, P. C.</span>PCT Int. WO 00/61783, <span class="NLM_month">Oct</span><span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Furneaux%2C+R.+H.%3B+Tyler%2C+P.+C.PCT+Int.+WO+00%2F61783%2C+Oct+2000."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yona, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yonaauthor=B.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYona%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RCD">3RCD</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RCD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RCD','PDB','3RCD'); return false;">PDB: 3RCD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i109"><a href="/doi/suppl/10.1021/jm2008634">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46254"></div></div></div></div></div><hr /></hr><p class="last">Methods used in molecular modeling, enzyme assays, cell line, and animal models, pharmacokinetics, metabolic stability, and structural analyses.  This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2008634/suppl_file/jm2008634_si_001.pdf">jm2008634_si_001.pdf (114.44 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2008634&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm2008634%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-23%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2008634" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6271da2c329d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
